image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
9b59ebfe9f86c270a59ec9298dd44fc2796037411ae0d8076c6690e13bd0dc0b.png | complex | <table><tr><td></td><td colspan="3">Cohort 1* - ELISA studies</td><td colspan="3">Cohort 2** - proteomic studies</td></tr><tr><td>Characteristics</td><td>CIS → CIS</td><td>CIS → CDMS</td><td><i>P</i>values</td><td>CIS → CIS</td><td>CIS → CDMS</td><td><i>P</i>values</td></tr><tr><td>n</td><td>27</td><td>29</td><td>-</td><td>18</td><td>18</td><td>-</td></tr><tr><td>Age (years)<sup>a</sup></td><td>28.1 (9.6)</td><td>27.4 (6.3)</td><td>0.724</td><td>31.7 (7.3)</td><td>30.2 (5.9)</td><td>0.308</td></tr><tr><td>Female/male (% female)</td><td>20/7 (74.1)</td><td>20/9 (69.0)</td><td>0.672</td><td>13/5 (72.2)</td><td>13/5 (72.2)</td><td>1</td></tr><tr><td>Follow-up time (years)<sup>a</sup></td><td>8.2 (4.2)</td><td>8.6 (3.3)</td><td>0.819</td><td>6.1 (3.6)</td><td>8.8 (2.7)</td><td>0.098</td></tr><tr><td>Clinical presentation</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Optic neuritis</td><td>15 (55.6)</td><td>8 (27.6)</td><td>0.206</td><td>9 (50.0)</td><td>3 (16.7)</td><td>0.152</td></tr><tr><td>Brainstem</td><td>4 (14.8)</td><td>7 (24.1)</td><td></td><td>2 (11.1)</td><td>5 (27.8)</td><td></td></tr><tr><td>Spinal</td><td>5 (18.5)</td><td>8 (27.6)</td><td></td><td>3 (16.7)</td><td>6 (33.3)</td><td></td></tr><tr><td>Others</td><td>3 (11.1)</td><td>6 (20.7)</td><td></td><td>4 (22.2)</td><td>4 (22.2)</td><td></td></tr><tr><td>CSF cells<sup>b</sup></td><td>0.5 (0-5.0)</td><td>2.0 (0-9.0)</td><td>0.337</td><td>0 (2.4-3.5)</td><td>4.0 (0-11.5)</td><td>0.059</td></tr><tr><td>Proteins (mg/dL)<sup>b</sup></td><td>33.0 (24.0-43.0)</td><td>37.0 (26.8-57.3)</td><td>0.391</td><td>32.5 (23.7-41.5)</td><td>29.5 (24.0-51.8)</td><td>0.705</td></tr></table> |
cc805f388fed30ba3dc12402ab4be797ad25728c85fddbb77657e6478cd44655.png | simple | <table><tr><td>Variable</td><td>Definition</td></tr><tr><td>Taxonomic class</td><td>Within this example we adopt the designation of taxonomic Specification from the NCBI's taxonomy database [63].</td></tr><tr><td>Injection.chemical</td><td>The chemical molecule injected into the brain of an animal as part of a tract-tracing experiment. These reagents are not confined to a specific type of chemical simply have the property of when injected into brain tissue, they are taken up and transported along axons by active processes in neurons. Early examples of these include tritiated amino acids [64], Horseradish peroxidase (HRP) [65] and notably Phaseolus <i>Leuco-Agglutinin </i>[66]. Tracer chemicals include fluorescent dyes and beads and even include more exotic materials such as viruses and Cholera Toxin. See [17,67-71] for reviews of the general and specialized methods used.</td></tr><tr><td>Injection.location</td><td>This refers to the extent of the complete injection site expressed in terms of its spatial relationships to identified brain structures from the Swanson atlas [32] and encoded into the neuroanatomical nomenclature specified from the BAMS system [72]</td></tr><tr><td>Mapped location</td><td>Similarly to Injection.location, this refers to the spatial extent of an individual region of labeling (judged by the scientist reporting the study to be relatively homogeneous) expressed in terms of its spatial relationships to named neuroanatomical terms from the BAMS ontology [72]</td></tr><tr><td>Labeling.type</td><td>A simple categorization of the part of the neuron that is labeled. This is a nominal data element with possible values 'cellular' (denoting that the neuronal cell bodies were labeled), ' fibers' (denoting that axonal fibers were labeled), or 'terminals' (denoting that axonal fibers with characteristics of a terminal region were labeled, including heavy branching and the presence of boutons).</td></tr><tr><td>Labeling.density</td><td>A simple, seven point ordinal scale with the following categories (in order): 'no label', 'very sparse label, 'sparse label', 'sparse/moderate label', 'moderate label', 'moderate/dense label' and 'dense label'. We also include an additional category to denote that labeling is present but with an unknown density.</td></tr></table> |
79dafe82091bb754076e78d3d05ac359ec8305435589d854c705841993d9483d.png | simple | <table><tr><td></td><td>Preoperative model</td><td>Postoperative model</td><td>Intra-ICU model</td></tr><tr><td>(Constant)</td><td>1.26</td><td>0.44</td><td>1.82</td></tr><tr><td>Expected session time (min)</td><td>1.10 (1.01–1.21)</td><td></td><td></td></tr><tr><td>Patient age (per decade)</td><td>1.16 (1.06–1.28)</td><td>1.20 (1.09–1.31)</td><td>1.09 (1.02–1.17)</td></tr><tr><td>FEV<sub>1 </sub>(l)</td><td>0.91 (0.81–1.03)</td><td>0.85 (0.75–0.96)</td><td></td></tr><tr><td>Gastroesophageal reflux disease (yes/no)</td><td>1.46 (1.14–1.89)</td><td>1.53 (1.19–1.96)</td><td></td></tr><tr><td>Vascular comorbidity (yes/no)</td><td>1.29 (1.01–1.66)</td><td>1.32 (1.03–1.69)</td><td></td></tr><tr><td>Neurological comorbidity (yes/no)</td><td>1.74 (1.24–2.43)</td><td>1.82 (1.31–2.53)</td><td></td></tr><tr><td>Previous chemotherapy (yes/no)</td><td>0.81 (0.68–0.97)</td><td></td><td></td></tr><tr><td>Previous radiotherapy (yes/no)</td><td></td><td></td><td>0.78 (0.63–0.97)</td></tr><tr><td>Transthoracic approach (yes/no)</td><td>2.13 (1.74–2.62)</td><td>1.79 (1.44–2.24)</td><td>1.21 (1.05–1.40)</td></tr><tr><td>Reconstruction using colon (yes/no)</td><td>1.56 (1.05–2.30)</td><td>1.52 (1.03–2.23)</td><td></td></tr><tr><td>Observed session time (min)</td><td></td><td>1.07 (0.98–1.16)</td><td></td></tr><tr><td>Volume administration of colloids (liter)</td><td></td><td>1.14 (1.01–1.29)</td><td></td></tr><tr><td>Absolute intraoperative blood loss (l)</td><td></td><td>0.94 (0.87–1.02)</td><td></td></tr><tr><td>Absolute intraoperative urine production (l)</td><td></td><td>1.12 (0.99–1.25)</td><td></td></tr><tr><td>Epidural analgesia administration (yes/no)</td><td></td><td>0.83 (0.69–1.01)</td><td></td></tr><tr><td>Respiratory minute volume (l)</td><td></td><td>1.09 (1.04–1.15)</td><td>1.05 (1.01–1.09)</td></tr><tr><td>Positive end-expiratory pressure (cmH<sub>2</sub>O)</td><td></td><td>1.03 (0.99–1.07)</td><td></td></tr><tr><td>Chylothorax surgical complication (yes/no)</td><td></td><td></td><td>1.31 (0.96–1.79)</td></tr><tr><td>Anastomosis leakage complication (yes/no)</td><td></td><td></td><td>1.83 (1.47–2.28)</td></tr><tr><td>Other complication (yes/no)</td><td></td><td></td><td>1.71 (1.38–2.10)</td></tr><tr><td>Pulmonary nonsurgical complication (yes/no)</td><td></td><td></td><td>1.97 (1.72–2.26)</td></tr><tr><td>Myocardial infarction (yes/no)</td><td></td><td></td><td>1.54 (0.93–2.56)</td></tr><tr><td>Infection (yes/no)</td><td></td><td></td><td>1.61 (1.25–2.07)</td></tr><tr><td>Other nonsurgical complication (yes/no)</td><td></td><td></td><td>1.41 (1.22–1.62)</td></tr><tr><td>Multiple r<sup>2</sup></td><td>21%</td><td>25%</td><td>56%</td></tr><tr><td>Optimism</td><td>6%</td><td>9%</td><td>11%</td></tr><tr><td>Optimism corrected r<sup>2</sup></td><td>15%</td><td>17%</td><td>45%</td></tr></table> |
fcde257c6b92eb3365bedc3f9ece46dc1aa525f86408b47978e4d47c5f9eecd7.png | simple | <table><tr><td>Variable, n (%)</td><td>n=841*</td></tr><tr><td>Gender (female) n=821*</td><td>689 (83.9)</td></tr><tr><td>Age: n= 819*</td><td> </td></tr><tr><td>>−25</td><td>88 (10.7)</td></tr><tr><td>25-35</td><td>172 (21.0)</td></tr><tr><td>35-45</td><td>215 (26.3)</td></tr><tr><td>45-55</td><td>205 (25.0)</td></tr><tr><td>55-<</td><td>139 (17.0)</td></tr><tr><td>Born not in Sweden, n=819*</td><td>389 (47.5)</td></tr><tr><td>Profession: n=798*</td><td> </td></tr><tr><td>Health care staff</td><td>678 (85.0)</td></tr><tr><td>Administrative staff</td><td>49 (6.1)</td></tr><tr><td>Food staff</td><td>15 (1.9)</td></tr><tr><td>Others:</td><td>56 (7.0)</td></tr></table> |
3b92798d3212ab62ae1394307a205b1ca7abd539ce5618208f51c035a9395050.png | simple | <table><tr><td>Concentration</td><td>EAC Control</td><td>PST 200 mg/kg</td><td>5-FU 20 mg/kg</td><td>PST + 5-FU</td></tr><tr><td>Tumor volume (mL)</td><td>9.7 ± 0.2</td><td>4.4 ± 0.34***</td><td>3.3 ± 0.6***</td><td>2.9 ± 0.29***</td></tr><tr><td> Body weight (g)</td><td>34.91 ± 1.9</td><td>30.8 ± 1.2**</td><td>26.21 ± 2.3**</td><td>25.12 ± 2.7**</td></tr><tr><td>PCV (mL)</td><td>3 ± 0.45</td><td>1.2 ± 0.1***</td><td>0.8 ± 0.1***</td><td>0.6 ± 0.2***</td></tr><tr><td>Mean survival time (Days)</td><td>20 ± 1</td><td>33 ± 2***</td><td>44 ± 0.57***</td><td>56 ± 1***</td></tr><tr><td>% Increase in life span (ILS)</td><td> —</td><td>65 ± 1***</td><td>120 ± 2***</td><td>180 ± 1***</td></tr><tr><td>Tumor cell count (10<sup>6</sup> cells/mL)</td><td>173 ± 0.43</td><td>51 ± 0.36***</td><td>29 ± 0.5***</td><td>25 ± 0.36***</td></tr><tr><td>Percentage of viable cells</td><td>92 ± 1</td><td>70 ± 2***</td><td>64 ± 0.57**</td><td>60 ± 1**</td></tr><tr><td>Percentage of nonviable cells</td><td>8 ± 1</td><td>30 ± 0.57***</td><td>36 ± 1***</td><td>40 ± 2***</td></tr><tr><td>Hb (G%) (12.2–16.2) gm/dL</td><td>7.2 ± 0.8</td><td>9.8 ± 1* </td><td>12 ± 1.4***</td><td>14 ± 1.9***</td></tr><tr><td> RBC (Million/cmm) (7–12.5) × 10<sup>6</sup>/mm<sup>3</sup></td><td>2.7 ± 0.4</td><td>3.6 ± 0.9<sup>ns</sup> </td><td>4.3 ± 1.3<sup>ns</sup> </td><td>5.1 ± 1.6** </td></tr><tr><td>TC (c/mm) (5100–11600)</td><td>18800 ± 100</td><td>11100 ± 50***</td><td>8500 ± 75***</td><td>8000 ± 60***</td></tr><tr><td>Platelets (/cmm) (160000–410000)</td><td>115000 ± 450</td><td>170000 ± 525***</td><td>200000 ± 550***</td><td>230000 ± 490***</td></tr></table> |
7e02c30d84ac8d55062214087321ee6b879607a733c9ecd1871f99235463fbcf.png | simple | <table><tr><td>Comparison</td><td>CYP19A1 vs. RORA*</td><td>A2BP1 vs. RORA</td><td>ITPR1 vs. RORA</td><td>NLGN1 vs. RORA</td></tr><tr><td>Correlation coefficient</td><td>0.99</td><td>0.83</td><td>0.72</td><td>0.81</td></tr><tr><td><i>P</i> val (2-tailed)</td><td>0.03</td><td>0.38</td><td>0.49</td><td>0.39</td></tr><tr><td>R<sup>2</sup></td><td>0.99</td><td>0.69</td><td>0.52</td><td>0.66</td></tr></table> |
af5538f8e06f9c099ed51cc948859f5d34c0fe2298a48506f8d78e51cf9f8320.png | complex | <table><tr><td>Characteristic</td><td>N (%)</td></tr><tr><td colspan="2">Sex</td></tr><tr><td>Male</td><td>58 (61.1)</td></tr><tr><td>Female</td><td>36 (38.8)</td></tr><tr><td>Missing</td><td>1 (1.1)</td></tr><tr><td colspan="2">Work-place</td></tr><tr><td>Ministry of Health</td><td>15 (15.7)</td></tr><tr><td>Tertiary/referral hospital</td><td>32 (33.7)</td></tr><tr><td>University</td><td>27 (28.4)</td></tr><tr><td>NGO</td><td>20 (21.1)</td></tr><tr><td>Missing</td><td>1 (1.1)</td></tr><tr><td colspan="2">Training completed</td></tr><tr><td>Bachelor of medicine/MD</td><td>59 (62.1)</td></tr><tr><td>Postgraduate training/MMED</td><td>8 (8.4)</td></tr><tr><td>MS/MPH</td><td>12 (12.6)</td></tr><tr><td>PhD</td><td>2 (2.1)</td></tr><tr><td>*Other</td><td>13 (13.7)</td></tr><tr><td>Missing</td><td>1(1.1)</td></tr><tr><td colspan="2">Current training</td></tr><tr><td>Postgraduate training/MMED</td><td>17 (18.9)</td></tr><tr><td>MS/MPH</td><td>16 (16.8)</td></tr><tr><td>PhD in a health related field (e.g. epidemiology or Health Services Research)</td><td>23 (24.2)</td></tr><tr><td>**Other</td><td>38 (40.0)</td></tr><tr><td>Missing</td><td>1 (1.1)</td></tr></table> |
c2b75a0e5ddc8374e1ee44be364e486f3f8f88b982ec6747ce1360a7a253182c.png | simple | <table><tr><td> </td><td>RA-UIP</td><td>IPF</td><td>Controls</td><td>p-value</td></tr><tr><td>Telomere length</td><td>0.663(1.476, 11.548)</td><td>1.118 (0.747, 9.867)</td><td>1.876 (0.038, 3.221)</td><td>0.170</td></tr></table> |
ea908f5d1a9ce9cf1b654f7f2d82efbf7b1e82679e906d757f0c66fe282d21b5.png | simple | <table><tr><td>Risk Factors</td><td>Odds Ratio for Anti-HEV IgM, 95% CI</td><td><i>P</i> value<sup>†</sup></td><td>Odds Ratio for Anti-HEV IgG, 95% CI</td><td><i>P</i> value<sup>γ</sup></td></tr><tr><td>CD4+ count >200cells/μl</td><td>5.109 [1.624–16.070]</td><td>0.005*</td><td>0.67 [.333–1.36]</td><td>0.273</td></tr><tr><td>Anti HCV Positive status</td><td>0.018 [0.006–0.056]</td><td><0.001*</td><td>5.35 [2.44–11.69]</td><td><0.001*</td></tr><tr><td>Residing in Kathmandu Valley</td><td>44.31 [14.507–135.353]</td><td><0.001*</td><td>37.73 [20.98–67.87]</td><td><0.001*</td></tr><tr><td>HIV viral load > 3log cps/ml</td><td>3.045 [1.25–7.39]</td><td><0.001*</td><td>4.43 [1.67–11.73]</td><td>0.001*</td></tr></table> |
55f68c9fc2a36c149ff5709c4fa82cdba5fa9e9499c006bd6d0aabd2d70e5341.png | simple | <table><tr><td><i>ID #</i></td><td><i>Age (yr)</i></td><td><i>Sex</i></td><td><i>RBT (w)</i></td><td><i>Symptoms</i></td><td><i>HP</i></td><td><i>ED</i></td><td><i>GH</i></td><td><i>PU</i></td><td><i>AD</i></td><td><i>RD</i></td></tr><tr><td>1</td><td>5.9</td><td>M</td><td>4</td><td></td><td></td><td></td><td></td><td>Severe</td><td></td><td></td></tr><tr><td>2</td><td>13.4</td><td>M</td><td>3</td><td>Arthralgia</td><td></td><td></td><td></td><td>Mild</td><td></td><td></td></tr><tr><td>3</td><td>5.4</td><td>M</td><td>6</td><td></td><td>+</td><td></td><td>+</td><td>Severe</td><td></td><td></td></tr><tr><td>4</td><td>5.4</td><td>M</td><td>3</td><td></td><td></td><td></td><td></td><td>Severe</td><td></td><td></td></tr><tr><td>5</td><td>10.8</td><td>F</td><td>3</td><td>Abdominal pain</td><td>+</td><td></td><td></td><td>Moderate</td><td></td><td></td></tr><tr><td>6</td><td>10.6</td><td>M</td><td>9</td><td></td><td></td><td>+</td><td></td><td>Severe</td><td>+</td><td></td></tr><tr><td>7</td><td>7.9</td><td>F</td><td>3</td><td></td><td></td><td>+</td><td></td><td>Severe</td><td>+</td><td></td></tr><tr><td>8</td><td>12.0</td><td>F</td><td>6</td><td></td><td>+</td><td></td><td>+</td><td>Severe</td><td>+</td><td></td></tr><tr><td>9</td><td>7.7</td><td>F</td><td>12</td><td>Abdominal pain, arthralgia,</td><td></td><td>+</td><td></td><td>Moderate</td><td></td><td></td></tr><tr><td>10</td><td>9.1</td><td>M</td><td>3</td><td>Abdominal pain, arthralgia,</td><td>+</td><td>+</td><td>+</td><td>Severe</td><td></td><td>+</td></tr><tr><td>11</td><td>9.2</td><td>M</td><td>2</td><td>Arthralgia</td><td>+</td><td></td><td></td><td>Severe</td><td></td><td></td></tr></table> |
28d685de80356d40969a60eb9b5ffdde865ad3e57a584a3fb0aee772b709b78f.png | complex | <table><tr><td colspan="2">Demographic category</td><td>N (%)</td></tr><tr><td colspan="2"><i>N</i></td><td>1184</td></tr><tr><td colspan="2"><i>Age (m,sd)</i></td><td>66.6 (10.8)</td></tr><tr><td colspan="2"><i>Age</i></td><td> </td></tr><tr><td colspan="2">18-45</td><td>45 (3.8)</td></tr><tr><td colspan="2">46-60</td><td>281 (23.7)</td></tr><tr><td colspan="2">61-70</td><td>394 (33.3)</td></tr><tr><td colspan="2">71-80</td><td>346 (29.3)</td></tr><tr><td colspan="2">81+</td><td>114 (9.7)</td></tr><tr><td colspan="2"><i>Gender</i></td><td> </td></tr><tr><td colspan="2">Male</td><td>720 (60.9)</td></tr><tr><td colspan="2"><i>Marital status</i></td><td> </td></tr><tr><td colspan="2">Single</td><td>118 (10.0)</td></tr><tr><td colspan="2">Married/partner</td><td>891 (75.2)</td></tr><tr><td colspan="2">Divorced</td><td>74 (6.3)</td></tr><tr><td colspan="2">Widowed</td><td>99 (8.4)</td></tr><tr><td colspan="2"><i>Length of time with diabetes</i></td><td> </td></tr><tr><td colspan="2">< 5 years</td><td>612 (51.7)</td></tr><tr><td colspan="2">> = 5 years</td><td>572 (48.3)</td></tr><tr><td colspan="2"><i>Diabetes management</i></td><td> </td></tr><tr><td colspan="2">Diet</td><td>321 (27.1)</td></tr><tr><td colspan="2">Tablets</td><td>711 (60.1)</td></tr><tr><td colspan="2">Insulin</td><td>148 (12.5)</td></tr><tr><td colspan="2"><i>Health status</i></td><td> </td></tr><tr><td><i>Diabetes related complications</i></td><td>None</td><td>710 (61.3)</td></tr><tr><td colspan="2">One or more</td><td>448 (38.7)</td></tr><tr><td colspan="2">Feet</td><td>257 (21.7)</td></tr><tr><td colspan="2">Eyes</td><td>266 (22.5)</td></tr><tr><td colspan="2">Kidneys</td><td>66 (5.6)</td></tr><tr><td><i>Other health complications</i></td><td>None</td><td>216 (18.5)</td></tr><tr><td colspan="2">One or more</td><td>952 (81.5)</td></tr><tr><td colspan="2">Arthritis</td><td>503 (43.2)</td></tr><tr><td colspan="2">Hypertension</td><td>513 (44.1)</td></tr><tr><td colspan="2">High cholesterol</td><td>588 (50.5)</td></tr><tr><td colspan="2">Heart conditions</td><td>108 (11.4)</td></tr><tr><td colspan="2">Depression/anxiety</td><td>207 (17.8)</td></tr><tr><td colspan="2"><i>EQ-5D index score</i></td><td>0.652 (0.32)</td></tr><tr><td colspan="2"><i>SF-6D index score</i></td><td>0.693 (0.16)</td></tr><tr><td colspan="2"><i>DHP-18</i> PD</td><td>17.93 (20.5)</td></tr><tr><td colspan="2">BA</td><td>21.53 (19.31)</td></tr><tr><td colspan="2">DE</td><td>35.93 (23.04)</td></tr><tr><td colspan="2"><i>Change in health baseline-follow up</i></td><td> </td></tr><tr><td colspan="2">Health improvement</td><td>186 (15.9)</td></tr><tr><td colspan="2">No change</td><td>717 (61.7)</td></tr><tr><td colspan="2">Health deterioration</td><td>260 (22.4)</td></tr></table> |
509b9a079e3e1231b869538b0e737321e1106372a725128c8b90ab93d1525dd6.png | complex | <table><tr><td>Parameter</td><td>Value</td></tr><tr><td colspan="2">General assumptions for the facility</td></tr><tr><td>rBuChE production level </td><td>25 kg rBuChE/year (bulk)</td></tr><tr><td>rBuChE doses per year</td><td>62,500 doses/year at 400 mg/dose</td></tr><tr><td>Downstream Recovery/purification yield</td><td>20%</td></tr><tr><td>Annual operating days</td><td>330 days</td></tr><tr><td>rBuChE production in plants following infiltration/incubation</td><td>125 kg rBuChE/year</td></tr><tr><td>Batch cycle time (time between start of new infiltration batches)</td><td>7 days</td></tr><tr><td>Batches per year</td><td>47</td></tr><tr><td>Base case rBuChE expression level</td><td>500 mg/kg FW at ~7 days after infiltration</td></tr><tr><td>Facility lifetime</td><td>15 years</td></tr><tr><td>Depreciation</td><td>Straight line over 10 years, 5% direct fixed capital salvage</td></tr><tr><td>Working capital</td><td>30 days of labor, materials, utilities, waste treatment</td></tr><tr><td>Lab/QC/QA costs</td><td>2% of total labor costs for plant growth and agroinfiltration sections, 15% of total labor costs for recovery and purification section</td></tr><tr><td>Start-up/validation costs</td><td>5% direct fixed capital</td></tr><tr><td colspan="2">Assumptions for indoor plant growth section</td></tr><tr><td>Mass per plant at 5 weeks</td><td>0.02 kg FW/plant</td></tr><tr><td>Tray size</td><td>4 ft × 4 ft</td></tr><tr><td>Number of plants per tray</td><td>256</td></tr><tr><td>Tobacco seed cost</td><td>$0.001/seed</td></tr><tr><td>Age at infiltration</td><td>4 weeks</td></tr><tr><td>Total number of plant batches in inventory</td><td>5 batches (just seeded, 1 wk old, 2 wk old, 3 wk old, 4 wk old—ready to infiltrate, 5 wk old—infiltrated, incubated and ready to harvest)</td></tr><tr><td>Total number of plants in inventory</td><td>~1.3 million</td></tr><tr><td>Total plant growth area</td><td>83,320 ft<sup>2</sup> total, or 10 levels with 8,332 ft<sup>2</sup> footprint</td></tr><tr><td>LED fixture costs</td><td>$40/ft<sup>2</sup> plant growth area (including capital cost factors for plant growth area as shown in Table 2)</td></tr><tr><td>LED energy costs</td><td>20 W/ft<sup>2</sup></td></tr><tr><td colspan="2">Assumptions for <i>Agrobacterium</i> production, vacuum infiltration, and plant incubation section</td></tr><tr><td>Agro “loading”—mass of recombinant <i>Agrobacterium</i> to mass of plant tissue</td><td>0.00001 kg dry weight (dw) bacteria/kg FW plant biomass</td></tr><tr><td><i>Agrobacterium</i> biomass density at 12 hours of culture</td><td>2.6 g dw/L = 0.0026 kg dw/L</td></tr><tr><td>Inoculum density used in seed train</td><td>1% V/V</td></tr><tr><td>Dilution factor between agroinfiltration solution and agrobacterial production fermentor</td><td>78</td></tr><tr><td>Percent weight change in plant tissue following vacuum agroinfiltration</td><td>30%</td></tr><tr><td>Trays processed per vacuum chamber (30 ft) per day</td><td>336 trays/chamber/day</td></tr><tr><td>“Excess” <i>Agrobacterium</i> solution used</td><td>87% of total infiltration solution</td></tr><tr><td>Incubation time for infiltrated plants</td><td>~7 days</td></tr><tr><td colspan="2">Assumptions for the rBuChE recovery and purification section</td></tr><tr><td>Overall yield in downstream processes</td><td>20%</td></tr><tr><td>Harvesting rate</td><td>3 trays/minute</td></tr><tr><td>IEX chromatography</td><td> </td></tr><tr><td> Binding capacity</td><td>20 mg/mL</td></tr><tr><td> Resin cost</td><td>$1,839/L</td></tr><tr><td> Number of reuse cycles</td><td>100</td></tr><tr><td>Affinity chromatography</td><td> </td></tr><tr><td> Binding capacity</td><td>3 mg/mL</td></tr><tr><td> Resin cost</td><td>$10,000/L</td></tr><tr><td> Number of reuse cycles</td><td>30</td></tr></table> |
28f5486beb4f5dbe37d3f68cbf4934ebe12b2bfd6fb6d271ee758b7fe7a275ed.png | complex | <table><tr><td> </td><td>Overall</td><td colspan="3">Ability to access to NSP syringes<sup>‡</sup></td><td>χ<sup>2</sup>-test</td><td colspan="3">Venue stratification</td><td>χ<sup>2</sup>-test</td></tr><tr><td> </td><td> </td><td><40%</td><td>40-70%</td><td>>70%</td><td>(χ<sup>2</sup>, <i>p</i>-value)</td><td>MDC</td><td>Community</td><td>NSP</td><td>(χ<sup>2</sup>, <i>p </i>value)</td></tr><tr><td> </td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td> </td><td>N (%)</td><td>N (%)</td><td>N (%)</td><td> </td></tr><tr><td colspan="10">Used drugs in the last 30 days (n = 402)*</td></tr><tr><td><i>Yes</i></td><td>398 (99.0)</td><td>139 (97.9)</td><td>55 (100)</td><td>204 (99.5)</td><td> </td><td>74 (94.9)</td><td>171 (100)</td><td>153 (100)</td><td> </td></tr><tr><td><i>No</i></td><td>4 (1.0)</td><td>3 (2.1)</td><td>0 (0)</td><td>1 (0.5)</td><td>2.89, p = 0.236</td><td>4 (5.1)</td><td>0 (0)</td><td>0 (0)</td><td>16.782, p < 0.001†</td></tr><tr><td colspan="10">Frequency of injecting drugs in the last 30 days (n = 392)</td></tr><tr><td><i><1 times / day</i></td><td>41 (10.5)</td><td>12 (8.8)</td><td>4 (7.4)</td><td>25 (12.4)</td><td> </td><td>7 (9.6)</td><td>19 (11.1)</td><td>15 (10.1)</td><td> </td></tr><tr><td><i>1-2 times / day</i></td><td>220 (56.1)</td><td>68 (50.0)</td><td>21 (38.9)</td><td>131 (64.9)</td><td> </td><td>37 (50.7)</td><td>109 (63.7)</td><td>74 (50.0)</td><td> </td></tr><tr><td><i>3-5 times / day</i></td><td>115 (29.3)</td><td>46 (33.8)</td><td>28 (51.9)</td><td>41 (20.3)</td><td> </td><td>22 (30.1)</td><td>39 (22.8)</td><td>54 (36.5)</td><td> </td></tr><tr><td><i>>6 times / day</i></td><td>16 (4.1)</td><td>10 (7.4)</td><td>1 (1.9)</td><td>5 (2.5)</td><td>29.439, p < 0.001†</td><td>7 (9.6)</td><td>4 (2.3)</td><td>5 (3.4)</td><td>15.236, p = 0.019†</td></tr><tr><td colspan="10">Times of repeated use per needle/syringe before disposal in the last 30 days (n = 389)</td></tr><tr><td><i>0</i></td><td>4 (1.0)</td><td>0 (0)</td><td>3 (5.9)</td><td>1 (0.5)</td><td> </td><td>0 (0)</td><td>0 (0)</td><td>4 (2.7)</td><td> </td></tr><tr><td><i>1</i></td><td>248 (63.8)</td><td>81 (58.7)</td><td>26 (51.0)</td><td>141 (70.5)</td><td> </td><td>49 (66.2)</td><td>111 (65.7)</td><td>88 (60.3)</td><td> </td></tr><tr><td><i>2-5</i></td><td>131 (33.7)</td><td>54 (39.1)</td><td>22 (43.1)</td><td>55 (27.5)</td><td> </td><td>21 (28.4)</td><td>57 (33.7)</td><td>53 (36.3)</td><td> </td></tr><tr><td><i>6-9</i></td><td>1 (0.3)</td><td>1 (0.7)</td><td>0 (0)</td><td>0 (0)</td><td> </td><td>1 (1.4)</td><td>0 (0)</td><td>0 (0)</td><td> </td></tr><tr><td><i>≥10</i></td><td>5 (1.3)</td><td>2 (1.4)</td><td>0 (0)</td><td>3 (1.5)</td><td>6.84, p = 0.033†</td><td>3 (4.1)</td><td>1 (0.6)</td><td>1 (0.7)</td><td>0.151, p = 0.927</td></tr><tr><td><i>Average ± SD</i></td><td>1.62 ± 1.32</td><td>1.80 ± 1.45</td><td>1.55 ± 0.86</td><td>1.52 ± 1.31</td><td> </td><td>1.93 ± 2.00</td><td>1.54 ± 1.05</td><td>1.56 ± 1.13</td><td> </td></tr><tr><td colspan="10">Shared syringes in the last 30 days (n = 400)</td></tr><tr><td>Yes</td><td>35 (8.8)</td><td>23 (16.3)</td><td>7 (12.7)</td><td>5 (2.5)</td><td> </td><td>15 (19.5)</td><td>4 (2.3)</td><td>16 (10.5)</td><td> </td></tr><tr><td>No</td><td>365 (91.2)</td><td>118 (83.7)</td><td>48 (87.3)</td><td>199 (97.5)</td><td>21.326, p < 0.001†</td><td>62 (80.5)</td><td>167 (97.7)</td><td>136 (89.5)</td><td>20.507, p < 0.001†</td></tr><tr><td colspan="10">Number of times shared syringes in the last 30 days (n = 29)</td></tr><tr><td><i>1</i></td><td>10 (34.5)</td><td>9 (45.0)</td><td>1 (16.7)</td><td>0 (0)</td><td> </td><td>8 (66.7)</td><td>0 (0)</td><td>2 (15.4)</td><td> </td></tr><tr><td><i>2-5</i></td><td>16 (55.2)</td><td>9 (45.0)</td><td>5 (83.3)</td><td>2 (66.7)</td><td> </td><td>4 (33.3)</td><td>3 (75.0)</td><td>9 (69.2)</td><td> </td></tr><tr><td><i>≥6</i></td><td>3 (10.3)</td><td>2 (10.0)</td><td>0 (0)</td><td>1 (33.3)</td><td>4.83, p = 0.090</td><td>0 (0)</td><td>1 (25.0)</td><td>2 (15.4)</td><td>5.780, p = 0.056</td></tr><tr><td><i>Average ± SD</i></td><td>4.28 ± 6.85</td><td>4.15 ± 7.37</td><td>2.17 ± 0.98</td><td>9.33 ± 9.29</td><td> </td><td>1.55 ± 0.93</td><td>6.75 ± 8.85</td><td>5.92 ± 8.78</td><td> </td></tr><tr><td colspan="10">Number of sharing partners in the last 30 days (n = 31)</td></tr><tr><td><i>1</i></td><td>10 (31.3)</td><td>5 (22.7)</td><td>5 (71.4)</td><td>0 (0)</td><td> </td><td>4 (28.6)</td><td>1 (25.0)</td><td>5 (35.7)</td><td> </td></tr><tr><td><i>2-5</i></td><td>20 (62.5)</td><td>15 (68.3)</td><td>2 (28.6)</td><td>3 (100)</td><td> </td><td>9 (64.3)</td><td>3 (75.0)</td><td>8 (57.1)</td><td> </td></tr><tr><td><i>6-9</i></td><td>1 (3.1)</td><td>1 (4.5)</td><td>0 (0)</td><td>0 (0)</td><td> </td><td>0 (0)</td><td>0 (0)</td><td>1 (7.1)</td><td> </td></tr><tr><td><i>≥10</i></td><td>1 (3.1)</td><td>1 (4.5)</td><td>0 (0)</td><td>0 (0)</td><td>6.73, p = 0.035†</td><td>1 (7.1%)</td><td>0 (0)</td><td>0 (0)</td><td>0.594, p = 0.743</td></tr><tr><td><i>Average ± SD</i></td><td>2.53 ± 1.98</td><td>2.82 ± 2.26</td><td>1.43 ± 0.79</td><td>3.00 ± 0.0</td><td> </td><td>2.64 ± 2.50</td><td>2.25 ± 0.96</td><td>2.85 ± 1.99</td><td> </td></tr><tr><td colspan="10">Maximum number of group sharing partners in the last 30 days (n = 32)</td></tr><tr><td><i>1</i></td><td>2 (6.3)</td><td>1 (4.5)</td><td>1 (14.3)</td><td>0 (0)</td><td> </td><td>1 (7.1)</td><td>0 (0)</td><td>1 (7.1)</td><td> </td></tr><tr><td><i>2-5</i></td><td>28 (87.5)</td><td>20 (90.9)</td><td>5 (71.4)</td><td>3 (100)</td><td> </td><td>13 (92.9)</td><td>4 (100)</td><td>11 (78.6)</td><td> </td></tr><tr><td><i>6-9</i></td><td>2 (6.3)</td><td>1 (4.5)</td><td>1 (14.3)</td><td>0 (0)</td><td>3.19, p = 0.203</td><td>0 (0)</td><td>0 (0)</td><td>2 (14.3)</td><td>0.867, p = 0.648</td></tr><tr><td><i>Average ± SD</i></td><td>2.94 ± 1.68</td><td>2.86 ± 1.42</td><td>3.00 ± 2.71</td><td>3.33 ± 0.58</td><td> </td><td>2.50 ± 0.76</td><td>2.50 ± 0.58</td><td>3.50 ± 2.35</td><td> </td></tr></table> |
1d0da38fa8ed4bb2af7166d5439f9faafcff1851c005892414764c6e34f78dd5.png | simple | <table><tr><td>Feature</td><td>Restenosis group (<i>n</i> = 74)</td><td>Non-restenosis group (<i>n</i> = 91)</td><td><i>P</i></td></tr><tr><td>Age (years)</td><td>65.4 ± 8.6</td><td>64.7 ± 8.0</td><td>0.583</td></tr><tr><td>Male, n (%)</td><td>52 (70.2)</td><td>60 (65.9)</td><td>0.553</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td>24.8 ± 3.6</td><td>24.1 ± 3.2</td><td>0.184</td></tr><tr><td>Hypertension, n (%)</td><td>19 (25.7)</td><td>22 (24.2)</td><td>0.825</td></tr><tr><td>Hyperlipidemia, n (%)</td><td>15 (20.3)</td><td>17 (18.7)</td><td>0.797</td></tr><tr><td>Renal dysfunction, n (%)</td><td>10 (13.5)</td><td>11 (12.1)</td><td>0.785</td></tr><tr><td>Diabetes, n (%)</td><td>21 (28.4)</td><td>6 (6.6)</td><td><0.001</td></tr><tr><td>Smoking, n (%)</td><td>59 (79.7)</td><td>27 (29.7)</td><td><0.001</td></tr><tr><td>Drinking, n (%)</td><td>33 (44.6)</td><td>40 (44.0)</td><td>0.935</td></tr><tr><td>SBP (mmHg)</td><td>137.8 ± 22.3</td><td>133.6 ± 21.5</td><td>0.221</td></tr><tr><td>DBP (mmHg)</td><td>73.4 ± 9.8</td><td>72.6 ± 7.7</td><td>0.558</td></tr><tr><td>HDL-C (mmol/L)</td><td>1.1 ± 0.3</td><td>1.2 ± 0.3</td><td>0.177</td></tr><tr><td>LDL-C (mmol/L)</td><td>3.0 ± 0.5</td><td>2.5 ± 0.3</td><td><0.001</td></tr><tr><td>Blood sugar, (mmol/L)</td><td>6.3 ± 2.0</td><td>5.4 ± 1.8</td><td><0.001</td></tr><tr><td>Stent mean diameter (mm)</td><td>7.4 ± 1.0</td><td>6.6 ± 1.0</td><td><0.001</td></tr></table> |
47eedd638e9a585e91b228d6842abe9d33a28d4ffde920d9904063deddaf591e.png | simple | <table><tr><td></td><td>With SD (n = 165)</td><td>Without SD (n = 35)</td><td>P</td></tr><tr><td></td><td>No (%)</td><td>No (%)</td><td></td></tr><tr><td>Gender (n = 200)</td><td></td><td></td><td>0.04</td></tr><tr><td>Women (n = 100)</td><td>88 (88.0)</td><td>12 (12.0)</td><td></td></tr><tr><td>Men (n = 100)</td><td>77 (77.0)</td><td>23 (23.0)</td><td></td></tr><tr><td>Age groups (years)</td><td></td><td></td><td>0.13</td></tr><tr><td>30-39</td><td>15(68.2)</td><td>7(31.8)</td><td></td></tr><tr><td>40-49</td><td>74(82.2)</td><td>16(17.8)</td><td></td></tr><tr><td>50-59</td><td>76(86.4)</td><td>12(13.6)</td><td></td></tr><tr><td>Diabetes status</td><td></td><td></td><td>0.35</td></tr><tr><td>Controlled</td><td>80(80.0)</td><td>20(20.0)</td><td></td></tr><tr><td>Uncontrolled</td><td>85(85.0)</td><td>15(15.0)</td><td></td></tr><tr><td>Duration of diabetes (years)</td><td></td><td></td><td>0.64</td></tr><tr><td>10-14</td><td>130(81.2)</td><td>30(18.8)</td><td></td></tr><tr><td>15-19</td><td>27(87.1)</td><td>4(12.9)</td><td></td></tr><tr><td>20-25</td><td>8(88.8)</td><td>1(11.2)</td><td></td></tr><tr><td>Hypertension</td><td></td><td></td><td>0.31</td></tr><tr><td>Yes</td><td>19(90.5)</td><td>2(9.5)</td><td></td></tr><tr><td>No</td><td>146(81.6)</td><td>33(18.4)</td><td></td></tr><tr><td>Type of diabetes</td><td></td><td></td><td>0.04*</td></tr><tr><td>Type 1</td><td>18 (100.0)</td><td>0.00</td><td></td></tr><tr><td>Type 2</td><td>147(80.8)</td><td>35(19.2)</td><td></td></tr></table> |
69394e9c10d41c487bc8341b9e43a56e99b0c2239b96237efefadb8edd7e4bde.png | simple | <table><tr><td></td><td>Value</td><td>Alternative Indicator</td></tr><tr><td>Waist circumference</td><td>* >94 cm in males, >80 cm in females** >102 cm in males, >88 cm in females</td><td></td></tr><tr><td>Raised blood pressure</td><td>Systolic ≥130 and/or diastolic ≥85 mm Hg</td><td>Treatment of previously diagnosed hypertension</td></tr><tr><td>Raised FPG</td><td>≥100 mg/dL (5.6 mmol/L)</td><td>Previously diagnosed of T2DM</td></tr><tr><td>Raised TG</td><td>>150 mg/dL (1.7 mmol/L)</td><td>Specific pharmacological treatment</td></tr><tr><td>Reduced HDL-C</td><td><40 mg/dL (1.0 mmol/L) in males<50 mg/dL (1.3 mmol/L) in females</td><td>Specific pharmacological treatment</td></tr></table> |
fcd47c531dda31a37cb1a01ab9f871a7db5d31a2d1a036c11fc0dad8f4b818d3.png | simple | <table><tr><td>Probe Set</td><td>z-score</td><td>DMFS</td><td>Gene Symbol</td><td>Gene Title</td></tr><tr><td>208905_at</td><td>4.29</td><td>-</td><td>CYCS</td><td>cytochrome c, somatic</td></tr><tr><td>204817_at</td><td>3.73</td><td>-</td><td>ESPL1</td><td>extra spindle poles like 1</td></tr><tr><td>38158_at</td><td>3.41</td><td>-</td><td>ESPL1</td><td>extra spindle poles like 1</td></tr><tr><td>204947_at</td><td>3.04</td><td>-</td><td>E2F1</td><td>E2F transcription factor 1</td></tr><tr><td>201111_at</td><td>3.04</td><td>-</td><td>CSE1L</td><td>CSE1 chromosome segregation 1-like</td></tr><tr><td>201636_at</td><td>2.97</td><td>-</td><td>FXR1</td><td>fragile X mental retardation, autosomal homolog 1</td></tr><tr><td>220048_at</td><td>2.82</td><td>-</td><td>EDAR</td><td>ectodysplasin A receptor</td></tr><tr><td>210766_s_at</td><td>2.75</td><td>-</td><td>CSE1L</td><td>CSE1 chromosome segregation 1-like</td></tr><tr><td>221567_at</td><td>2.66</td><td>-</td><td>NOL3</td><td>nucleolar protein 3 (apoptosis repressor with CARD domain)</td></tr><tr><td>213829_x_at</td><td>2.65</td><td>-</td><td>TNFRSF6B</td><td>tumor necrosis factor receptor superfamily, member 6b, decoy</td></tr><tr><td>201112_s_at</td><td>2.57</td><td>-</td><td>CSE1L</td><td>CSE1 chromosome segregation 1-like</td></tr><tr><td>212353_at</td><td>2.51</td><td>-</td><td>SULF1</td><td>sulfatase 1</td></tr><tr><td>208822_s_at</td><td>2.47</td><td>-</td><td>DAP3</td><td>death associated protein 3</td></tr><tr><td>209462_at</td><td>2.37</td><td>-</td><td>APLP1</td><td>amyloid beta (A4) precursor-like protein 1</td></tr><tr><td>203005_at</td><td>2.29</td><td>-</td><td>LTBR</td><td>lymphotoxin beta receptor (TNFR superfamily, member 3)</td></tr><tr><td>202731_at</td><td>4.01</td><td>+</td><td>PDCD4</td><td>programmed cell death 4</td></tr><tr><td>206150_at</td><td>3.57</td><td>+</td><td>TNFRSF7</td><td>tumor necrosis factor receptor superfamily, member 7</td></tr><tr><td>202730_s_at</td><td>3.18</td><td>+</td><td>PDCD4</td><td>programmed cell death 4</td></tr><tr><td>209539_at</td><td>3.14</td><td>+</td><td>ARHGEF6</td><td>Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6</td></tr><tr><td>212593_s_at</td><td>3.07</td><td>+</td><td>PDCD4</td><td>programmed cell death 4</td></tr><tr><td>204933_s_at</td><td>2.96</td><td>+</td><td>TNFRSF11B</td><td>tumor necrosis factor receptor superfamily, member 11b</td></tr><tr><td>209831_x_at</td><td>2.43</td><td>+</td><td>DNASE2</td><td>deoxyribonuclease II, lysosomal</td></tr><tr><td>203187_at</td><td>2.38</td><td>+</td><td>DOCK1</td><td>dedicator of cytokinesis 1</td></tr><tr><td>210164_at</td><td>2.34</td><td>+</td><td>GZMB</td><td>granzyme B</td></tr></table> |
c4145e619e195616d7c6febb6a55d4199e867d03e4d4935586d89106d50b1623.png | simple | <table><tr><td></td><td>Connecticut (n = 631 visits) %</td><td>Washington (n = 1186 visits) %</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td> female</td><td>76</td><td>74</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td> Median</td><td>43 years</td><td>42 years</td></tr><tr><td> 0–15 years</td><td>12.8</td><td>10.9</td></tr><tr><td> 16–34 years</td><td>16.4</td><td>20.9</td></tr><tr><td> 35–64 years</td><td>63.0</td><td>58.5</td></tr><tr><td> 65 years+</td><td>7.8</td><td>9.7</td></tr><tr><td>Race</td><td></td><td></td></tr><tr><td> White</td><td>97</td><td>96</td></tr><tr><td>Smoking status:</td><td></td><td></td></tr><tr><td> non-smokers</td><td>95</td><td>94</td></tr><tr><td>Type of major problem<sup>a</sup></td><td></td><td></td></tr><tr><td> Acute problem</td><td>22</td><td>23</td></tr><tr><td> Chronic problem, routine</td><td>53</td><td>56</td></tr><tr><td> Chronic problem, flare up</td><td>20</td><td>18</td></tr><tr><td> Pre/post-surgery/injury</td><td>1</td><td>1</td></tr><tr><td> Non-illness care</td><td>5</td><td>6</td></tr><tr><td>Primary reason for visit<sup>b</sup></td><td></td><td></td></tr><tr><td> Fatigue</td><td>6.1</td><td>6.0</td></tr><tr><td> Headache</td><td>4.4</td><td>3.8</td></tr><tr><td> Back symptoms</td><td>4.4</td><td>6.5</td></tr><tr><td> Skin rashes</td><td>4.2</td><td>2.5</td></tr><tr><td> Menopausal symptoms</td><td>3.7</td><td>2.0</td></tr><tr><td> Bowel function changes</td><td>3.5</td><td>2.0</td></tr><tr><td> Anxiety or Depression</td><td>3.2</td><td>5.1</td></tr><tr><td> Allergies to food, milk</td><td>3.0</td><td>3.6</td></tr><tr><td> Sinus symptoms</td><td>2.8</td><td><2</td></tr><tr><td> Upper respiratory symptoms</td><td>2.6</td><td><2</td></tr><tr><td> Cough</td><td>2.4</td><td><2</td></tr><tr><td> Neck symptoms</td><td>2.3</td><td>3.3</td></tr><tr><td> Infectious disease</td><td>2.2</td><td><2</td></tr><tr><td> Ear infection symptoms</td><td>2.2</td><td><2</td></tr><tr><td> Abdominal pain/cramps</td><td>2.2</td><td>2.7</td></tr><tr><td> Menstrual problems</td><td><2</td><td>2.1</td></tr><tr><td>Diagnosis by naturopathic physician<sup>c</sup></td><td></td><td></td></tr><tr><td> Menopausal disorders</td><td>4.9</td><td>3.1</td></tr><tr><td> Allergies</td><td>4.6</td><td>6.3</td></tr><tr><td> Back conditions</td><td>3.5</td><td>5.8</td></tr><tr><td> Fibromyalgia</td><td>3.0</td><td>2.0</td></tr><tr><td> Sinusitis</td><td>2.9</td><td><2</td></tr><tr><td> Fatigue</td><td>2.4</td><td>2.7</td></tr><tr><td> Headache</td><td>2.2</td><td>3.1</td></tr><tr><td> Upper respiratory infections</td><td>2.0</td><td><2</td></tr><tr><td> Neck conditions</td><td><2</td><td>3.3</td></tr><tr><td> Depression</td><td><2</td><td>2.6</td></tr><tr><td> Asthma</td><td><2</td><td>2.2</td></tr><tr><td> Anxiety</td><td><2</td><td>2.1</td></tr><tr><td> Dermatitis</td><td><2</td><td>2.0</td></tr><tr><td>New patients</td><td>22</td><td>22</td></tr><tr><td>Payment</td><td></td><td></td></tr><tr><td> Private insurance</td><td>60</td><td>43</td></tr><tr><td> Worker's compensation</td><td>0</td><td>3</td></tr><tr><td> Personal injury</td><td>0</td><td>3</td></tr><tr><td> Self-pay</td><td>37</td><td>48</td></tr><tr><td> Other</td><td>3</td><td>3</td></tr></table> |
e1bfc751d4dea106864d43fe1704093bb68ffcb18f09a74c7109c7d15ef0b9a1.png | simple | <table><tr><td>Scopus</td><td>Query</td><td>Research in:</td><td>Items found</td></tr><tr><td>#1</td><td>“Sensory integration” OR “multisensory integration” OR “crossmodal integration” OR “cross-modal integration” OR “intersensory integration” OR “multimodal integration” OR “crossmodal illusion*” OR “cross-modal illusion*” OR multisensory OR crossmodal OR cross-modal OR “crossmodal sensory integration” OR “cross-modal sensory integration” OR “multisensory interaction*”</td><td>Article Title, Abstract, Keywords</td><td>11,005</td></tr><tr><td>#2</td><td>Measurement* OR Test* OR performance OR assessment* OR “Test development” OR “task performance” OR “disability evaluation” OR “Feasibility studies” OR validity OR reliability OR study* OR results*</td><td>Article Title, Abstract, Keywords</td><td>14,411,633</td></tr><tr><td>#3</td><td>Combine #1 AND #2</td><td></td><td>5127</td></tr><tr><td>#4</td><td>Limit to (Humans OR human) AND (Limit to (DOCTYPE, article))</td><td></td><td>3241</td></tr><tr><td>#5</td><td>Limit to (“aged”, “aging”)</td><td></td><td>394</td></tr><tr><td>#6</td><td>Exclude (“Speech perception”, “Speech Perception”, “Speech”)</td><td></td><td>351</td></tr><tr><td>#7</td><td>Exclude (“Alzheimer Disease”, “Alzheimer disease”, “Parkinson Disease”, “Parkinson disease”, “Aphasia”, “Dementia”, “Disease severity”, “Brain damage”, “Brain injury”, “Stroke”, “Neglect”, “Brain damage, chronic”, “Cerebrovascular accident”, “Cognition disorders”, “Neurologic disease”, “Schizophrenia”)</td><td></td><td>308</td></tr></table> |
38f717e25ed2cf4c9e67361dd1e8916a2b42fae69be3eb88329b1b93c2b9f63f.png | complex | <table><tr><td>Therapeutic Strategy</td><td>Gene/System</td><td>Strong Points</td><td>Weak Points</td></tr><tr><td rowspan="2">Tumor Suppressor gene</td><td><i>p53</i></td><td>Altered gene in a high percentage of OC.The use of Gendicine (a recombinant human Ad-p53) has been approved in the treatment of OC in China. Several clinical trials are currently ongoing.</td><td>Not useful in cells with a normal <i>p53</i> gene.No therapeutic benefit in the first clinical trials due to the use of a wrong delivery system.</td></tr><tr><td><i>WWOX</i></td><td>Promising results in vivoInhibition of proliferation and promotion of apoptosis in OCSC.</td><td>It has not been evaluated in clinical trials in OC.</td></tr><tr><td rowspan="2">Oncofactor inhibition strategies</td><td><i>EGFR</i></td><td>Gene widely studied in cancer.Its use increases the sensitivity to chemotherapy</td><td>It has not been evaluated in vivo or in clinical trials in OC.</td></tr><tr><td>CLDN3</td><td>Several strategies of silencing have been studied in OC (siRNA and shRNA).Promising results in vivo, with inhibition of malignant ascites formation.</td><td>It has not been evaluated in clinical trials in OC.</td></tr><tr><td rowspan="2">Suicide gene therapy</td><td>HVS-TK</td><td>Strategy widely studied in gene therapy for cancer.Several clinical trials are currently ongoing.Promising results in vivo and in clinical trials.Bystander effect.</td><td>Not phase 2 or 3 clinical trials published.</td></tr><tr><td>DT-A</td><td>Promising results in vivo, with minimal cytotoxicity.</td><td>It has not been evaluated in clinical trials in OC.</td></tr><tr><td rowspan="2">Antiangiogenic gene therapy</td><td>VEGFRs</td><td>Promising results in vivo, with inhibition of ascities formation.Synergist effect in combination with chemotherapy.</td><td>It has not been evaluated in clinical trials in OC.The work showed increased proliferation of tumour cells with the use of VEGFR2 and Ti2 in combination with PTX and carboplatin.</td></tr><tr><td>Endostatin</td><td>Promising results in vivo.Clinical trials have been carried out in other types of cancer.</td><td>Transient expression due to humoral immune response if adenovirus is used as delivery system.It has not been evaluated in clinical trials in OC.</td></tr><tr><td rowspan="2">Genetic immunopotentiation</td><td>IL-12</td><td>Potent immune-modulatory properties and ability to inhibit tumour angiogenesis.Promising results in vivo.Several clinical trials are currently ongoing or have been completed.It has showed to be safe and feasible in phase I trials.</td><td>Poor clinical benefits in the completed phase II trial.</td></tr><tr><td>CAR-T cell</td><td>Possibility of target any specific tumour antigen.Promising preliminary results in clinical trials in OC.</td><td>Important side effects caused in patients.</td></tr><tr><td rowspan="2">Multi-Drug Resistance</td><td><i>MDR1</i></td><td>Several strategies have been developed to knockdown it.Its silencing enhances sensitivity to anticancer drugs.Promising results in vivo.</td><td>It has not been evaluated in clinical trials in OC.</td></tr><tr><td><i>Survivin</i></td><td>Several strategies targeting this gene have been developed, including combined therapy with anticancer drugs. Promising results in vivo.</td><td>It has not been evaluated in clinical trials in OC.</td></tr><tr><td>Oncolytic virotherapy</td><td>VSV</td><td>Can be genetically designed to deliver therapeutic genes.A phase I trial is currently ongoing.</td><td>Neurotoxicity and Induction of neutralizing antibodies.IFN response intact in most OC cells, blocking virus replication.</td></tr></table> |
69efdeace0f8923c2e247b7ef9db5c271c07b0230a864b94e0afb11b0d2abe6d.png | simple | <table><tr><td>RGB Only</td><td>NIR Only</td><td>Early Fusion</td><td>Late Fusion</td></tr><tr><td>0.816</td><td>0.797</td><td>0.799</td><td>0.838</td></tr></table> |
7f5492d22de3bf1389bc6ad2c91f5566ba0b2485ff60347e705afb242a476fd4.png | complex | <table><tr><td rowspan="2" colspan="2">Physical activity in leisure time (hours per week)</td><td rowspan="2"></td><td colspan="2">Women</td><td colspan="2">Men</td></tr><tr><td>Adjustment for age</td><td>Additional adjustment<sup>a</sup></td><td>Adjustment for age</td><td>Additional adjustment<sup>a</sup></td></tr><tr><td colspan="2"></td><td>Total</td><td>9616</td><td>9199</td><td>8452</td><td>8130</td></tr><tr><td>Light</td><td>Hard</td><td>Score</td><td>RR (95 % CI)</td><td>RR (95 % CI)</td><td>RR (95 % CI)</td><td>RR (95 % CI)</td></tr><tr><td><1</td><td>0</td><td>1</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td><td>1.00 (reference)</td></tr><tr><td>≥1</td><td>0</td><td>2</td><td>0.94 (0.83–1.05)</td><td>0.97 (0.86–1.09)</td><td>0.96 (0.82–1.13)</td><td>1.03 (0.87–1.21)</td></tr><tr><td></td><td><1<sup>b</sup></td><td>3</td><td>0.92 (0.81–1.05)</td><td>0.99 (0.87–1.13)</td><td>0.88 (0.75–1.03)</td><td>0.96 (0.82–1.14)</td></tr><tr><td></td><td>1–2</td><td>4</td><td>0.81 (0.71–0.93)</td><td>0.89 (0.77–1.03)</td><td>0.71 (0.60–0.85)</td><td>0.81 (0.68–0.97)</td></tr><tr><td></td><td>≥3</td><td>5</td><td>0.94 (0.77–1.14)</td><td>1.05 (0.86–1.27)</td><td>0.85 (0.70–1.03)</td><td>0.96 (0.79–1.17)</td></tr><tr><td colspan="3"><i>P,</i> categorical effect</td><td>0.045</td><td>0.36</td><td>0.001</td><td>0.06</td></tr><tr><td colspan="3"><i>P</i>, linear effect<sup>c</sup></td><td>0.016</td><td>0.46</td><td>0.001</td><td>0.07</td></tr><tr><td colspan="3"><i>P</i>, quadratic effect<sup>d</sup></td><td>0.39</td><td>0.56</td><td>0.33</td><td>0.69</td></tr></table> |
a745fd450fa951612865d068f9ee91554b4ec3e93ead84e03141709e5632b762.png | simple | <table><tr><td>Material</td><td><i>E</i><sup>1/3</sup>/<i>ρ</i> (GPa<sup>1/3</sup>/(Mg/m<sup>3</sup>))</td><td><i>η</i></td></tr><tr><td>Cast iron</td><td>0.63</td><td>1.2 × 10<sup>−3</sup>–1.7 × 10<sup>−3</sup></td></tr><tr><td>Steel</td><td>0.77</td><td>6.0 × 10<sup>−4</sup>–1.0 × 10<sup>−3</sup></td></tr><tr><td>Al alloys</td><td>1.50</td><td>2.0 × 10<sup>−4</sup>–4.0 × 10<sup>−4</sup></td></tr><tr><td>Mg alloys</td><td>1.90</td><td>1.0 × 10<sup>−3</sup>–1.0 × 10<sup>−2</sup></td></tr><tr><td>Al corrugated sandwich</td><td>2.52</td><td>1.0 × 10<sup>−3</sup>–1.0 × 10<sup>−2</sup></td></tr><tr><td>Al foams</td><td>2.67</td><td>4.0 × 10<sup>−3</sup>–1.0 × 10<sup>−2</sup></td></tr><tr><td>CFRP (unidirectional)</td><td>4.00</td><td>1.5 × 10<sup>−3</sup>–3.0 × 10<sup>−3</sup></td></tr></table> |
c65ebf8c337e0486a864fa1ea1fc968b60ff4b62e44b85a4a2af0932623d262f.png | complex | <table><tr><td></td><td colspan="6">Lactate (μm)</td></tr><tr><td></td><td colspan="3">d-Lactate</td><td colspan="3">l-lactate</td></tr><tr><td>Cell line</td><td>Plus methylglyoxal</td><td>Minus methylglyoxal</td><td>Net</td><td>Plus methylglyoxal</td><td>Minus methylglyoxal</td><td>Net</td></tr><tr><td colspan="7"><i>T. brucei</i></td></tr><tr><td>Procyclics</td><td>22 ± 3</td><td>10 ± 2</td><td>12</td><td>148 ± 7</td><td>24 ± 3</td><td>124</td></tr><tr><td>Bloodstream forms</td><td>68 ± 9</td><td>50 ± 2</td><td>18</td><td>355 ± 42</td><td>134 ± 18</td><td>221</td></tr><tr><td colspan="7">pLew100–luciferase</td></tr><tr><td>Procyclics</td><td>17 ± 2</td><td>9 ± 1</td><td>8</td><td>134 ± 12</td><td>19 ± 2</td><td>115</td></tr><tr><td>Bloodstream forms</td><td>59 ± 2</td><td>48 ± 3</td><td>11</td><td>329 ± 26</td><td>118 ± 21</td><td>211</td></tr><tr><td colspan="7">pLew100–<i>Tc</i>GLO1</td></tr><tr><td>Procyclics</td><td>57 ± 4a</td><td>19 ± 2</td><td>38</td><td>122 ± 9</td><td>22 ± 2</td><td>100</td></tr><tr><td>Bloodstream forms</td><td>183 ± 24a</td><td>71 ± 5</td><td>112</td><td>308 ± 14</td><td>105 ± 8</td><td>203</td></tr></table> |
3a5d3a40978d02331ce86e1204c1e73c4695937fbebc3972bd22a02c34deb0bf.png | simple | <table><tr><td>Characteristics</td><td>Study group (N= 19)</td><td>Control group (N= 19)</td><td>p-value</td></tr><tr><td>Fertilization rate</td><td>95.33%</td><td>84.4%</td><td>0.11</td></tr><tr><td>cleavage rate</td><td>89.56%</td><td>87.74%</td><td>0.76</td></tr><tr><td>Implantation rate</td><td>17.64%</td><td>7.4%</td><td>0.14</td></tr><tr><td>Chemical pregnancy rate/cycle [n (%)]</td><td>8 (47.1%)</td><td>3 (16.7%)</td><td>0.07</td></tr><tr><td>Clinical pregnancy rate/cycle [n (%)]</td><td>7 (41.2%)</td><td>3 (16.7%)</td><td>0.14</td></tr><tr><td>Ongoing pregnancy rate [n (%)]</td><td>6 (85.7%)</td><td>3 (100%)</td><td>1</td></tr><tr><td>Clinical abortion rate [n (%)]</td><td>2 (11.8%)</td><td>0 (0%)</td><td>0.22</td></tr></table> |
6918aa5a82dc792efdfad299daf756e956cdb4a33e9dac8e8096357549aa5826.png | simple | <table><tr><td> </td><td>Brightness</td><td>Contrast</td><td>Entropy</td><td>Clarity</td></tr><tr><td>Original image</td><td>57.15</td><td>311.36</td><td>6.29</td><td>38.21</td></tr><tr><td>IEABPM</td><td>77.42</td><td>441.67</td><td>10.18</td><td>59.83</td></tr><tr><td>IIEABPM</td><td>79.26</td><td>487.82</td><td>14.01</td><td>73.85</td></tr></table> |
b8a8b49c3b01d34bb4880149fed1558712d59cef87f6c4a9b2a8df557c281790.png | complex | <table><tr><td></td><td colspan="2">Sex (n)</td><td colspan="2">Age (years)</td><td colspan="2">Side (n)</td></tr><tr><td></td><td>Female</td><td>Male</td><td>Median</td><td>Range</td><td>Right</td><td>Left</td></tr><tr><td>total</td><td>8</td><td>8</td><td>34</td><td>20–76</td><td>11</td><td>5</td></tr></table> |
ccbb20ea4422e097df276795f7c1d7d45e0d9d79df81b175ebd6cab8e7e00bf4.png | simple | <table><tr><td>Variable</td><td><i>r</i></td><td>P-value</td></tr><tr><td>Age, years</td><td>0.023</td><td>0.400</td></tr><tr><td>Gender</td><td>0.031</td><td>0.359</td></tr><tr><td>Course of disease, years</td><td>0.267</td><td>0.002</td></tr><tr><td>SBP, mmHg</td><td>0.429</td><td><0.001</td></tr><tr><td>DBP, mmHg</td><td>0.438</td><td><0.001</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>0.204</td><td>0.013</td></tr><tr><td>HbA1c, %</td><td>0.179</td><td>0.025</td></tr><tr><td>FBG, mmol/l</td><td>0.164</td><td>0.037</td></tr><tr><td>TG, mmol/l</td><td>0.208</td><td>0.011</td></tr><tr><td>TC, mmol/l</td><td>0.156</td><td>0.044</td></tr><tr><td>HDL-C, mmol/l</td><td>−0.194</td><td>0.020</td></tr><tr><td>LDL-C, mmol/l</td><td>0.193</td><td>0.021</td></tr><tr><td>VLDL-C, mmol/l</td><td>0.168</td><td>0.036</td></tr><tr><td>apoCIII, μg/ml</td><td>0.501</td><td><0.001</td></tr></table> |
6064f08e5ece8d39f4e8fed3eefaccdc118b548a55ec13ac952cabbcd2c9e078.png | simple | <table><tr><td>Concomitant conditions</td><td>Number</td><td>Percent</td></tr><tr><td>Heart disease</td><td>37</td><td>33.9</td></tr><tr><td>Current smokers</td><td>36</td><td>33.0</td></tr><tr><td>Diabetes mellitus</td><td>26</td><td>23.9</td></tr><tr><td>Osteoarthritis</td><td>24</td><td>22.0</td></tr><tr><td>Previous cancer</td><td>22</td><td>20.2</td></tr><tr><td>Peripheral arterial disease</td><td>19</td><td>17.4</td></tr><tr><td>Kidney disease</td><td>17</td><td>13.8</td></tr><tr><td>Gout/chondrocalcinosis</td><td>15</td><td>13.8</td></tr><tr><td>Alcohol abuse</td><td>13</td><td>11.9</td></tr><tr><td>Lung disease</td><td>12</td><td>11.0</td></tr><tr><td>Oral corticosteroids</td><td>10</td><td>9.2</td></tr><tr><td>Skin ulceration</td><td>10</td><td>9.2</td></tr><tr><td>Eschars</td><td>9</td><td>8.2</td></tr><tr><td>Liver disease</td><td>7</td><td>6.4</td></tr><tr><td>Rheumatoid arthritis and other inflammatory rheumatic disease</td><td>7</td><td>6.4</td></tr><tr><td>Intra-articular corticosteroids</td><td>3</td><td>2.8</td></tr><tr><td>Intravenous drug abuse</td><td>2</td><td>1.8</td></tr></table> |
5ecd26dcc204108f35cdf0bc336a447479b9c3400760d3fb3308bf25a7081d36.png | simple | <table><tr><td> </td><td>Total specimen length (cm)</td></tr><tr><td>Cook</td><td>4.73</td></tr><tr><td>Boston Scientific</td><td>2.98</td></tr><tr><td>Olympus</td><td>4.26</td></tr><tr><td>Covidien</td><td>5.07</td></tr><tr><td>Trucut</td><td>1.55</td></tr></table> |
3865ddc10901ce7361589116ca3264438bbe0b5006867ad894bebd25d76b8574.png | complex | <table><tr><td> </td><td colspan="4">Boys</td><td colspan="4">Girls</td><td rowspan="3"><i>P</i>-value</td></tr><tr><td> </td><td><i>n</i></td><td>HBP</td><td>HNBP</td><td>HT</td><td><i>n</i></td><td>HBP</td><td>HNBP</td><td>HT</td></tr><tr><td colspan="10">Fourth graders (age 9–10 years)</td></tr><tr><td> SBP</td><td>661</td><td>53 (8.0)</td><td>51 (7.7)</td><td>2 (0.3)</td><td>636</td><td>46 (7.2)</td><td>42 (6.6)</td><td>4 (0.6)</td><td>0.603</td></tr><tr><td> DBP</td><td>661</td><td>72 (10.9)</td><td>68 (10.3)</td><td>4 (0.6)</td><td>636</td><td>73 (11.5)</td><td>61 (9.6)</td><td>12 (1.9)</td><td>0.792</td></tr><tr><td> SBP and/or DBP</td><td>661</td><td>105 (15.9)</td><td>100 (15.1)</td><td>5 (0.8)</td><td>636</td><td>100 (15.8)</td><td>85 (13.4)</td><td>15 (2.4)</td><td>0.939</td></tr><tr><td colspan="10"> </td></tr><tr><td colspan="10">Seventh graders (age 12–13 years)</td></tr><tr><td> SBP</td><td>566</td><td>28 (4.9)</td><td>28 (4.9)</td><td>0 (0.0)</td><td>522</td><td>24 (4.6)</td><td>24 (4.6)</td><td>0 (0.0)</td><td>0.887</td></tr><tr><td> DBP</td><td>566</td><td>42 (7.4)</td><td>42 (7.4)</td><td>0 (0.0)</td><td>522</td><td>41 (7.9)</td><td>38 (7.3)</td><td>3 (0.6)</td><td>0.820</td></tr><tr><td> SBP and/or DBP</td><td>566</td><td>63 (11.1)</td><td>63 (11.1)</td><td>0 (0.0)</td><td>522</td><td>56 (10.8)</td><td>53 (10.2)</td><td>3 (0.6)</td><td>0.846</td></tr></table> |
c6022497e6fc4d084172f5391d3ef55815f7769306beaa580d6c1210e09eb890.png | simple | <table><tr><td>Round</td><td>Positive Selection (+)</td><td>PCR Cycles</td><td>Negative Selection (–)</td><td>PCR Cycles</td></tr><tr><td>1</td><td>Immobilized Target (IT) 24 h</td><td>9</td><td>–</td><td>–</td></tr><tr><td>2</td><td>IT 18 h</td><td>15</td><td>BSA Immobilized Negative Target (INT) 22 h</td><td>16</td></tr><tr><td>3</td><td>IT 13 h</td><td>13</td><td>BSA INT 26 h</td><td>17</td></tr><tr><td>4</td><td>IT 7 h</td><td>18</td><td>Exotoxin A INT 22 h</td><td>16</td></tr><tr><td>5</td><td>IT 3 h</td><td>11</td><td>Exotoxin A INT 26 h</td><td>15</td></tr><tr><td>6</td><td>IT 30 min</td><td>17</td><td>BSA INT 24 h</td><td>12</td></tr><tr><td>7</td><td>IT 5 min, Competitive Elution with 1 mg/mL free alpha toxin, 5 min</td><td>17</td><td>IT 5 min, Competitive Elution with 1 mg/mL free BSA, 5 min</td><td>16</td></tr><tr><td>8</td><td>IT 5 s, Competitive Elution with 1 mg/mL free alpha toxin, 5 s</td><td>15</td><td>IT 5 s, Competitive Elution with 20 μg/mL free exotoxin a, 6 h</td><td>13</td></tr><tr><td>9</td><td>IT 5 s, Competitive Elution with 10 μg/mL free alpha toxin, 5 s</td><td>12</td><td>IT 5 s, Competitive Elution with 20 μg/mL free cholera toxin, 6 h</td><td>13</td></tr><tr><td>10</td><td>IT 5 s, Competitive Elution with 5 μg/mL free alpha toxin, 5 s</td><td>12</td><td>IT 5 s, Competitive Elution with 20 μg/mL free toxin B, 6 h</td><td>13</td></tr><tr><td>11</td><td>IT 5 s, Competitive Elution with 2.5 μg/mL free alpha toxin, 5 s</td><td>19</td><td>IT 5 s, Competitive Elution with 20 μg/mL free BSA, 24 h</td><td>7</td></tr><tr><td>12</td><td>IT 5 s, Competitive Elution with 1 μg/mL free alpha toxin, 5 s</td><td>10</td><td>–</td><td>–</td></tr></table> |
9302dbc8f6ffc1a3f10b1f7a3bf8a3cf5a0202bf7275ac1b20bdc0407ca03eb7.png | simple | <table><tr><td>No. <sup>a</sup></td><td>Protein name <sup>b</sup></td><td>C<sub>d</sub><sup>c</sup></td><td>No.</td><td>Protein name</td><td>C<sub>b</sub><sup>d</sup></td><td>No.</td><td>Protein name</td><td>C<sub>c</sub><sup>e</sup></td></tr><tr><td>175</td><td>EGFR</td><td>0.411</td><td>166</td><td>PGH2</td><td>0.177</td><td>207</td><td>KPCA</td><td>0.500</td></tr><tr><td>149</td><td>ADRB1</td><td>0.404</td><td>234</td><td>PP2BA</td><td>0.109</td><td>126</td><td>MK01</td><td>0.496</td></tr><tr><td>156</td><td>BKRB2</td><td>0.404</td><td>207</td><td>KPCA</td><td>0.093</td><td>232</td><td>MK03</td><td>0.496</td></tr><tr><td>170</td><td>DRD1</td><td>0.404</td><td>252</td><td>HCD2</td><td>0.082</td><td>234</td><td>PP2BA</td><td>0.496</td></tr><tr><td>194</td><td>ACM3</td><td>0.404</td><td>126</td><td>MK01</td><td>0.082</td><td>175</td><td>EGFR</td><td>0.447</td></tr><tr><td>195</td><td>ACM2</td><td>0.404</td><td>232</td><td>MK03</td><td>0.082</td><td>149</td><td>ADRB1</td><td>0.445</td></tr><tr><td>197</td><td>ACM5</td><td>0.404</td><td>175</td><td>EGFR</td><td>0.069</td><td>156</td><td>BKRB2</td><td>0.445</td></tr><tr><td>198</td><td>ACM1</td><td>0.404</td><td>282</td><td>TYRO</td><td>0.049</td><td>170</td><td>DRD1</td><td>0.445</td></tr><tr><td>209</td><td>5HT2C</td><td>0.404</td><td>192</td><td>AOFA</td><td>0.036</td><td>194</td><td>ACM3</td><td>0.445</td></tr><tr><td>210</td><td>5HT2A</td><td>0.404</td><td>261</td><td>ADH1B</td><td>0.027</td><td>195</td><td>ACM2</td><td>0.445</td></tr></table> |
eb5e7216e4a6aeb9d7691582da5585b1657a034321f8d4a750e7c72debb34c23.png | complex | <table><tr><td></td><td colspan="3">E-learning group</td><td colspan="3">Non-e-learning group</td><td></td></tr><tr><td>n</td><td>Mean rate</td><td>SD</td><td>n</td><td>Mean rate</td><td>SD</td><td></td></tr><tr><td>Overall</td><td>151</td><td>1·24</td><td>0·26</td><td>144</td><td>1·00</td><td>0·16</td><td>a</td></tr><tr><td>Lower score group</td><td>86</td><td>1·34</td><td>0·29</td><td>80</td><td>1·03</td><td>0·18</td><td>a</td></tr><tr><td>Higher score group</td><td>65</td><td>1·19</td><td>0·14</td><td>64</td><td>1·03</td><td>0·11</td><td>a</td></tr><tr><td>Less experienced group</td><td>84</td><td>1·28</td><td>0·26</td><td>72</td><td>0·98</td><td>0·17</td><td>a</td></tr><tr><td>More experienced group</td><td>67</td><td>1·19</td><td>0·26</td><td>72</td><td>1·03</td><td>0·14</td><td>a</td></tr><tr><td>Asia-Oceania</td><td>32</td><td>1·33</td><td>0·34</td><td>30</td><td>1·05</td><td>0·17</td><td>a</td></tr><tr><td>Europe</td><td>22</td><td>1·18</td><td>0·24</td><td>21</td><td>0·94</td><td>0·23</td><td>b</td></tr><tr><td>Latin America</td><td>97</td><td>1·23</td><td>0·23</td><td>93</td><td>1·00</td><td>0·13</td><td>a</td></tr></table> |
3b97b77b764db39997b88887f069fd7d36ef3c617e201838834fe5f9707e4c1c.png | simple | <table><tr><td>Patient</td><td>Age</td><td>EGA</td><td>Parity</td><td>PMH/comorbidities</td><td>Symptoms</td><td>Outcome</td></tr><tr><td>1</td><td>37</td><td>13</td><td>G6P2122</td><td>None</td><td>Urinary retention, bilateral costo-vertebral tenderness and thick white discharge on speculum exam</td><td>Self-catheterization, Pessary</td></tr><tr><td>2</td><td>42</td><td>13</td><td>G5P3013</td><td>Infertility, LEEP, salpingectomy</td><td>Urinary retention</td><td>Self-catheterization, pessary placement</td></tr><tr><td>3</td><td>22</td><td>21</td><td>G15P5009</td><td>Multiple spontaneous abortions, clotting disorder</td><td>Urinary retention, LUQ pain, nausea</td><td>Pessary placement</td></tr></table> |
9a84fecd4ce98ec49d6c502fac4fa9376d6e6535eff5a3283b1719442223fdc9.png | simple | <table><tr><td>Dimension of Governance</td><td>What it captures -</td></tr><tr><td>Control of corruption</td><td>Perceptions of the extent to which public power is exercised for private gain, including both petty and grand forms of corruption, as well as “capture” of the state by elites and private interests</td></tr><tr><td>Government effectiveness</td><td>Perceptions of the quality of public services, the quality of the civil service and the degree of its independence from political pressures, the quality of policy formulation and implementation, and the credibility of the government’s commitment to such policies</td></tr><tr><td>Political stability</td><td>Perceptions of the likelihood that the government will be destabilized or overthrown by unconstitutional or violent means, including politically-motivated violence and terrorism</td></tr><tr><td>Regulatory quality</td><td>Perceptions of the ability of the government to formulate and implement sound policies and regulations that permit and promote private sector development</td></tr><tr><td>Rule of law</td><td>Perceptions of the extent to which agents have confidence in and abide by the rules of society, and in particular the quality of contract enforcement, property rights, the police, and the courts, as well as the likelihood of crime and violence</td></tr><tr><td>Voice and accountability</td><td>Perceptions of the extent to which a country’s citizens are able to participate in selecting their government, as well as freedom of expression, freedom of association, and a free media</td></tr></table> |
c3c48bcd85a1a5177a3ef741f3cea6339ae416adc3b6de0a72b1448f45f1f476.png | complex | <table><tr><td rowspan="2">AgeLesion</td><td colspan="2">≤ 20</td><td colspan="2">20 < age ≤ 40</td><td colspan="2">> 40</td><td rowspan="2">Fisher’sExact Test</td></tr><tr><td>Frequency</td><td>Percentage</td><td>Frequency</td><td>Percentage</td><td>Frequency</td><td>Percentage</td></tr><tr><td> Odontogenic cysts </td><td> 10 </td><td> 16.9 </td><td> 36 </td><td> 61.0 </td><td> 13 </td><td> 22.0 </td><td rowspan="4">20.62 df=4 <i>p</i>< 0.0001</td></tr><tr><td> Odontogenic tumors </td><td> 1 </td><td> 9.1 </td><td> 10 </td><td> 90.9 </td><td> 0 </td><td> 0 </td></tr><tr><td> Other lesions </td><td> 17 </td><td> 6.3 </td><td> 138 </td><td> 51.3 </td><td> 114 </td><td> 42.4 </td></tr><tr><td> Total </td><td> 28 </td><td> 8.2 </td><td> 184 </td><td> 54.2 </td><td> 127 </td><td> 37.4 </td></tr></table> |
a52c0f276b273a14ad1a6b8424887106601733310cc62e7d326ad01ecfac1bd2.png | simple | <table><tr><td>Studies</td><td>Outcomes reported</td><td>Types of participants</td></tr><tr><td>Cavallasca 2008 [16]</td><td>Stillbirth, prematurity, low for gestational age</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Huong 2006 [12]</td><td>Fetal death, pre-eclampsia, arterial occlusion, arterial and venous thrombosis, premature</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Ideguchi 2013 [17]</td><td>Stillbirth</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Luo 2015 [18]</td><td>Preterm, fetal loss</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Mecacci 2009 [19]</td><td>Preterm, low birth weight</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Paramo 2002 [11]</td><td>Fetal loss</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Muñoz Rodriguez 2000 [13]</td><td>Miscarriage, arterial and venous thrombosis, thrombocytopenia</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Tarr 2007 [14]</td><td>Fetal loss, and thrombosis</td><td>SLE versus SAPS in pregnancy</td></tr><tr><td>Ko 2011 [20]</td><td>Miscarriage, stillbirth, preterm</td><td>SLE versus SAPS in pregnancy</td></tr></table> |
b346f7725803f9cd8a9a3ab5fac49dbf2448a9e6d1dbdcbfdf90bd775265750b.png | simple | <table><tr><td><i>Patients/City and State of origin</i></td><td><i>Sex</i></td><td><i>Age</i></td><td><i>rN-Bac</i><i>OD</i></td><td><i>rN-E. coli</i><i>OD</i></td><td><i>Results<sup>1</sup></i></td><td><i>Patients/City and State of origin</i></td><td><i>Sex</i></td><td><i>Age</i></td><td><i>rN-Bac</i><i>OD</i></td><td><i>rN-E. coli</i><i>OD</i></td><td><i>Results<sup>1</sup></i></td></tr><tr><td>1-Par-SC</td><td>M</td><td>20</td><td>0.109</td><td>0.139</td><td>(-)/(-)</td><td>26-Par-SC</td><td>M</td><td>24</td><td>0.219</td><td>0.240</td><td>(-)/(-)</td></tr><tr><td>2-Par-SC</td><td>F</td><td>31</td><td>0.167</td><td>0.141</td><td>(-)/(-)</td><td>27-Par-SC</td><td>M</td><td>69</td><td>0.782</td><td>0.992</td><td>(+)/(+)</td></tr><tr><td>3-Bel-SC</td><td>M</td><td>35</td><td>0.181</td><td>0.191</td><td>(-)/(-)</td><td>28-Par-SC</td><td>M</td><td>31</td><td>0.137</td><td>0.118</td><td>(-)/(-)</td></tr><tr><td>4-Bel-SC</td><td>F</td><td>50</td><td>1.058</td><td>0.912</td><td>(+)/(+)</td><td>29-Bel-SC</td><td>F</td><td>59</td><td>0.156</td><td>0.194</td><td>(-)/(-)</td></tr><tr><td>5-Par-SC</td><td>M</td><td>42</td><td>0.098</td><td>0.167</td><td>(-)/(-)</td><td>30-Bel-SC</td><td>M</td><td>30</td><td>0.194</td><td>0.173</td><td>(-)/(-)</td></tr><tr><td>6-Par-SC</td><td>M</td><td>86</td><td>1.218</td><td>1.054</td><td>(+)/(+)</td><td>31-Bel-SC</td><td>M</td><td>27</td><td>0.149</td><td>0.181</td><td>(-)/(-)</td></tr><tr><td>7-Par-SC</td><td>M</td><td>48</td><td>1.023</td><td>1.162</td><td>(+)/(+)</td><td>32-Par-SC</td><td>F</td><td>46</td><td>0.107</td><td>0.081</td><td>(-)/(-)</td></tr><tr><td>8-Par-SC</td><td>F</td><td>47</td><td>0.137</td><td>0.179</td><td>(-)/(-)</td><td>33-Bel-SC</td><td>F</td><td>18</td><td>0.864</td><td>0.719</td><td>(+)/(+)</td></tr><tr><td>9-Bel-SC</td><td>F</td><td>31</td><td>0.121</td><td>0.140</td><td>(-)/(-)</td><td>34-Par-SC</td><td>M</td><td>57</td><td>0.186</td><td>0.202</td><td>(-)/(-)</td></tr><tr><td>10-Bel-SC</td><td>F</td><td>37</td><td>0.129</td><td>0.104</td><td>(-)/(-)</td><td>35-Par-SC</td><td>M</td><td>40</td><td>0.243</td><td>0.217</td><td>(-)/(-)</td></tr><tr><td>11-Bel-SC</td><td>F</td><td>21</td><td>0.108</td><td>0.096</td><td>(-)/(-)</td><td>36-Par-SC</td><td>M</td><td>31</td><td>0.154</td><td>0.091</td><td>(-)/(-)</td></tr><tr><td>12-Par-SC</td><td>M</td><td>29</td><td>0.089</td><td>0.102</td><td>(-)/(-)</td><td>37-Par-SC</td><td>F</td><td>19</td><td>0.147</td><td>0.137</td><td>(-)/(-)</td></tr><tr><td>13-Par-SC</td><td>F</td><td>27</td><td>0.911</td><td>0.816</td><td>(+)/(+)</td><td>38-Par-SC</td><td>F</td><td>56</td><td>1.534</td><td>1.209</td><td>(+)/(+)</td></tr><tr><td>14-Bel-SC</td><td>M</td><td>45</td><td>0.097</td><td>0.089</td><td>(-)/(-)</td><td>39-Par-SC</td><td>F</td><td>26</td><td>0.136</td><td>0.143</td><td>(-)/(-)</td></tr><tr><td>15-Bel-SC</td><td>M</td><td>40</td><td>0.162</td><td>0.143</td><td>(-)/(-)</td><td>40-Bel-SC</td><td>M</td><td>62</td><td>0.098</td><td>0.079</td><td>(-)/(-)</td></tr><tr><td>16-Par-SC</td><td>F</td><td>39</td><td>0.141</td><td>0.156</td><td>(-)/(-)</td><td>41-Par-SC</td><td>F</td><td>76</td><td>0.942</td><td>0.985</td><td>(+)/(+)</td></tr><tr><td>17-Bel-SC</td><td>F</td><td>52</td><td>0.182</td><td>0.167</td><td>(-)/(-)</td><td>42-Par-SC</td><td>F</td><td>74</td><td>0.137</td><td>0.199</td><td>(-)/(-)</td></tr><tr><td>18-Bel-SC</td><td>M</td><td>56</td><td>1.102</td><td>0.977</td><td>(+)/(+)</td><td>43-Bel-SC</td><td>F</td><td>51</td><td>0.139</td><td>0.142</td><td>(-)/(-)</td></tr><tr><td>19-Par-SC</td><td>F</td><td>31</td><td>0.116</td><td>0.095</td><td>(-)/(-)</td><td>44-Bel-SC</td><td>F</td><td>27</td><td>1.367</td><td>1.418</td><td>(+)/(+)</td></tr><tr><td>20-Par-SC</td><td>F</td><td>60</td><td>0.087</td><td>0.073</td><td>(-)/(-)</td><td>45-Bel-SC</td><td>M</td><td>43</td><td>0.142</td><td>0.125</td><td>(-)/(-)</td></tr><tr><td>21-Par-SC</td><td>F</td><td>27</td><td>0.213</td><td>0.192</td><td>(-)/(-)</td><td>46-Bel-SC</td><td>M</td><td>36</td><td>0.101</td><td>0.089</td><td>(-)/(-)</td></tr><tr><td>22-Par-SC</td><td>M</td><td>39</td><td>0.183</td><td>0.207</td><td>(-)/(-)</td><td>47-Par-SC</td><td>F</td><td>31</td><td>0.128</td><td>0.151</td><td>(-)/(-)</td></tr><tr><td>23-Par-SC</td><td>F</td><td>57</td><td>1.006</td><td>1.355</td><td>(+)/(+)</td><td>48-Par-SC</td><td>M</td><td>20</td><td>0.191</td><td>0.168</td><td>(-)/(-)</td></tr><tr><td>24-Bel-SC</td><td>M</td><td>24</td><td>0.173</td><td>0.197</td><td>(-)/(-)</td><td>49-Par-SC</td><td>M</td><td>48</td><td>0.639</td><td>0.567</td><td>(+)/(+)</td></tr><tr><td>25-Par-SC</td><td>M</td><td>37</td><td>0.094</td><td>0.056</td><td>(-)/(-)</td><td>50-Bel-SC</td><td>F</td><td>38</td><td>0.208</td><td>0.231</td><td>(-)/(-)</td></tr></table> |
4e0ff349ed991d81a161e7a0ce16bb7c72ba5139a4cf1b3dd999a84707008a9a.png | simple | <table><tr><td>Symptoms of respiratory disease</td><td>YES</td><td>NO</td><td>% Positive answers</td></tr><tr><td>Do you cough frequently? (796 answers)</td><td>173</td><td>623</td><td>27.8</td></tr><tr><td>Do you frequently have sputum production with cough? (802 a.)</td><td>281</td><td>521</td><td>53.9</td></tr><tr><td>Do you complain of dyspnea under mild efforts? (808 a.)</td><td>278</td><td>530</td><td>52.4</td></tr><tr><td>During physical activity do you have more shortness of breath than your companions of the same age? <i>N</i> = 764</td><td>278</td><td>496</td><td>56</td></tr><tr><td>Do you perceive wheezing in your chest when you breathe under effort? (792a.)</td><td>113</td><td>679</td><td>16.6</td></tr><tr><td>Do you perceive wheezing in your chest when you breathe at night? (599 a.)</td><td>69</td><td>530</td><td>13</td></tr><tr><td>Do you frequently catch a cold lasting more than that of other people you know? (811 a.)</td><td>186</td><td>625</td><td>29.8</td></tr></table> |
99c3efc732447909c73e05f621888f4314067a3e33a47286224d2367e67bd96b.png | simple | <table><tr><td>Class</td><td>Species</td><td>T (°C)</td><td>ERK</td><td>%AT-rich</td><td>%GC-rich</td></tr><tr><td>Mammalia</td><td>Mus musculus</td><td>36.9</td><td>-16.32</td><td>23.22</td><td>24.56</td></tr><tr><td>Mammalia</td><td>Rattus norvegicus</td><td>37.3</td><td>-16.27</td><td>22.82</td><td>24.91</td></tr><tr><td>Mammalia</td><td>Human</td><td>37</td><td>-16.11</td><td>23.82</td><td>24.31</td></tr><tr><td>Mammalia</td><td>Bos taurus</td><td>38</td><td>-15.97</td><td>23.14</td><td>25.00</td></tr><tr><td>Birds</td><td>Gallus gallus</td><td>39</td><td>-16.01</td><td>23.59</td><td>24.83</td></tr><tr><td>Reptilia</td><td>Anolis carolinensis</td><td>26 (24- 28)</td><td>-17.03</td><td>23.75</td><td>24.45</td></tr><tr><td>Amphibia</td><td>Xenopus laevis</td><td>21(18-22)</td><td>-16.53</td><td>25.29</td><td>22.52</td></tr><tr><td>Amphibia</td><td>Xenopus tropicalis</td><td>25 (23-28)</td><td>-16.53</td><td>25.22</td><td>22.72</td></tr><tr><td>Fish</td><td>Danio rerio</td><td>28.5</td><td>-16.76</td><td>23.85</td><td>23.45</td></tr><tr><td>Fish</td><td>Tetraodon nigroviridis</td><td>27(25-28)</td><td>-16.53</td><td>25.22</td><td>22.72</td></tr><tr><td>Fish</td><td>Takifugu rubripes</td><td>25(23-26)</td><td>-17.17</td><td>23.31</td><td>23.8</td></tr><tr><td><i>p</i></td><td></td><td>0.0080</td><td>0.0075</td><td>0.25</td><td>0.13</td></tr></table> |
bc6dbee4451fe698d344f99c420bb1034ce8bcf2165b0cca51164a3d895f57cf.png | simple | <table><tr><td></td><td>Initial population iTFA intakes,<sup>2</sup> E%</td></tr><tr><td>Base case</td><td>0.3<sup>3</sup></td></tr><tr><td>Scenario 1</td><td>0.15</td></tr><tr><td>Scenario 2</td><td>0.45</td></tr><tr><td>Scenario 3</td><td>0.7</td></tr></table> |
6634274af53bdf7c362be4a3d0e32a4340021d03ebdceb3c1201fe9e099165b0.png | simple | <table><tr><td>Trait</td><td>Variantidentifier</td><td>Chr</td><td>Position</td><td>ea/nea</td><td>Eaf</td><td>Beta</td><td>s.e.</td><td><i>P</i>-value</td><td>Q<i>P</i>-value</td><td><i>N</i>samples</td><td>Candidategene</td><td>eQTL</td><td>Function</td></tr><tr><td>Glycine</td><td>chr3:125905336:D</td><td>3</td><td>125905336</td><td>A/ACCTGACCCTGAC</td><td>0.40</td><td>0.07</td><td>0.01</td><td>1.1 × 10<sup>−9</sup></td><td>0.03</td><td>17,541</td><td><i>SLC41A3</i></td><td>—</td><td>TFBS</td></tr><tr><td>Glycine</td><td>rs140348140</td><td>9</td><td>5877295</td><td>TA/T</td><td>0.05</td><td>0.33</td><td>0.03</td><td>3.7 × 10<sup>−40</sup></td><td>4.7 × 10<sup>−6</sup></td><td>17,535</td><td><i>GLDC</i></td><td>—</td><td>—</td></tr><tr><td>otPUFA</td><td>rs186183604</td><td>11</td><td>67128733</td><td>A/G</td><td>0.04</td><td>−0.24</td><td>0.04</td><td>3.2 × 10<sup>−11</sup></td><td>0.71</td><td>13,545</td><td><i>CLCF1</i></td><td>—</td><td>Intron;<i>LOC</i><i>100130987</i></td></tr><tr><td>Alanine</td><td>rs4554975</td><td>12</td><td>47201814</td><td>G/A</td><td>0.64</td><td>−0.07</td><td>0.01</td><td>6.1 × 10<sup>−13</sup></td><td>0.76</td><td>24,792</td><td><i>SLC38A4</i></td><td>—</td><td>Intron</td></tr><tr><td>Histidine</td><td>rs7954638</td><td>12</td><td>96314795</td><td>A/C</td><td>0.48</td><td>−0.08</td><td>0.01</td><td>7.3 × 10<sup>−15</sup></td><td>0.53</td><td>19,240</td><td><i>HAL</i></td><td><i>AMDH1</i></td><td>Intron;CCDC38</td></tr><tr><td>Histidine</td><td>rs1998848</td><td>14</td><td>21492229</td><td>A/G</td><td>0.05</td><td>0.15</td><td>0.02</td><td>4.9 × 10<sup>−10</sup></td><td>0.06</td><td>19,239</td><td><i>NDRG2</i></td><td>—</td><td>TFBS/5'UTR</td></tr><tr><td>Pyruvate</td><td>rs74249229</td><td>16</td><td>69979271</td><td>T/C</td><td>0.05</td><td>−0.15</td><td>0.02</td><td>2.1 × 10<sup>−11</sup></td><td>0.17</td><td>23,561</td><td><i>PDPR</i></td><td>—</td><td>—</td></tr><tr><td>Glycine</td><td>rs10083777</td><td>16</td><td>81065282</td><td>T/C</td><td>0.17</td><td>−0.11</td><td>0.01</td><td>3.0 × 10<sup>−13</sup></td><td>0.92</td><td>18,732</td><td><i>GCSH</i></td><td><i>GCSH,</i><i>ATMIN</i>,<i>LOC</i><i>102724325</i></td><td>TFBS</td></tr></table> |
33f1377865c2b02958a4c4e4364cd61327a2f05a27a01b3c1f10afbb44597cb8.png | simple | <table><tr><td>Supplement Name</td><td>Male, <i>n</i> = 152, <i>n</i> (%)</td><td>Female, <i>n</i> = 224, <i>n</i> (%)</td><td><i>p</i> value</td></tr><tr><td>B Vitamin Complex</td><td>10 (6.6) <sup>b</sup></td><td>32 (14.3) <sup>a</sup></td><td>0.020</td></tr><tr><td>Calcium</td><td>14 (9.2) <sup>b</sup></td><td>83 (37.1) <sup>a</sup></td><td><0.001</td></tr><tr><td>Fish Oil</td><td>10 (6.6) <sup>b</sup></td><td>30 (13.4) <sup>a</sup></td><td>0.041</td></tr><tr><td>Green Tea</td><td>6 (3.9) <sup>b</sup></td><td>29 (12.9) <sup>a</sup></td><td>0.003</td></tr><tr><td>Magnesium</td><td>6 (3.9) <sup>b</sup></td><td>31 (13.8) <sup>a</sup></td><td>0.001</td></tr><tr><td>Omega 3,6,9</td><td>13 (8.6) <sup>b</sup></td><td>36 (16.1) <sup>a</sup></td><td>0.042</td></tr><tr><td>Vitamin D</td><td>33 (21.7) <sup>b</sup></td><td>84 (37.5) <sup>a</sup></td><td>0.001</td></tr></table> |
864e55b0b5d2117756a69bb95cff7e7b6cbee4f29c1bd7481c35238f202dd39d.png | complex | <table><tr><td colspan="9">Dietary Fiber (g/day)</td></tr><tr><td>Age (y)</td><td><i>n</i></td><td>2001–2010</td><td>2001–2002</td><td>2003–2004</td><td>2005–2006</td><td>2007–2008</td><td>2009–2010</td><td><i>p</i>-value for trend</td></tr><tr><td>4–18</td><td>14,973</td><td>13.2 ± 0.1</td><td>12.8 ± 0.2</td><td>13.2 ± 0.3</td><td>13.2 ± 0.3</td><td>13.0 ± 0.4</td><td>13.9 ±0.3 </td><td>0.016</td></tr><tr><td>19–50</td><td>13,268</td><td>16.1 ± 0.2</td><td>16.2 ± 0.4</td><td>15.7 ± 0.4</td><td>15.7 ± 0.4</td><td>15.8 ± 0.5</td><td>17.0 ± 0.4</td><td>0.16</td></tr><tr><td>51+</td><td>11,541</td><td>16.1 ± 0.2</td><td>16.2 ± 0.5</td><td>15.2 ± 0.3</td><td>15.8 ± 0.3</td><td>16.1 ± 6</td><td>17.0 ± 0.2</td><td>0.03</td></tr></table> |
7a94c72e4074a373c33cd74bfee65d5d3ebaf7412f149ad2d73394dc8bf3a649.png | simple | <table><tr><td>Aim</td><td>Instrument</td><td>Applied to</td><td>t<sub>0</sub></td><td>t<sub>6</sub></td><td>t<sub>12</sub></td><td>t<sub>24</sub></td><td>t<sub>h</sub></td></tr><tr><td>Anamnestic data</td><td>Baseline CRF</td><td>GP</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Quality of life of patient</td><td>EQ-5D</td><td>Patient, informal caregiver and GP</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Cognitive function patient</td><td>MMSE</td><td>GP</td><td>X</td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><td></td><td>DEMTECT</td><td>GP</td><td>X</td><td></td><td></td><td></td><td></td></tr><tr><td>Evaluation of antidementiva therapy</td><td>CRF</td><td>GP</td><td></td><td>X</td><td></td><td></td><td></td></tr><tr><td>Global health status of the patient</td><td>CGI</td><td>GP</td><td>X</td><td>X</td><td>X</td><td>X</td><td></td></tr><tr><td>Behavioural problems patient</td><td>NOSGER (Subtest)</td><td>Informal caregiver</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>ADL patient</td><td>Barthel-Index</td><td>Informal caregiver</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>IADL patient</td><td>NOSGER (Subtest)</td><td>Informal caregiver</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Caregiver burden</td><td>BSFC</td><td>Informal caregiver</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Resource use, situation of caregiver</td><td>Questionnaire</td><td>Informal caregiver</td><td>X</td><td></td><td>X</td><td>X</td><td></td></tr><tr><td>Nursing home placement (reasons)</td><td>Questionnaire</td><td>Informal caregiver and GP</td><td></td><td></td><td></td><td></td><td>X</td></tr></table> |
ab7685e94cf5d9cd2d0f1e63342323f327f757c6fa286d2b644068831730dbeb.png | complex | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td><td>Evidence code</td></tr><tr><td rowspan="8"> </td><td rowspan="8">Current classification</td><td>Domain <i>Bacteria</i></td><td>TAS [19]</td></tr><tr><td>Phylum <i>Proteobacteria</i></td><td>TAS [20]</td></tr><tr><td>Class <i>Alphaproteobacteria</i></td><td>TAS [21]</td></tr><tr><td>Order <i>Rhizobiales</i></td><td>TAS [22,23]</td></tr><tr><td>Family <i>Phyllobacteriaceae</i></td><td>TAS [23,24]</td></tr><tr><td>Genus <i>Mesorhizobium</i></td><td>TAS [16]</td></tr><tr><td>Species <i>Mesorhizobium loti</i></td><td>TAS [3]</td></tr><tr><td>Strain NZP2037</td><td>TAS [3]</td></tr><tr><td> </td><td>Gram stain</td><td>Negative</td><td>IDA</td></tr><tr><td> </td><td>Cell shape</td><td>Rod</td><td>IDA</td></tr><tr><td> </td><td>Motility</td><td>Motile</td><td>IDA</td></tr><tr><td> </td><td>Sporulation</td><td>Non-sporulating</td><td>NAS</td></tr><tr><td> </td><td>Temperature range</td><td>Mesophile</td><td>NAS</td></tr><tr><td> </td><td>Optimum temperature</td><td>28°C</td><td>NAS</td></tr><tr><td> </td><td>Salinity</td><td>Unknown</td><td>NAS</td></tr><tr><td>MIGS-22</td><td>Oxygen requirement</td><td>Aerobic</td><td>TAS [3]</td></tr><tr><td> </td><td>Carbon source</td><td>Various</td><td>TAS [16,25]</td></tr><tr><td> </td><td>Energy source</td><td>chemoorganotroph</td><td>TAS [16,25]</td></tr><tr><td>MIGS-6</td><td>Habitat</td><td>Soil, root nodule, host</td><td>TAS [3]</td></tr><tr><td>MIGS-15</td><td>Biotic relationship</td><td>Free living, Symbiotic</td><td>TAS [3]</td></tr><tr><td>MIGS-14</td><td>Pathogenicity</td><td>None</td><td>NAS</td></tr><tr><td> </td><td>Biosafety level</td><td>1</td><td>TAS [26]</td></tr><tr><td> </td><td>Isolation</td><td>Root nodule of <i>Lotus divaricatus</i></td><td>TAS [27]</td></tr><tr><td>MIGS-4</td><td>Geographic location</td><td>Adjacent Palmerston North Airport, NZ</td><td>TAS [1]</td></tr><tr><td>MIGS-5</td><td>Nodule collection date</td><td>1961</td><td>TAS [1]</td></tr><tr><td>MIGS-4.1</td><td>Latitude</td><td>-40.1914</td><td>TAS [1]</td></tr><tr><td>MIGS-4.2</td><td>Longitude</td><td>175.3701</td><td>TAS [1]</td></tr><tr><td>MIGS-4.3</td><td>Depth</td><td>5 cm</td><td>IDA</td></tr><tr><td>MIGS-4.4</td><td>Altitude</td><td>46 meters</td><td>IDA</td></tr></table> |
b4064554ce1c0e952866d4b0072c51dd8ca3ce2c700107b1dcca3b671d9aefd8.png | complex | <table><tr><td rowspan="2">Item</td><td colspan="2">Protein source</td><td colspan="2">Protein level</td><td rowspan="2">SEM</td><td colspan="3"><i>P</i></td></tr><tr><td>Cottonseed meal</td><td>Soybean meal</td><td>12 %</td><td>14 %</td><td>Source</td><td>Level</td><td>Source × Level</td></tr><tr><td>Initial body weight, kg</td><td>90.30</td><td>88.80</td><td>90.30</td><td>88.70</td><td>1.86</td><td>0.58</td><td>0.56</td><td>0.93</td></tr><tr><td>Final body weight, kg</td><td>115.40</td><td>112.30</td><td>114.50</td><td>113.10</td><td>1.87</td><td>0.16</td><td>0.48</td><td>0.90</td></tr><tr><td>Average daily feed intake, kg/d</td><td>3.04</td><td>2.87</td><td>3.02</td><td>2.89</td><td>0.05</td><td>0.03</td><td>0.09</td><td>0.11</td></tr><tr><td>Gain-to-feed ratio</td><td>0.29</td><td>0.28</td><td>0.28</td><td>0.29</td><td>0.01</td><td>0.30</td><td>0.63</td><td>0.77</td></tr><tr><td>Average daily gain, kg/d</td><td>0.90</td><td>0.81</td><td>0.86</td><td>0.85</td><td>0.03</td><td>0.08</td><td>0.80</td><td>0.66</td></tr><tr><td>Total protein deposition<sup>a</sup>, kg</td><td>17.90</td><td>17.30</td><td>17.70</td><td>17.50</td><td>0.26</td><td>0.15</td><td>0.48</td><td>0.90</td></tr><tr><td>Serum urea nitrogen, mmol/L</td><td>7.54</td><td>7.19</td><td>6.50</td><td>8.23</td><td>0.45</td><td>0.59</td><td>0.01</td><td>0.24</td></tr><tr><td>Daily N intake, g/d</td><td>64.63</td><td>61.18</td><td>58.28</td><td>67.54</td><td>1.15</td><td>0.04</td><td><0.01</td><td>0.91</td></tr><tr><td>Daily N deposition, g/d</td><td>20.43</td><td>20.87</td><td>20.53</td><td>20.76</td><td>0.22</td><td>0.17</td><td>0.47</td><td>0.91</td></tr><tr><td>Daily N excretion, g/d</td><td>44.20</td><td>40.30</td><td>37.70</td><td>46.8</td><td>1.31</td><td>0.05</td><td><0.01</td><td>0.93</td></tr><tr><td>N efficiency<sup>b</sup>, kg/kg</td><td>0.32</td><td>0.35</td><td>0.35</td><td>0.31</td><td>0.01</td><td>0.06</td><td><0.01</td><td>0.90</td></tr></table> |
ebe294426e85ba237ea86019b35b28f70f232f3f772a2146d734a1f0c1e7eb12.png | simple | <table><tr><td>Study</td><td>Number of patients</td><td>Morbidity</td><td>Mortality</td></tr><tr><td>Yamaguchi et al.</td><td>107</td><td>-</td><td>5.8%</td></tr><tr><td>Talamini et al. </td><td>106</td><td>47%</td><td>3.8%</td></tr><tr><td>Beger et al.</td><td>98</td><td>-</td><td>3.2%</td></tr><tr><td>Nagakawa et al.</td><td>1423</td><td>-</td><td>1.3%</td></tr><tr><td>Di Giorgio et al. </td><td>94</td><td>48%</td><td>9.3%</td></tr></table> |
fb3e4f0226969bf7ae6a9464b546416c93c83e28d39186560202a62ada4aa550.png | simple | <table><tr><td>Group</td><td>Cases </td><td>Osteomyelitis healed (%)</td><td>Bone union</td></tr><tr><td>IRI and soft tissue defects </td><td>152</td><td>131 (86.2%)</td><td>147 (96.7%)</td></tr><tr><td>Simple IRI</td><td>65</td><td>57 (87.7%)</td><td>64 (98.5%)</td></tr><tr><td>Total </td><td>217</td><td>188 (86.6%)</td><td>211 (97.2%)</td></tr></table> |
e11a856cda833c0917eaa97e148fdb7c6e9c5c98da471eac29bcbeab5d10920a.png | simple | <table><tr><td>Selenoprotein gene</td><td>Brief information in the NCBI database.</td></tr><tr><td><i>SPS</i></td><td>XM_002129490 PREDICTED: similar to selenophosphate synthetase 1 (LOC100182599)</td></tr><tr><td><i>SelH</i></td><td>XM_002124882 PREDICTED: similar to Selenoprotein H (SelH) (LOC100184326)</td></tr><tr><td><i>SelO</i></td><td>XM_002124815 PREDICTED: similar to predicted protein (LOC100179326)</td></tr><tr><td><i>SelS</i></td><td>XM_002131362 PREDICTED: similar to selenoprotein S (LOC100186840)</td></tr><tr><td><i>DsbA</i></td><td>XM_002126620 PREDICTED: hypothetical protein LOC100182954 (LOC100182954)</td></tr><tr><td><i>SelK</i></td><td>XM_002128679 PREDICTED: similar to selenoprotein K (LOC100184686)</td></tr><tr><td><i>TR3</i></td><td>XM_002131964 PREDICTED: similar to thioredoxin reductase 3 (LOC100178436)</td></tr><tr><td><i>Gpx c</i></td><td>XM_002121522 PREDICTED: Ciona intestinalis similar to C11E4.1 (LOC100182197)</td></tr></table> |
9e8b365511d256e4b787bf66a9e4005acd937741f06770355212680b19fc9d2b.png | simple | <table><tr><td><i>Predictor</i></td><td><i>β</i></td><td><i>t</i></td><td><i>p</i></td></tr><tr><td>Distance</td><td>3.810</td><td>2.575</td><td>0.012</td></tr><tr><td>Time of day</td><td>−0.067</td><td>−0.622</td><td>0.536</td></tr><tr><td>SUL</td><td>0.119</td><td>1.101</td><td>0.274</td></tr></table> |
f90cf2996f7f9b3c83f8b6209070a5d37585dacb4aee8ce8bae43b1026d0d93f.png | simple | <table><tr><td>Culture #</td><td>Culture duration (days)</td><td>Final culture density per ml ( × 10<sup>8</sup>)</td><td>No. of generations in the culture (<i>n</i>)</td><td>Total no. of generations (cumul)</td><td>GEN.</td><td>First evolved mutant isolated</td><td>Second evolved mutant isolated</td></tr><tr><td>1</td><td>3</td><td>1.2</td><td>11.2</td><td>11.2</td><td>0</td><td>BYAT580-0 [E] a, b, c</td><td> </td></tr><tr><td>2</td><td>7</td><td>1.2</td><td>8.9</td><td>20.1</td><td> </td><td> </td><td> </td></tr><tr><td>3</td><td>4</td><td>1.0</td><td>7.6</td><td>27.8</td><td> </td><td> </td><td> </td></tr><tr><td>4</td><td>2</td><td>1.8</td><td>8.5</td><td>36.3</td><td> </td><td> </td><td> </td></tr><tr><td>5</td><td>6</td><td>1.7</td><td>8.4</td><td>44.7</td><td> </td><td> </td><td> </td></tr><tr><td>6</td><td>3</td><td>2.0</td><td>8.6</td><td>53.3</td><td>60</td><td>BYAT580-60 [E] a, b, c</td><td>BYAT580-61 [E] b</td></tr><tr><td>7</td><td>3</td><td>1.9</td><td>8.6</td><td>61.9</td><td>70</td><td>BYAT580-70 [E] a, b</td><td>BYAT580-71 [E] b</td></tr><tr><td>8</td><td>2</td><td>1.8</td><td>8.5</td><td>70.4</td><td>80</td><td>BYAT580-80 [E] a, b</td><td>BYAT580-81 [E] b</td></tr><tr><td>9</td><td>2</td><td>1.7</td><td>8.4</td><td>78.8</td><td>90</td><td>BYAT580-90 [E] a, b</td><td> </td></tr><tr><td>10</td><td>3</td><td>1.7</td><td>8.4</td><td>87.2</td><td>100</td><td>BYAT580-100 [E] a, b</td><td>BYAT580-101 [E] b</td></tr><tr><td>11</td><td>2</td><td>2.0</td><td>8.6</td><td>95.8</td><td>110</td><td>BYAT580-110 [E] a, b</td><td> </td></tr><tr><td>12</td><td>2</td><td>1.5</td><td>8.2</td><td>104.1</td><td> </td><td> </td><td> </td></tr><tr><td>13</td><td>5</td><td>1.6</td><td>8.3</td><td>112.4</td><td>120</td><td>BYAT580-120 [E] a, b, c</td><td>BYAT580-121 [E] a, b</td></tr><tr><td>14</td><td>2</td><td>1.7</td><td>8.4</td><td>120.8</td><td>130</td><td>BYAT580-130 [E] a, b</td><td> </td></tr><tr><td>15</td><td>3</td><td>1.5</td><td>8.2</td><td>129.0</td><td>140</td><td>BYAT580-140 [M] a, b</td><td>BYAT580-141 [E] a, b</td></tr><tr><td>16</td><td>2</td><td>2.0</td><td>8.6</td><td>137.7</td><td>150</td><td>BYAT580-150 [E] a, b</td><td>BYAT580-151 [E+M]* a, b</td></tr><tr><td>17</td><td>2</td><td>1.5</td><td>8.2</td><td>145.9</td><td> </td><td> </td><td> </td></tr><tr><td>18</td><td>3</td><td>1.6</td><td>8.3</td><td>154.2</td><td> </td><td> </td><td> </td></tr><tr><td>19</td><td>4</td><td>1.8</td><td>8.5</td><td>162.7</td><td>170</td><td>BYAT580-170 [E+M] a, b</td><td>BYAT580-171 [E+M] a, b</td></tr><tr><td>20</td><td>3</td><td>1.9</td><td>8.6</td><td>171.3</td><td> </td><td> </td><td> </td></tr><tr><td>21</td><td>4</td><td>1.9</td><td>8.6</td><td>179.9</td><td>190</td><td>BYAT580-190 [E] a, b</td><td>BYAT580-191 [E] a, b</td></tr><tr><td>22</td><td>10</td><td>2.3</td><td>8.8</td><td>188.7</td><td> </td><td> </td><td> </td></tr><tr><td>23</td><td>10</td><td>2.4</td><td>8.9</td><td>197.6</td><td>200</td><td>BYAT580-200 [M] a, b, c</td><td>BYAT580-201 [E+M]* a, b</td></tr></table> |
ad29e18a07f26741e50a663d2f8879104eea9861bd526805acbda86b797af0c2.png | complex | <table><tr><td rowspan="2">Country</td><td rowspan="2">Antimicrobial class</td><td colspan="2">Correlation coefficient</td></tr><tr><td>Cattle</td><td>Pigs</td></tr><tr><td>Denmark</td><td>Aminoglycosides</td><td>−0.91</td><td>−0.61</td></tr><tr><td>Switzerland</td><td>Aminoglycosides</td><td>−0.94</td><td>−0.90</td></tr><tr><td>Denmark</td><td>Cephalosporins and fluoroquinolones</td><td>0.63</td><td>−0.87</td></tr><tr><td>Switzerland</td><td>Cephalosporins and fluoroquinolones</td><td>0.40</td><td>NA</td></tr><tr><td>Denmark</td><td>Macrolides</td><td>−0.88</td><td>−0.31</td></tr><tr><td>Switzerland</td><td>Macrolides</td><td>−0.97</td><td>−0.89</td></tr><tr><td>Denmark</td><td>Penicillins</td><td>0.41</td><td>−0.13</td></tr><tr><td>Switzerland</td><td>Penicillins</td><td>−0.07</td><td>0.02</td></tr><tr><td>Denmark</td><td>Sulfonamides/trimethoprim</td><td>−0.90</td><td>0.37</td></tr><tr><td>Switzerland</td><td>Sulfonamides/trimethoprim</td><td>−1.00</td><td>−0.93</td></tr><tr><td>Denmark</td><td>Tetracyclines</td><td>−0.62</td><td>−0.71</td></tr><tr><td>Switzerland</td><td>Tetracyclines</td><td>−0.83</td><td>−0.98</td></tr><tr><td>Denmark</td><td>Others</td><td>0.94</td><td>−0.27</td></tr><tr><td>Switzerland</td><td>Others</td><td>NA</td><td>−0.66</td></tr><tr><td>Denmark</td><td>Total antimicrobial consumption</td><td>−0.29</td><td>−0.47</td></tr><tr><td>Switzerland</td><td>Total antimicrobial consumption</td><td>−0.98</td><td>−0.97</td></tr></table> |
f18f682db8cfd5cf99a04b6c038d4172f57bb3a2dbcdb6d2cd951d0f50cab297.png | simple | <table><tr><td>Number</td><td>Case number</td><td>Exon</td><td>Nucleotide change</td><td>Amino acid</td></tr><tr><td>1</td><td>36T</td><td>19</td><td>c.2199A>G</td><td>p.P733P</td></tr><tr><td>2</td><td>41T</td><td>19</td><td>c.2202A>G</td><td>p.E734E</td></tr><tr><td>3</td><td>10T</td><td>19</td><td>c.2250A>G</td><td>p.A750A</td></tr><tr><td>4</td><td>56T</td><td>19</td><td>c.2262A>G</td><td>p.K754K</td></tr><tr><td>5</td><td>26T, 48T</td><td>20</td><td>c.2286A>G</td><td>p.E762E</td></tr><tr><td>6</td><td>32T</td><td>21</td><td>c.2523G>A</td><td>p.R841R</td></tr><tr><td>7</td><td>8T</td><td>21</td><td>c.2544G>A</td><td>p.P848P</td></tr><tr><td>8</td><td>20T</td><td>22</td><td>c.2634C>T</td><td>p.I878I</td></tr><tr><td>9</td><td>5T</td><td>22</td><td>c.2673T>C</td><td>p.Y891Y</td></tr><tr><td>10</td><td>6T</td><td>23</td><td>c.2757T>C</td><td>p.P919P</td></tr><tr><td>11</td><td>45T</td><td>23</td><td>c.2793A>G</td><td>p.E931E</td></tr></table> |
967e6b140482ec1ba18e91b34139a1c7c18b1dc5e3154a86af1aa061257c1a7e.png | complex | <table><tr><td>Molecular variation</td><td>df</td><td>SS</td><td>MS</td><td>%</td><td>Φ<sub>PT</sub></td></tr><tr><td colspan="6">All 20 populations grouped in two regions</td></tr><tr><td> Among regions</td><td>1</td><td>1108.988</td><td>1108.988</td><td>14</td><td>0.42</td></tr><tr><td> Among populations within regions</td><td>18</td><td>3639.084</td><td>202.171</td><td>28</td><td></td></tr><tr><td> Within populations</td><td>277</td><td>6727.767</td><td>24.288</td><td>57</td><td></td></tr><tr><td colspan="6">All 20 populations together</td></tr><tr><td> Among populations</td><td>19</td><td>4748.072</td><td>249.899</td><td>38</td><td>0.38</td></tr><tr><td> Within populations</td><td>277</td><td>6727.767</td><td>24.288</td><td>62</td><td></td></tr><tr><td colspan="6">10 populations from Switzerland</td></tr><tr><td> Among populations</td><td>9</td><td>1578.940</td><td>175.438</td><td>29</td><td>0.29</td></tr><tr><td> Within populations</td><td>140</td><td>3497.067</td><td>24.979</td><td>71</td><td></td></tr><tr><td colspan="6">10 populations from Germany</td></tr><tr><td> Among populations</td><td>9</td><td>2060.144</td><td>228.905</td><td>37</td><td>0.37</td></tr><tr><td> Within populations</td><td>137</td><td>3230.700</td><td>23.582</td><td>63</td><td></td></tr></table> |
13b711d33cccae5ea46d43ffb3f5ef660209b54cf87afe21ab5c38483b5cd5d1.png | complex | <table><tr><td></td><td colspan="6">Year</td></tr><tr><td></td><td>2000</td><td>2001</td><td>2002</td><td>2003</td><td>2004</td><td>2005</td></tr><tr><td>Total</td><td>24.6</td><td>26.1</td><td>27.3</td><td>27.5</td><td>28.2</td><td>28.0</td></tr><tr><td>Mother's Education</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> No school</td><td>28.9</td><td>30.7</td><td>32.3</td><td>33.7</td><td>32.7</td><td>33.4</td></tr><tr><td> Primary school</td><td>25.8</td><td>27.7</td><td>28.8</td><td>29.9</td><td>31.1</td><td>30.0</td></tr><tr><td> Junior high school</td><td>23.3</td><td>24.8</td><td>26.6</td><td>27.4</td><td>25.6</td><td>27.5</td></tr><tr><td> High school</td><td>20.7</td><td>22.3</td><td>23.0</td><td>24.1</td><td>22.0</td><td>24.0</td></tr><tr><td> > High</td><td>16.3</td><td>14.9</td><td>20.2</td><td>19.4</td><td>17.0</td><td>18.7</td></tr><tr><td>Expenditure Quintile**</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Lowest</td><td>28.3</td><td>28.9</td><td>32.1</td><td>33.1</td><td>30.7</td><td>32.8</td></tr><tr><td> Second</td><td>24.8</td><td>27.5</td><td>28.1</td><td>28.8</td><td>29.3</td><td>28.6</td></tr><tr><td> Middle</td><td>24.4</td><td>26.7</td><td>25.7</td><td>27.0</td><td>27.1</td><td>26.8</td></tr><tr><td> Fourth</td><td>21.2</td><td>24.2</td><td>23.5</td><td>25.4</td><td>23.7</td><td>25.3</td></tr><tr><td> Highest</td><td>18.1</td><td>18.3</td><td>19.5</td><td>21.1</td><td>20.3</td><td>20.3</td></tr></table> |
6e45850b32d79ee9b149ba441332bc63c1f1e28163942407f9cc0558f9d7eb9f.png | simple | <table><tr><td></td><td>Group A(min)</td><td>Group B(min)</td><td>Group C(min)</td><td>Group D(min)</td><td>Group E(min)</td><td>Group F(min)</td><td>Group G(min)</td><td>Group H(min)</td><td>Group I(min)</td></tr><tr><td>U87</td><td>64</td><td>0.29</td><td>0.57</td><td>27</td><td>54</td><td>27</td><td>54</td><td>32</td><td>64</td></tr><tr><td>U251</td><td>64</td><td>0.29</td><td>0.57</td><td>25</td><td>50</td><td>25</td><td>50</td><td>32</td><td>64</td></tr><tr><td>SHG44</td><td>64</td><td>0.29</td><td>0.57</td><td>28</td><td>56</td><td>28</td><td>56</td><td>32</td><td>64</td></tr></table> |
5197997774cc6b73868478ac8d55497e8f27d9e75550bc917b015534536837d8.png | complex | <table><tr><td></td><td></td><td colspan="2">JA ALGO</td><td colspan="4">ParBiConstruct</td></tr><tr><td>P</td><td>k</td><td>RES.MEM(Mb)</td><td>SHR.MEM(Mb)</td><td>RES.MEM(Mb)</td><td>efficiency</td><td>SHR.MEM(Mb)</td><td>efficiency</td></tr><tr><td>8</td><td>21</td><td>903.714</td><td>3.690</td><td>244.603</td><td>3.695</td><td>3.328</td><td>1.109</td></tr><tr><td>8</td><td>27</td><td>675.516</td><td>3.638</td><td>146.750</td><td>4.603</td><td>3.232</td><td>1.126</td></tr><tr><td>8</td><td>33</td><td>289.787</td><td>3.588</td><td>62.580</td><td>4.631</td><td>3.007</td><td>1.193</td></tr><tr><td>8</td><td>35</td><td>116.938</td><td>7.527</td><td>14.625</td><td>7.996</td><td>2.397</td><td>3.140</td></tr><tr><td>12</td><td>21</td><td>681.664</td><td>4.782</td><td>156.875</td><td>4.345</td><td>4.256</td><td>1.124</td></tr><tr><td>12</td><td>27</td><td>265.304</td><td>6.882</td><td>91.219</td><td>2.908</td><td>3.889</td><td>1.769</td></tr><tr><td>12</td><td>33</td><td>241.630</td><td>4.721</td><td>46.805</td><td>5.163</td><td>3.675</td><td>1.285</td></tr><tr><td>12</td><td>35</td><td>94.548</td><td>7.518</td><td>12.276</td><td>7.702</td><td>2.771</td><td>2.713</td></tr><tr><td>16</td><td>21</td><td>501.175</td><td>5.726</td><td>152.995</td><td>3.276</td><td>5.175</td><td>1.107</td></tr><tr><td>16</td><td>27</td><td>333.487</td><td>11.730</td><td>77.523</td><td>4.302</td><td>4.823</td><td>2.432</td></tr><tr><td>16</td><td>33</td><td>166.395</td><td>5.714</td><td>42.746</td><td>3.893</td><td>4.628</td><td>1.235</td></tr><tr><td>16</td><td>35</td><td>68.851</td><td>8.172</td><td>13.578</td><td>5.071</td><td>3.443</td><td>2.374</td></tr><tr><td>24</td><td>21</td><td>344.888</td><td>8.081</td><td>105.723</td><td>3.262</td><td>7.133</td><td>1.133</td></tr><tr><td>24</td><td>27</td><td>214.681</td><td>16.271</td><td>61.674</td><td>3.481</td><td>6.690</td><td>2.432</td></tr><tr><td>24</td><td>33</td><td>115.630</td><td>7.830</td><td>34.583</td><td>3.344</td><td>5.959</td><td>1.314</td></tr><tr><td>24</td><td>35</td><td>52.110</td><td>10.082</td><td>15.990</td><td>3.259</td><td>4.472</td><td>2.254</td></tr><tr><td>32</td><td>21</td><td>260.063</td><td>10.413</td><td>86.157</td><td>3.018</td><td>9.070</td><td>1.148</td></tr><tr><td>32</td><td>27</td><td>179.657</td><td>20.550</td><td>49.737</td><td>3.612</td><td>8.096</td><td>2.538</td></tr><tr><td>32</td><td>33</td><td>95.790</td><td>9.968</td><td>34.180</td><td>2.803</td><td>7.495</td><td>1.330</td></tr><tr><td>32</td><td>35</td><td>47.602</td><td>11.290</td><td>15.289</td><td>3.113</td><td>4.905</td><td>2.302</td></tr><tr><td>48</td><td>21</td><td>186.225</td><td>14.109</td><td>71.073</td><td>2.620</td><td>12.405</td><td>1.137</td></tr><tr><td>48</td><td>27</td><td>112.237</td><td>19.623</td><td>47.596</td><td>2.358</td><td>11.255</td><td>1.744</td></tr><tr><td>48</td><td>33</td><td>75.059</td><td>11.996</td><td>30.929</td><td>2.427</td><td>9.070</td><td>1.323</td></tr><tr><td>48</td><td>35</td><td>37.500</td><td>10.643</td><td>19.576</td><td>1.916</td><td>6.764</td><td>1.573</td></tr><tr><td>64</td><td>21</td><td>150.324</td><td>17.311</td><td>63.449</td><td>2.369</td><td>14.640</td><td>1.182</td></tr><tr><td>64</td><td>27</td><td>105.692</td><td>23.570</td><td>43.590</td><td>2.425</td><td>12.975</td><td>1.817</td></tr><tr><td>64</td><td>33</td><td>66.095</td><td>14.168</td><td>31.853</td><td>2.075</td><td>10.653</td><td>1.330</td></tr><tr><td>64</td><td>35</td><td>38.823</td><td>12.159</td><td>22.275</td><td>1.743</td><td>8.096</td><td>1.502</td></tr></table> |
ab30d3bb6858ca583321dd08f72823559c562b2b76c14aec9af9f5a1954a491c.png | simple | <table><tr><td></td><td>%</td><td>Search Meaning (50.6 ± 25.9)</td><td>Message Disease (70.4 ± 20.9)</td><td>Trust Guidance (70.0 ± 26.5)</td><td>Support External (59.0 ± 23.9)</td><td>Support Internal (62.3 ± 24.3)</td></tr><tr><td>sex</td><td></td><td>**</td><td>**</td><td>*</td><td>**</td><td>*</td></tr><tr><td>female</td><td>70</td><td>54.7 ± 26.0</td><td>73.4 ± 20.3</td><td>72.9 ± 24.4</td><td>61.8 ± 23.1</td><td>64.9 ± 22.6</td></tr><tr><td>male</td><td>30</td><td>40.8 ± 22.9</td><td>63.4 ± 20.8</td><td>63.0 ± 30.0</td><td>52.4 ± 24.5</td><td>55.6 ± 27.1</td></tr><tr><td>age</td><td></td><td>(*)</td><td></td><td>**</td><td>*</td><td>*</td></tr><tr><td>< 30 years</td><td>3</td><td>31.8 ± 19.8</td><td>60.9 ± 24.6</td><td>40.6 ± 20.5</td><td>38.0 ± 18.1</td><td>43.0 ± 20.7</td></tr><tr><td>30–49 years</td><td>38</td><td>49.7 ± 26.2</td><td>70.4 ± 20.2</td><td>63.4 ± 26.9</td><td>55.3 ± 23.4</td><td>58.8 ± 23.9</td></tr><tr><td>50–69 years</td><td>45</td><td>54.2 ± 26.2</td><td>72.2 ± 19.6</td><td>74.7 ± 24.9</td><td>62.5 ± 22.4</td><td>65.8 ± 23.2</td></tr><tr><td>> 70 years</td><td>12</td><td>46.2 ± 23.6</td><td>67.7 ± 25.7</td><td>79.8 ± 23.5</td><td>63.4 ± 28.2</td><td>64.5 ± 28.0</td></tr><tr><td>marital status</td><td></td><td>*</td><td></td><td>*</td><td>*</td><td></td></tr><tr><td>married</td><td>65</td><td>47.2 ± 26.0</td><td>69.3 ± 21.3</td><td>70.1 ± 27.0</td><td>56.1 ± 24.6</td><td>60.5 ± 26.0</td></tr><tr><td>living with partner</td><td>11</td><td>52.5 ± 20.1</td><td>73.3 ± 21.3</td><td>57.1 ± 24.7</td><td>58.3 ± 16.8</td><td>63.2 ± 13.9</td></tr><tr><td>divorced</td><td>9</td><td>65.0 ± 26.9</td><td>75.4 ± 19.3</td><td>74.1 ± 25.8</td><td>69.9 ± 19.7</td><td>68.5 ± 24.7</td></tr><tr><td>alone</td><td>10</td><td>55.9 ± 29.6</td><td>71.3 ± 20.4</td><td>72.3 ± 25.8</td><td>61.6 ± 27.2</td><td>65.9 ± 23.7</td></tr><tr><td>widowed</td><td>5</td><td>51.4 ± 17.8</td><td>68.2 ± 19.6</td><td>84.3 ± 17.8</td><td>73.5 ± 18.2</td><td>62.5 ± 22.9</td></tr><tr><td>education<sup>1</sup></td><td></td><td>**</td><td>**</td><td></td><td>**</td><td>**</td></tr><tr><td>level 1</td><td>25</td><td>36.6 ± 24.9</td><td>58.6 ± 20.4</td><td>69.0 ± 26.1</td><td>55.0 ± 24.1</td><td>58.9 ± 24.6</td></tr><tr><td>level 2</td><td>29</td><td>44.4 ± 27.8</td><td>67.8 ± 19.5</td><td>68.9 ± 29.6</td><td>50.6 ± 25.7</td><td>53.5 ± 29.2</td></tr><tr><td>level 3</td><td>37</td><td>65.5 ± 24.7</td><td>76.9 ± 16.7</td><td>75.8 ± 19.8</td><td>68.2 ± 19.2</td><td>69.1 ± 15.3</td></tr><tr><td>other</td><td>9</td><td>65.5 ± 24.94</td><td>74.6 ± 21.6</td><td>74.2 ± 21.2</td><td>67.9 ± 19.8</td><td>75.0 ± 19.0</td></tr><tr><td>disease</td><td></td><td>**</td><td>**</td><td>**</td><td>**</td><td>**</td></tr><tr><td>Cancer</td><td>51</td><td>55.4 ± 24.6</td><td>73.8 ± 19.7</td><td>74.2 ± 23.4</td><td>62.3 ± 22.5</td><td>64.3 ± 22.3</td></tr><tr><td>Multiple Sclerosis</td><td>24</td><td>35.8 ± 22.5</td><td>59.0 ± 19.1</td><td>56.8 ± 28.0</td><td>48,0 ± 23.3</td><td>52.9 ± 25.8</td></tr><tr><td>Chronic diseases</td><td>16</td><td>56.5 ± 25.7</td><td>75.0 ± 19.3</td><td>69.8 ± 27.5</td><td>63.1 ± 26.1</td><td>68.6 ± 26.1</td></tr><tr><td>Acute diseases</td><td>7</td><td>44.7 ± 26.4</td><td>74.8 ± 27.1</td><td>76.4 ± 30.6</td><td>60.6 ± 23.9</td><td>67.6 ± 23.9</td></tr><tr><td>duration of disease</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>< 0.5 years</td><td>19</td><td>48.2 ± 26.1</td><td>73.3 ± 18.6</td><td>68.8 ± 27.7</td><td>58.4 ± 21.7</td><td>63.3 ± 20.2</td></tr><tr><td>0.5–1 years</td><td>12</td><td>53.1 ± 24.9</td><td>79.0 ± 19.7</td><td>67.9 ± 28.6</td><td>58.1 ± 20.6</td><td>58.0 ± 26.0</td></tr><tr><td>1–3 years</td><td>26</td><td>54.1 ± 24.4</td><td>72.5 ± 20.2</td><td>71.1 ± 23.1</td><td>60.6 ± 22.9</td><td>63.7 ± 22.9</td></tr><tr><td>3–5 years</td><td>12</td><td>46.8 ± 27.6</td><td>61.9 ± 19.4</td><td>66.4 ± 28.2</td><td>56.7 ± 26.1</td><td>56.7 ± 28.3</td></tr><tr><td>> 5 years</td><td>31</td><td>47.3 ± 26.4</td><td>70.8 ± 22.1</td><td>68.0 ± 28.1</td><td>56.7 ± 27.0</td><td>61.9 ± 26.0</td></tr><tr><td>confession</td><td></td><td>**</td><td></td><td>**</td><td>**</td><td>**</td></tr><tr><td>Christian</td><td>80</td><td>52.9 ± 25.4</td><td>71.2 ± 20.8</td><td>76.0 ± 21.3</td><td>62.2 ± 22.8</td><td>63.8 ± 24.3</td></tr><tr><td>Others</td><td>3</td><td>58.3 ± 18.0</td><td>70.8 ± 17.1</td><td>85.4 ± 15.7</td><td>65.7 ± 23.5</td><td>83.0 ± 16.8</td></tr><tr><td>None</td><td>17</td><td>38.7 ± 26.9</td><td>67.0 ± 22.2</td><td>38.2 ± 28.3</td><td>41.7 ± 22.8</td><td>50.9 ± 22.4</td></tr><tr><td>Spiritual attitude</td><td></td><td>**</td><td>**</td><td>**</td><td>**</td><td>**</td></tr><tr><td>R+S+</td><td>32</td><td>71.1 ± 20.2</td><td>77.9 ± 18.5</td><td>85.4 ± 15.0</td><td>75.7 ± 14.0</td><td>74.6 ± 19.9</td></tr><tr><td>R+S-</td><td>36</td><td>42.1 ± 21.0</td><td>68.2 ± 19.8</td><td>81.3 ± 16.6</td><td>59.1 ± 20.3</td><td>61.8 ± 22.2</td></tr><tr><td>R-S+</td><td>9</td><td>66.8 ± 14.7</td><td>76.7 ± 22.0</td><td>50.2 ± 15.6</td><td>63.8 ± 20.6</td><td>67.9 ± 16.7</td></tr><tr><td>R-S-</td><td>23</td><td>29.0 ± 17.6</td><td>61.1 ± 21.3</td><td>37.8 ± 22.6</td><td>33.3 ± 19.0</td><td>42.9 ± 23.6</td></tr></table> |
e53590bd9ac702a095f345455af7cdd10bac6c8b7b1ecf9976d909e3dbce591a.png | complex | <table><tr><td>WHO region</td><td>One registration authority</td><td>Registration guidelines</td><td>Require WHOPES recommendations</td><td>WHOPES as sole basis</td></tr><tr><td>Africa</td><td></td><td>82 (14/17)</td><td></td><td>45 (13/29)</td><td></td><td>79 (23/29)</td><td></td><td>48 (11/23)</td></tr><tr><td>Americas</td><td></td><td>71 (12/17)</td><td></td><td>73 (19/26)</td><td></td><td>60 (15/25)</td><td></td><td>13 (2/15)</td></tr><tr><td>Eastern Mediterranean</td><td></td><td>42 (5/12)</td><td></td><td>67 (10/15)</td><td></td><td>80 (12/15)</td><td></td><td>42 (5/12)</td></tr><tr><td>Europe</td><td></td><td>60 (3/5)</td><td></td><td>100 (5/5)</td><td></td><td>80 (4/5)</td><td></td><td>25 (1/4)</td></tr><tr><td>Southeast Asia</td><td></td><td>80 (4/5)</td><td></td><td>86 (6/7)</td><td></td><td>71 (5/7)</td><td></td><td>0 (0/5)</td></tr><tr><td>Western Pacific</td><td></td><td>79 (15/19)</td><td></td><td>50 (12/24)</td><td></td><td>80 (16/20)</td><td></td><td>19 (3/16)</td></tr><tr><td>All</td><td></td><td>71 (53/75)</td><td></td><td>61 (65/106)</td><td></td><td>74 (75/101)</td><td></td><td>29 (22/75)</td></tr><tr><td colspan="9">Data are the percentage of countries responding positively to each question in each region. Values in parentheses are number of positive responses/number of countries that responded to each question.</td></tr></table> |
7628c3fb13d7ff8d14120846d8a1be34a2a04e9e748130f38852f583a95997cc.png | simple | <table><tr><td>Locus</td><td>Observed, bp</td><td><i>N<sub>a</sub></i></td><td>Fluorescence</td></tr><tr><td>M_fav4</td><td>375-391</td><td>5</td><td>FAM</td></tr><tr><td>maMS2-5</td><td>280-328</td><td>20</td><td>FAM</td></tr><tr><td>maMS8</td><td>197-203</td><td>3</td><td>FAM</td></tr><tr><td>M_fav6</td><td>387-429</td><td>11</td><td>HEX</td></tr><tr><td>M_fav7</td><td>453-498</td><td>9</td><td>HEX</td></tr><tr><td>maMS2-8</td><td>187-205</td><td>10</td><td>NED</td></tr></table> |
64d7616afc6259992bd149910f1887bd97e2a8a114f9abdd890e070287832ba5.png | complex | <table><tr><td></td><td></td><td>Nevi</td><td>Primary melanomas</td><td>Metastases</td><td><i>p</i>-values</td><td>AUC [95 % C.I.]</td></tr><tr><td>Ki-67 index</td><td>Mean [95%C.I.]</td><td>1.7 % [1.3–2.1]</td><td>21.7 % [18.9–24.3]</td><td>29.9 % [24.9–35]</td><td><i>p</i> < 0.001</td><td>- nevi vs primary melanomas : 0.959 [0.925–0.981]- benign vs malignant tumours (with metastases): 0.966 [0.94–0.983]</td></tr><tr><td>p16 (% of stained cells)</td><td>Mean [95%C.I.]</td><td>60.5 % [54.4–66.7]</td><td>24.8 % [18.9–30.7]</td><td>16.2 % [9.1–23.3]</td><td><i>p</i> < 0.001</td><td>- nevi vs primary melanomas : 0.778 [0.719–0.830]- benign vs malignant tumours (with metastases): 0.804 [0.756–0.847]</td></tr><tr><td rowspan="3">HMB45 gradient</td><td>Yes:</td><td>44.6 %</td><td>10.3 %</td><td rowspan="3">N. A.</td><td rowspan="3"><i>p</i> < 0.001</td><td rowspan="3">0.74 [0.678–0.795]</td></tr><tr><td>Doubtful:</td><td>24.3 %</td><td>14.7 %</td></tr><tr><td>No:</td><td>31.1 %</td><td>75 %</td></tr><tr><td rowspan="8">p16-Ki67 combined score</td><td>Score 0:</td><td>48.6 %</td><td>0 %</td><td>0 %</td><td rowspan="8">-</td><td rowspan="8">0.982 [0.955–0.995]</td></tr><tr><td>Score 1:</td><td>33.8 %</td><td>0 %</td><td>0 %</td></tr><tr><td>Score 2:</td><td>16.2 %</td><td>10.9 %</td><td>3.8 %</td></tr><tr><td>Score 3:</td><td>0 %</td><td>10.9 %</td><td>6.4 %</td></tr><tr><td>Score 4:</td><td>0 %</td><td>26.9 %</td><td>21.8 %</td></tr><tr><td>Score 5:</td><td>0 %</td><td>13.5 %</td><td>15.4 %</td></tr><tr><td>Score 6:</td><td>1.4 %</td><td>14.7 %</td><td>16.7 %</td></tr><tr><td>Score 7:</td><td>0 %</td><td>23.1 %</td><td>35.9 %</td></tr><tr><td rowspan="10">p16-Ki67-HMB45 combined score</td><td>Score 0:</td><td>20.2 %</td><td>0 %</td><td rowspan="10">N.A.</td><td rowspan="10">-</td><td rowspan="10">0.987 [0.963–0.997]</td></tr><tr><td>Score 1:</td><td>25.7 %</td><td>0 %</td></tr><tr><td>Score 2:</td><td>35.1 %</td><td>0 %</td></tr><tr><td>Score 3:</td><td>16.2 %</td><td>1.3 %</td></tr><tr><td>Score 4:</td><td>1.4 %</td><td>13.5 %</td></tr><tr><td>Score 5:</td><td>0 %</td><td>13.5 %</td></tr><tr><td>Score 6:</td><td>0 %</td><td>26.9 %</td></tr><tr><td>Score 7:</td><td>0 %</td><td>16.7 %</td></tr><tr><td>Score 8:</td><td>1.4 %</td><td>12.8 %</td></tr><tr><td>Score 9:</td><td>0 %</td><td>15.4 %</td></tr></table> |
0c4f7189a1e58f422442c0d267c26e931da7120aff84bea6c3fa53a8de544d09.png | simple | <table><tr><td>Variables</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td><td>15</td></tr><tr><td>Total risk score</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Protective score</td><td>.32**</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Active coping</td><td>− .02</td><td>− .11</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Passive coping</td><td>− .11</td><td>− .04</td><td>.21*</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Living situation</td><td>− .01</td><td>.10</td><td>− .05</td><td>− .20*</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Social participation</td><td>− .16</td><td>− .09</td><td>.04</td><td>− .16</td><td>.31**</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Health</td><td>− .02</td><td>− .02</td><td>.08</td><td>− .13</td><td>− .04</td><td>.26*</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Finances</td><td>.15</td><td>.04</td><td>− .03</td><td>− .14</td><td>.08</td><td>.25*</td><td>.17</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Family relations</td><td>.11</td><td>− .16</td><td>− .08</td><td>− .44**</td><td>.15</td><td>.13</td><td>.05</td><td>.19</td><td>–</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Safety</td><td>.10</td><td>− .09</td><td>− .16</td><td>− .24*</td><td>− .11</td><td>.05</td><td>.16</td><td>.26*</td><td>.25*</td><td>–</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive esteem</td><td>− .01</td><td>− .01</td><td>− .06</td><td>− .22*</td><td>.06</td><td>− .05</td><td>.21*</td><td>.15</td><td>.06</td><td>.25*</td><td>–</td><td></td><td></td><td></td><td></td></tr><tr><td>Negative esteem</td><td>.18</td><td>.13</td><td>− .20</td><td>− .44**</td><td>.12</td><td>− .03</td><td>.17</td><td>.10</td><td>.28**</td><td>.22*</td><td>.45**</td><td>–</td><td></td><td></td><td></td></tr><tr><td>Fulfilment</td><td>.07</td><td>− .10</td><td>.09</td><td>− .37**</td><td>.28**</td><td>.40**</td><td>.20*</td><td>.19</td><td>.45**</td><td>.31**</td><td>.32**</td><td>.45**</td><td>–</td><td></td><td></td></tr><tr><td>Framework</td><td>− .05</td><td>− .15</td><td>.32**</td><td>− .13</td><td>.08</td><td>.10</td><td>.03</td><td>− .02</td><td>.04</td><td>.20</td><td>.31**</td><td>.21*</td><td>.47**</td><td>–</td><td></td></tr><tr><td>Delinquency</td><td>.17</td><td>.08</td><td>− .25*</td><td>− .03</td><td>− .10</td><td>− .12</td><td>− .08</td><td>.05</td><td>− .03</td><td>.16</td><td>.02</td><td>.11</td><td>− .06</td><td>.01</td><td>–</td></tr><tr><td>Psychosocial problems</td><td>.13</td><td>.08</td><td>.09</td><td>.37**</td><td>− .17</td><td>− .22*</td><td>− .28**</td><td>− .03</td><td>− .18</td><td>− .05</td><td>− .16</td><td>− .15</td><td>− .25*</td><td>− .10</td><td>.40**</td></tr></table> |
7ab13bf36720d0316024f08a2a376610c8f6408e1c28a5532c84afbf717540f3.png | complex | <table><tr><td colspan="3">Sample activities of social skills training (for children)</td></tr><tr><td>Session number</td><td>Session topics</td><td>Sample activities<sup>†</sup></td></tr><tr><td>1,14,15,20</td><td>Pragmatic speech skills</td><td>Knowing how to introduce themselves in public, such as vocal volume and the manner of standing.</td></tr><tr><td>2,11</td><td>Problem solving skills</td><td>Knowing how to request assistance or help from other people. Setting a difficult scene and learning the general rules of socially appropriate behaviors by using videotape.</td></tr><tr><td>3,4,5,6,</td><td>Friendship skills</td><td>Understanding the time, inviting to play, borrowing things, refusing a request politely and responding to rejection when a request is refused.</td></tr><tr><td>7,8,9</td><td>Self-regulation skills</td><td>Understanding feelings, such as knowing and controlling emotions when they lose a game, dealing with desires.</td></tr><tr><td>10,12,13,16</td><td>Nonverbal communication skills</td><td>Knowing the feelings of friends, such as practicing facial expressions in a mirror or face-to-face and asking about the feelings and emotions of others.</td></tr><tr><td>17,18,19</td><td>Shopping skills</td><td>Knowing shopping rules and paying with money at the cafe.</td></tr><tr><td colspan="3">Outline of mothers’ program</td></tr><tr><td>Session number</td><td colspan="2">Session topics</td></tr><tr><td>1</td><td colspan="2">Introducing themselves and understanding the concepts of the program.</td></tr><tr><td>2,6,9,13,19</td><td colspan="2">Watching the children’s program through a one-way mirror, understanding the TEACCH method and joining SST with their children.</td></tr><tr><td>3</td><td colspan="2">Learning about development of HFA from a child psychiatrist.</td></tr><tr><td>4,7,8</td><td colspan="2">Setting a goal for daily life, individual consultation by social workers and peer counseling.</td></tr><tr><td>5,10,11,12,14,18</td><td colspan="2">Learning parent training, such as making manuals for their children or using effective instructions and communication with positive feedback.</td></tr><tr><td>15,16,17</td><td colspan="2">Consulting about educational support for elementary school, and making a support system and a "support-book".</td></tr><tr><td>20</td><td colspan="2">Joining the farewell ceremony and practicing positive feedback with their children.</td></tr></table> |
6d5e44444ca22fde9401656f0cda76f53c2ab613b23a2e4f1d5998ebc31f9fee.png | complex | <table><tr><td>Factors</td><td><i>P-</i>value</td><td>Odds ratio</td><td colspan="2">95% CI of odds ratio</td><td>Observed power</td></tr><tr><td></td><td></td><td></td><td>Lower</td><td>Upper</td><td></td></tr><tr><td>Age ≧50 yr</td><td>0.221</td><td>1.784</td><td>0.705</td><td>4.510</td><td>0.261</td></tr><tr><td>RAI (+)</td><td>0.046</td><td>2.601</td><td>1.015</td><td>6.664</td><td>0.371</td></tr><tr><td>ACTH ≧5 pg/mL</td><td>0.038</td><td>2.759</td><td>1.060</td><td>7.185</td><td>0.428</td></tr><tr><td>ADH ≧30 pg/mL</td><td>0.038</td><td>2.576</td><td>1.051</td><td>6.313</td><td>0.343</td></tr></table> |
2c0fc0d3613a36f05be9151e4727617f0c945dd93ba35a3466cd9069c82d18c5.png | simple | <table><tr><td>AIN-93M</td><td>Standard diet (w/w)</td><td>High fat-fructose diet (w/w)</td></tr><tr><td>Corn starch</td><td>46%</td><td>46%</td></tr><tr><td>Dextrin</td><td>15.5%</td><td>15.5%</td></tr><tr><td>Casein vitamin free</td><td>14%</td><td>14%</td></tr><tr><td>Sucrose</td><td>10%</td><td>28%</td></tr><tr><td>Fructose</td><td>—</td><td>20%</td></tr><tr><td>Powdered cellulose</td><td>5%</td><td>5%</td></tr><tr><td>Soybean oil</td><td>4%</td><td>4% + 18% (lard)</td></tr><tr><td>AIN 93M mineral mix</td><td>3.5%</td><td>3.5%</td></tr><tr><td>AIN 93 vitamin mix</td><td>1%</td><td>1%</td></tr><tr><td>Choline bitartrate</td><td>0.25%</td><td>0.25%</td></tr><tr><td>L-Cystine</td><td>0.18%</td><td>0.18%</td></tr><tr><td>t-Butylhydroquinone</td><td>0.0008%</td><td>0.0008%</td></tr><tr><td>Energy (Kcal/30 g/day)</td><td>114</td><td>141</td></tr></table> |
ee07bb6df6d803fffde2770a71849fe16a4ace7dae231b81ce476746ed1c37ff.png | complex | <table><tr><td rowspan="2">miRNAs</td><td colspan="3">IPMN</td><td colspan="3">PDAC</td><td rowspan="2">p-value</td></tr><tr><td>Mean</td><td colspan="2">Quartiles</td><td>Mean</td><td colspan="2">Quartiles</td></tr><tr><td>miR-16</td><td>0.063</td><td>0.011</td><td>0.140</td><td>0.157</td><td>0.081</td><td>0.272</td><td>0.028</td></tr><tr><td>miR-17</td><td>0.007</td><td>0.004</td><td>0.009</td><td>0.019</td><td>0.009</td><td>0.033</td><td>0.005</td></tr><tr><td>miR-181a</td><td>0.021</td><td>0.001</td><td>0.030</td><td>0.073</td><td>0.018</td><td>0.182</td><td>0.008</td></tr><tr><td>miR-187</td><td>1.315</td><td>0.192</td><td>5.399</td><td>0.170</td><td>0.061</td><td>0.811</td><td>0.010</td></tr></table> |
c2219618814bfa1268f90b01cf214d780285016f816093f4fa21ced7457ad2b0.png | simple | <table><tr><td>Reference</td><td>Year</td><td>Age (years)</td><td>Sex</td><td>Chief Clinical presentation</td><td>Site</td><td>Size (mm)</td><td>Operation</td><td>Follow up (months)</td></tr><tr><td>Inai et al. [16]</td><td>1989</td><td>17</td><td>Male</td><td>Hematoemesis</td><td>Papilla of Vater</td><td>20</td><td>PD</td><td>NED 32</td></tr><tr><td>Hashimoto et al. [17]</td><td>1992</td><td>47</td><td>Male</td><td>Incidental findings</td><td>Papilla of Vater</td><td>65</td><td>PD</td><td>NED 14</td></tr><tr><td>Takabayashi et al. [18]</td><td>1993</td><td>63</td><td>Female</td><td>Abdominal pain</td><td>Papilla of Vater</td><td>32</td><td>PPPD</td><td>NED 24</td></tr><tr><td>Tomic et al. [19]</td><td>1996</td><td>74</td><td>Female</td><td>Abdominal pain, vomiting, weight loss</td><td>Pancreas</td><td>40</td><td>PD</td><td>NED 19</td></tr><tr><td>Sundararajan et al. [1]</td><td>2003</td><td>67</td><td>Female</td><td>Incidental findings</td><td>Second part of duodenum</td><td>50</td><td>PD</td><td>NED 9</td></tr><tr><td>Bucher et al. [20]</td><td>2004</td><td>31</td><td>Female</td><td>Anemia, subclinical jaundice</td><td>Papilla of Vater</td><td>30</td><td>PPPD</td><td>NED 44</td></tr><tr><td>Wong et al. [10]</td><td>2005</td><td>49</td><td>Female</td><td>Melena</td><td>Duodenum</td><td>14</td><td>PPPD</td><td>NED 12</td></tr><tr><td>Witkiewicz et al. [21]</td><td>2007</td><td>38</td><td>Female</td><td>Abdominal pain</td><td>Papilla of Vater</td><td>15</td><td>PPPD</td><td>NR</td></tr><tr><td>Mann et al. [22]</td><td>2009</td><td>17</td><td>Female</td><td>Abdominal pain, vomiting, weight loss</td><td>Duodenum</td><td>NR</td><td>PPPD</td><td>NR</td></tr><tr><td>Present case</td><td>2010</td><td>61</td><td>Male</td><td>Epigastralgia, tarry stool</td><td>Papilla of Vater</td><td>30</td><td>PPPD</td><td>NED 6</td></tr></table> |
fd443580c0042494de8ae66e4ec04743a07bf394f27de0640b9c3c9ec93fe18b.png | simple | <table><tr><td>Parameter</td><td>Estimate</td><td>SE</td><td>95% CI</td><td>P</td><td>OR</td></tr><tr><td>Intercept</td><td>3.2</td><td>0.8</td><td>1.6 to 4.9</td><td><0.01</td><td></td></tr><tr><td>Number of anastomoses</td><td>-0.30</td><td>0.17</td><td>-0.64 to 0.05</td><td>0.09</td><td>0.74</td></tr><tr><td>Operation time</td><td>-0.003</td><td>0.001</td><td>-0.006 to -0.001</td><td>0.01</td><td>0.997</td></tr></table> |
780ca5447bdb49356e6951b790a5a56a5bf1557309bfb44f31eb8593302c67f5.png | simple | <table><tr><td></td><td>1 Set of Medial Branch Blocks (n=28)Median (IQR)or n (%)</td><td>2 Sets of Medial Branch Blocks (n=27)Median (IQR)or n (%)</td><td>P value</td></tr><tr><td>≥50% improvement in function</td><td>13 (46%)</td><td>17 (63%)</td><td>0.22</td></tr><tr><td>Reduction in NRS pain score</td><td>2 (1, 5)</td><td>2 (0, 4)</td><td>0.56</td></tr><tr><td>≥50% improvement in pain</td><td>12 (43%)</td><td>16 (59%)</td><td>0.21</td></tr><tr><td>Change in Morphine eq</td><td>0 (0, 10)</td><td>1.7 (0, 10)</td><td>0.57</td></tr><tr><td>Change in MQS III score</td><td>2.7(0, 9.6)</td><td>3.4 (0, 11.6)</td><td>0.35</td></tr></table> |
12c0c3f7b81a8b55bd4f31b4e964a5a085ffe7c8aaf9e54768be3f9e166016db.png | complex | <table><tr><td>FPI-6</td><td>Side</td><td>10 years8%Mean ± SD(CI)</td><td>11 years22%Mean ± SD(CI)</td><td>12 years26%Mean ± SD(CI)</td><td>13 years25%Mean ± SD(CI)</td><td>14 years19%Mean ± SD(CI)</td><td><i>p</i>-value</td></tr><tr><td rowspan="2">Total score</td><td>R</td><td>2.74 ± 2.22(4.18; 0.26)</td><td>3.91 ± 2.63(4,59; 0.67)</td><td>3.01 ± 2.77(4.73; 0.81)</td><td>2.58 ± 2.79(4.75; 0.83)</td><td>2.91 ± 2.88(4.84; 0.92)</td><td>0.141</td></tr><tr><td>L</td><td>3.65 ± 2.38(4.34; 0.42)</td><td>4.16 ± 2.63(4.59; 0.67)</td><td>3.61 ± 2.78(4.74; 0.82)</td><td>3.27 ± 2.79(4.75; 0.83)</td><td>3.51 ± 2.97(4.93; 1,01)</td><td>0.024<sup>11–13</sup>*</td></tr></table> |
fc834f80287b8c5f2feb14dd546bc7143247feacc1b1db627e7f10421494a229.png | complex | <table><tr><td></td><td>Bias 2–1</td><td>Bias 3–2</td><td>SD 2–1</td><td>SD 3–2</td><td>Δ Bias</td><td>Δ SD</td><td>Bias 2–1</td><td>Bias 3–2</td><td>SD 2–1</td><td>SD 3–2</td><td>Δ Bias</td><td>Δ SD</td></tr><tr><td></td><td colspan="6">Expert 1</td><td colspan="6">Expert 2</td></tr><tr><td>R-TFA</td><td>1</td><td>0</td><td>2.31</td><td>1.97</td><td>0</td><td>−0.34</td><td>0</td><td>0</td><td>1.55</td><td>2.09</td><td>0</td><td>0.54</td></tr><tr><td>R-TTA</td><td>1</td><td>0</td><td>5.94</td><td>2.25</td><td>−1</td><td>−3.69</td><td>0</td><td>0</td><td>1.71</td><td>1.90</td><td>0</td><td>0.19</td></tr><tr><td>L-TFA</td><td>0</td><td>0</td><td>5.39</td><td>1.55</td><td>−1</td><td>−3.84</td><td>0</td><td>0</td><td>1.20</td><td>1.89</td><td>0</td><td>0.69</td></tr><tr><td>L-TTA</td><td>2</td><td>0</td><td>2.36</td><td>3.21</td><td>0</td><td>0.85</td><td>0</td><td>0</td><td>2.25</td><td>1.76</td><td>0</td><td>−0.49</td></tr><tr><td>R-FAA</td><td>0</td><td>0</td><td>5.12</td><td>1.97</td><td>−2</td><td>−3.15</td><td>0</td><td>0</td><td>1.89</td><td>1.55</td><td>0</td><td>−0.34</td></tr><tr><td>L-FAA</td><td>0</td><td>0</td><td>3.15</td><td>1.63</td><td>0</td><td>−1.52</td><td>0</td><td>0</td><td>1.65</td><td>1.71</td><td>0</td><td>0.06</td></tr><tr><td>Average</td><td></td><td></td><td>4.05</td><td>2.10</td><td>−0.67</td><td>−1.95</td><td></td><td></td><td>1.71</td><td>1.82</td><td>0.00</td><td>0.11</td></tr><tr><td></td><td colspan="6">Non-expert 1</td><td colspan="6">Non-expert 2</td></tr><tr><td>R-TFA</td><td>0</td><td>0</td><td>3.34</td><td>2.42</td><td>0</td><td>−0.92</td><td>0</td><td>0</td><td>3.49</td><td>2.33</td><td>0</td><td>−1.16</td></tr><tr><td>R-TTA</td><td>6</td><td>0</td><td>16.04</td><td>2.10</td><td>−6</td><td>−13.94</td><td>1</td><td>0</td><td>5.97</td><td>3.90</td><td>−1</td><td>−2.07</td></tr><tr><td>L-TFA</td><td>0</td><td>0</td><td>3.14</td><td>1.48</td><td>0</td><td>−1.66</td><td>0</td><td>1</td><td>4.19</td><td>3.74</td><td>1</td><td>−0.45</td></tr><tr><td>L-TTA</td><td>2</td><td>0</td><td>8.76</td><td>3.22</td><td>−2</td><td>−5.54</td><td>1</td><td>0</td><td>4.64</td><td>4.20</td><td>−1</td><td>−0.44</td></tr><tr><td>R-FAA</td><td>0</td><td>0</td><td>4.80</td><td>2.82</td><td>0</td><td>−1.98</td><td>0</td><td>1</td><td>4.63</td><td>4.92</td><td>1</td><td>0.29</td></tr><tr><td>L-FAA</td><td>1</td><td>1</td><td>7.32</td><td>4.49</td><td>0</td><td>−2.83</td><td>0</td><td>0</td><td>3.82</td><td>3.59</td><td>0</td><td>−0.23</td></tr><tr><td>Average</td><td></td><td></td><td>7.23</td><td>2.76</td><td>−1.33</td><td>−4.48</td><td></td><td></td><td>4.46</td><td>3.78</td><td>0.00</td><td>−0.68</td></tr></table> |
57b99f6641c4ee69620552f55421e30353156284ea757fa77541eaf38bee4033.png | simple | <table><tr><td>Location</td><td>Time period (ms)</td><td>Location (<i>y,z</i>)</td><td><i>Z</i><sub>obs</sub></td><td><i>Z</i><sub>crit</sub></td></tr><tr><td>Study</td></tr><tr><td>Left STS</td><td>383–409</td><td>(-53, 4)</td><td>2.636</td><td>2.50</td></tr><tr><td>Right STS</td><td>588–614</td><td>(-58, 23)</td><td>2.674</td><td>2.57</td></tr><tr><td></td><td>691</td><td>(-58, 17)</td><td>2.446</td><td>2.53</td></tr><tr><td>Scene preview – correct trial only</td></tr><tr><td>Left STS</td><td>716–742</td><td>(-63, -1)</td><td>2.925</td><td>2.71</td></tr><tr><td>Left DLPFC</td><td>307</td><td>(47, 34)</td><td>2.729</td><td>2.61</td></tr><tr><td></td><td>1254–1305</td><td>(37, 34)</td><td>2.926</td><td>2.73</td></tr><tr><td></td><td>1459–1484</td><td>(49, 32)</td><td>2.872</td><td>2.66</td></tr><tr><td></td><td>1663–1715</td><td>(37, 34)</td><td>2.875</td><td>2.79</td></tr><tr><td>Right DLPFC</td><td>1305</td><td>(34, 34)</td><td>2.665</td><td>2.63</td></tr><tr><td></td><td>1561</td><td>(42, 34)</td><td>3.026</td><td>2.91</td></tr><tr><td>Scene preview – all trails</td></tr><tr><td>Left STS</td><td>486–511</td><td>(-63, 7)</td><td>2.387</td><td>2.32</td></tr><tr><td></td><td>716–742</td><td>(-61, -1)</td><td>3.391</td><td>2.73</td></tr><tr><td></td><td>1254</td><td>(-46, -3)</td><td>2.566</td><td>2.71</td></tr><tr><td>Left DLPFC</td><td>307</td><td>(47, 34)</td><td>2.609</td><td>2.59</td></tr><tr><td></td><td>1100–1126</td><td>(32, 34)</td><td>3.711</td><td>2.84</td></tr><tr><td></td><td>1128–1331</td><td>(37, 32)</td><td>3.459</td><td>2.72</td></tr><tr><td></td><td>1663–1715</td><td>(37, 34)</td><td>2.992</td><td>2.77</td></tr><tr><td>Right DLPFC</td><td>281</td><td>(22, 24)</td><td>2.978</td><td>2.97</td></tr><tr><td></td><td>1279</td><td>(34, 32)</td><td>2.848</td><td>2.80</td></tr></table> |
c012bdd7b3d95fe3f6027377733aa188b7392726ae1013cdaf4cf9b2deb70a5d.png | complex | <table><tr><td>Variables</td><td colspan="3">PE at school*</td><td colspan="3">Leisure PA **</td><td colspan="3">Active commuting**</td><td colspan="3">LPA***</td></tr><tr><td> </td><td>%</td><td>PR</td><td>95% CI</td><td>%</td><td>PR</td><td>95% CI</td><td>%</td><td>PR</td><td>95% CI</td><td>%</td><td>PR</td><td>95% CI</td></tr><tr><td>Total</td><td>38.7</td><td> </td><td>28.6-48.7</td><td>67.5</td><td> </td><td>66.7-68.3</td><td>61.9</td><td> </td><td>59.9-64.0</td><td>28.8</td><td> </td><td>28.1-29.5</td></tr><tr><td colspan="3">Physical education at school</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>-</td><td>-</td><td>-</td><td>65.5</td><td>1</td><td> </td><td>61.2</td><td>1</td><td> </td><td>24.1</td><td>1</td><td> </td></tr><tr><td>Yes</td><td>-</td><td>-</td><td>-</td><td>70.6</td><td>1.00</td><td>0.99-1.02</td><td>62.9</td><td>0.97</td><td>0.95-0.98</td><td>36.6</td><td>1.36</td><td>1.29-1.44</td></tr><tr><td colspan="3">Leisure time physical activity</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>35</td><td>1</td><td> </td><td>-</td><td>-</td><td>-</td><td>56</td><td>1</td><td> </td><td>0.3</td><td>1</td><td> </td></tr><tr><td>Yes</td><td>40</td><td>1.00</td><td>0.98-1.03</td><td>-</td><td>-</td><td>-</td><td>64.8</td><td>1.04</td><td>1.02-1.06</td><td>41.5</td><td>12.5</td><td>11.17-13.97</td></tr><tr><td colspan="3">Active commuting</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>No</td><td>37.6</td><td>1</td><td> </td><td>62.5</td><td>1</td><td> </td><td>-</td><td>-</td><td>-</td><td>19</td><td>1</td><td> </td></tr><tr><td>Yes</td><td>39.4</td><td>0.95</td><td>0.93-0.98</td><td>70.6</td><td>1.03</td><td>1.02-1.04</td><td>-</td><td>-</td><td>-</td><td>35</td><td>1.63</td><td>1.59-1.67</td></tr><tr><td colspan="2">Level of physical activity</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Inactive</td><td>34.6</td><td>1</td><td> </td><td>55.6</td><td>1</td><td> </td><td>56.6</td><td>1</td><td> </td><td>-</td><td>-</td><td>-</td></tr><tr><td>Active</td><td>48.9</td><td>1.33</td><td>1.22-1.45</td><td>96.8</td><td>1.66</td><td>1.65-1.67</td><td>74.9</td><td>1.30</td><td>1.28-1.33</td><td>-</td><td>-</td><td>-</td></tr><tr><td colspan="3">Sedentary behavior</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>< 2 hours/day</td><td>37.8</td><td>1</td><td> </td><td>68.4</td><td>1</td><td> </td><td>58.2</td><td>1</td><td> </td><td>28</td><td>1</td><td> </td></tr><tr><td>> 2 hours/day</td><td>39.3</td><td>0.99</td><td>0.94-1.05</td><td>66.7</td><td>0.98</td><td>0.97-0.99</td><td>64.2</td><td>1.11</td><td>1.09-1.13</td><td>29.5</td><td>1.04</td><td>1.01-1.06</td></tr><tr><td colspan="3">Diet score</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>1st tertile</td><td>38.2</td><td>1</td><td> </td><td>63.5</td><td>1</td><td> </td><td>39.2</td><td>1</td><td> </td><td>26.7</td><td>1</td><td> </td></tr><tr><td>2nd tertile</td><td>38.2</td><td>1.00</td><td>0.97-1.02</td><td>67.2</td><td>1.04</td><td>1.03-1.06</td><td>38.5</td><td>1.01</td><td>0.98-1.03</td><td>26.7</td><td>0.94</td><td>0.92-0.97</td></tr><tr><td>3rd tertile</td><td>39.5</td><td>1.00</td><td>0.97-1.03</td><td>72</td><td>1.07</td><td>1.06-1.08</td><td>36.3</td><td>1.04</td><td>1.01-1.07</td><td>33</td><td>1.09</td><td>1.07-1.12</td></tr><tr><td>Cigarettes</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>49.9</td><td>1</td><td> </td><td>69</td><td>1</td><td> </td><td>61.7</td><td>1</td><td> </td><td>33.3</td><td>1</td><td> </td></tr><tr><td>No</td><td>38.1</td><td>0.93</td><td>0.89-0.96</td><td>67.4</td><td>0.99</td><td>0.97-1.02</td><td>61.9</td><td>1.05</td><td>0.99-1.10</td><td>28.7</td><td>0.99</td><td>0.95-1.05</td></tr><tr><td>Alcohol</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>42.9</td><td>1</td><td> </td><td>68.8</td><td>1</td><td> </td><td>62.1</td><td>1</td><td> </td><td>31.5</td><td>1</td><td> </td></tr><tr><td>No</td><td>37.2</td><td>0.96</td><td>0.93-0.99</td><td>67</td><td>0.97</td><td>0.96-0.99</td><td>61.9</td><td>1.01</td><td>0.99-1.02</td><td>28</td><td>0.94</td><td>0.92-0.95</td></tr><tr><td>Drugs</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>53.2</td><td>1</td><td> </td><td>72</td><td>1</td><td> </td><td>65.4</td><td>1</td><td> </td><td>40.8</td><td>1</td><td> </td></tr><tr><td>No</td><td>38.3</td><td>0.94</td><td>0.89-0.99</td><td>67.4</td><td>1.02</td><td>0.99-1.04</td><td>61.8</td><td>0.98</td><td>0.93-1.00</td><td>28.6</td><td>0.93</td><td>0.89-0.97</td></tr></table> |
2554a9f505e3f53309e8b18dac6c3c1cf2dbec58c5782cb789878c660572dd4d.png | simple | <table><tr><td></td><td>Phase</td><td>Metric</td><td>Expert</td><td>Novice</td></tr><tr><td>LSA</td><td>Descending aorta</td><td>Median force (N)</td><td>0.03</td><td>0.07</td></tr><tr><td></td><td>Arch vessel</td><td>FIT (N s)</td><td>0.63</td><td>1.47</td></tr><tr><td>LCCA</td><td>Descending aorta</td><td>Median force (N)</td><td>0.04</td><td>0.06</td></tr><tr><td></td><td>Arch vessel</td><td>Mean force (N)</td><td>0.11*</td><td>0.39</td></tr><tr><td></td><td></td><td>Median force (N)</td><td>0.10*</td><td>0.20</td></tr><tr><td></td><td></td><td>Max. force (N)</td><td>0.54*</td><td>1.75</td></tr><tr><td></td><td></td><td>FIT (N s)</td><td>1.71*</td><td>9.11</td></tr><tr><td></td><td></td><td>STDEV (N)</td><td>0.09*</td><td>0.42</td></tr><tr><td></td><td></td><td>No. peaks</td><td>0*</td><td>12</td></tr><tr><td>RCCA</td><td>Descending aorta</td><td>Median force (N)</td><td>0.03</td><td>0.05</td></tr><tr><td></td><td>Arch vessel</td><td>Mean force (N)</td><td>0.13*</td><td>0.24</td></tr><tr><td></td><td></td><td>Median force (N)</td><td>0.07*</td><td>0.13</td></tr><tr><td></td><td></td><td>Max force (N)</td><td>0.84*</td><td>1.40</td></tr><tr><td></td><td></td><td>FIT (N s)</td><td>2.23</td><td>3.26</td></tr><tr><td></td><td></td><td>STDEV (N)</td><td>0.12*</td><td>0.3</td></tr><tr><td></td><td></td><td>No. peaks</td><td>0*</td><td>4</td></tr></table> |
5d7cdb0d11a3df16bf2d7d66b93149c0240d4cfe83ca588daf42aad9570ba7c7.png | simple | <table><tr><td>Genotype groups</td><td>BIS scale</td><td>BAS drive</td><td>BAS fun seeking</td><td>BAS reward responsiveness</td><td>BIS11 attentional impulsiveness</td><td>BIS11 motor impulsiveness</td><td>BIS11 non-planning impulsiveness</td></tr><tr><td>LL</td><td>3.01 ± 0.12</td><td>3.12 ± 0.09</td><td>3.11 ± 0.1</td><td>3.41 ± 0.09</td><td>16.4 ± 0.6</td><td>23.5 ± 0.8</td><td>22.18 ± 1</td></tr><tr><td>HH</td><td>2.88 ± 0.12</td><td>3.03 ± 0.1</td><td>2.95 ± 0.1</td><td>3.30 ± 0.09</td><td>16.5 ± 0.6</td><td>23.9 ± 0.8</td><td>23.8 ± 1</td></tr></table> |
af771b9ab2f7f78e6e57adf47c811d2d4d0514e5edb4ee2e7f39f7a7c5f7498d.png | simple | <table><tr><td>Target gene (rat)</td><td>Primer sequence</td><td>Predicted length (bp)</td></tr><tr><td><i>β</i>-catenin</td><td>F:CTCCCCTGACAGAGTTGCT R:ATGTCCAGTCCGAGATCAGC</td><td>187</td></tr><tr><td>CCND1</td><td>F:GCGTACCCTGACACCAATCT R:CTCTTCGCACTTCTGCTCCT</td><td>180</td></tr><tr><td>c-Myc</td><td>F:GCTCCTCGCGTTATTTGAAG R:TTCTCTTCCTCGTCGCAGAT</td><td>152</td></tr><tr><td>GSK-3<i>β</i></td><td>F:TCCGATTGCGGTATTTCTT R:TCACAGGGAGTGTCTGCTT</td><td>138</td></tr><tr><td>Bcl-2</td><td>F:AGTACCTGAACCGGCATCTG R:CAGGTATGCACCCAGAGTGA</td><td>173</td></tr><tr><td>Bax</td><td>F:CGAGCTGATCAGAACCATCA R:CTCAGCCCATCTTCTTCCAG</td><td>191</td></tr><tr><td>Caspase-3</td><td>F:GGACCTGTGGACCTGAAAAA R:GCATGCCATATCATCGTCAG</td><td>159</td></tr><tr><td>Caspase-8</td><td>F:CTGGGAAGGATCGACGATTA R:TGGTCACCTCATCCAAAAC</td><td>100</td></tr><tr><td>Caspase-9</td><td>F:CTCAGGCCAGAGGTTCTCAC R:GGGCAGAAGTTCACGTTGTT</td><td>173</td></tr></table> |
91d14c65d6aa183433a765c53fb99bedf783987037f0dcb197891fdb4ab4f666.png | complex | <table><tr><td rowspan="3"></td><td>Unadjusted model</td><td>Adjusted model 1</td><td>Adjusted model 2 recoded e-cig variable</td><td>Adjusted model 3 imputed model m = 20</td></tr><tr><td rowspan="2">OR (99 % CI)</td><td>OR (99 % CI)</td><td>OR (99 % CI)</td><td>OR (99 % CI)</td></tr><tr><td><i>n</i> = 2824</td><td><i>n</i> = 3363</td><td><i>n</i> = 3808</td></tr><tr><td>Recall tobacco supermarket</td><td>1.79 (1.05 to 3.06)</td><td>0.92 (0.64 to 1.32)</td><td>0.95 (0.60 to 1.51)</td><td>0.97 (0.56 to 1.70)</td></tr><tr><td>Recall tobacco small shop</td><td>2.74 (1.81 to 4.16)</td><td>1.96 (1.45 to 2.65)</td><td>2.19 (1.48 to 3.23)</td><td>1.98 (1.17 to 3.35)</td></tr><tr><td>Recall internet tobacco ads</td><td>1.53 (1.41 to 1.67)</td><td>1.14 (1.02 to 1.28)</td><td>1.14 (0.95 to 1.36)</td><td>1.19 (0.92 to 1.53)</td></tr><tr><td>Never smoked tobacco</td><td></td><td>0.06 (0.03 to 0.09)</td><td>0.05 (0.03 to 0.09)</td><td>0.05 (0.03 to 0.08)</td></tr><tr><td>Tried an e-cigarette</td><td></td><td>3.22 (1.74 to 5.95)</td><td>3.12 (1.66 to 5.89)</td><td>3.08 (1.79 to 5.29)</td></tr><tr><td>Gender- male</td><td></td><td>0.88 (0.62 to 1.24)</td><td>0.94 (0.72 to 1.22)</td><td>0.99 (0.75 to 1.33)</td></tr><tr><td>Ethnic group-non-white</td><td></td><td>0.76 (0.36 to 1.61)</td><td>0.76 (0.52 to 1.10)</td><td>0.85 (0.47 to 1.53)</td></tr><tr><td>Age</td><td></td><td>1.23 (1.00 to 1.52)</td><td>1.23 (1.04 to 1.46)</td><td>1.24 (1.07 to 1.43)</td></tr><tr><td>FAS low</td><td></td><td>1</td><td>1</td><td>1</td></tr><tr><td>FAS medium</td><td></td><td>1.46 (0.95 to 2.24)</td><td>1.39 (0.85 to 2.27)</td><td>1.44 (1.01 to 2.04)</td></tr><tr><td>FAS high</td><td></td><td>1.72 (0.97 to 3.05)</td><td>1.72 (0.92 to 3.24)</td><td>1.81 (1.03 to 3.18)</td></tr></table> |
1e008fc03bb921399ca0b3c1a63cebaf1bc63e3c880f620efe16be1160cfc186.png | complex | <table><tr><td>Tissue</td><td colspan="2">Pooled mean (SD)</td><td>Mean difference (95% CI)</td></tr><tr><td> </td><td>64-row</td><td>128-row</td><td> </td></tr><tr><td>Lung</td><td>93.90 (1.89)</td><td>93.30 (2.03)</td><td>0.60 (-0.66 to 1.86)</td></tr><tr><td>Bone</td><td>93.28 (2.32)</td><td>92.15 (3.63)</td><td>1.13 (-0.82 to 3.08)</td></tr><tr><td>Vessel</td><td>91.60 (3.31)</td><td>89.90 (4.84)</td><td>1.70 (-0.95 to 4.35)</td></tr><tr><td>Organ</td><td>89.60 (3.92)</td><td>85.98 (7.87)</td><td>3.62 (-0.36 to 7.60)</td></tr><tr><td>Fluid/Fat</td><td>92.98 (3.39)</td><td>90.78 (4.43)</td><td>2.20 (-0.33 to 4.73)</td></tr></table> |
70cdf0bc1ef1460bcadab1521135ae22cabd14583a8152cbb393437138ffc8ec.png | simple | <table><tr><td>Index</td><td>Abbreviation</td><td>Threshold</td><td>Reference</td></tr><tr><td>Chi-square</td><td>χ<sup>2</sup></td><td>>0.05</td><td>[51]</td></tr><tr><td>Normed Comparative Fit</td><td>CFI</td><td>≥0.90</td><td>[53]</td></tr><tr><td>Goodness-of-Fit Index</td><td>GFI</td><td>≥0.90</td><td>[54]</td></tr><tr><td>Adjusted-Goodness-of-Fit Index</td><td>AGFI</td><td>≥0.90</td><td>[54]</td></tr><tr><td>Chis-square/Degrees of Freedom</td><td>(χ<sup>2</sup>)/df</td><td><2</td><td>[50,55]</td></tr><tr><td>Root Mean Square Error of Approximation</td><td>RMSEA</td><td><0.05 or <0.08</td><td>[56]</td></tr></table> |
277212991e11282cf48b2caaa072e579f8181072cb7816aca36e162411d937eb.png | complex | <table><tr><td></td><td>Stimulus</td><td>40 ml VS 80 ml</td><td>40 ml VS 120 ml</td><td>80 ml VS 120 ml</td></tr><tr><td rowspan="2">IBS</td><td><i>P</i> value</td><td>0.377</td><td>0.039</td><td>0.002</td></tr><tr><td>95%CI</td><td>−0.192–0.498</td><td>−0.614–0.016</td><td>−0.752–0.185</td></tr><tr><td rowspan="2">Controls</td><td><i>P</i> value</td><td>0.684</td><td>0.876</td><td>0.549</td></tr><tr><td>95%CI</td><td>−0.223–0.149</td><td>−0.215–0.250</td><td>−0.132–0.240</td></tr></table> |
d1df363e3105f3ed037d7083c745561d81c655bd9ba7039803fc5c108cf026b4.png | complex | <table><tr><td></td><td colspan="4">Prevalence (*1000 subjects)</td><td colspan="2">Incidence (*1000 person years)</td></tr><tr><td></td><td colspan="2">31/12/2001</td><td colspan="2">31/12/2004</td><td colspan="2">Mean 2002 – 2004</td></tr><tr><td></td><td>males</td><td>females</td><td>males</td><td>females</td><td>males</td><td>females</td></tr><tr><td>Under 45 years</td><td>5.6</td><td>4.2</td><td>5.5</td><td>5</td><td>1.3</td><td>1.1</td></tr><tr><td></td><td>5.3–5.9</td><td>4–4.5</td><td>5.2–5.8</td><td>4.7–5.3</td><td>1.2–1.4</td><td>1–1.2</td></tr><tr><td>45–54 years</td><td>40.1</td><td>21</td><td>41.2</td><td>19.4</td><td>6.7</td><td>3.5</td></tr><tr><td></td><td>39–42</td><td>19–23</td><td>40–43</td><td>18–21</td><td>6.3–7.2</td><td>3.2–3.8</td></tr><tr><td>55–64 years</td><td>91.2</td><td>55</td><td>99.9</td><td>56.6</td><td>12.8</td><td>7.6</td></tr><tr><td></td><td>89–95</td><td>53–57</td><td>97–102</td><td>55–59</td><td>12.2–13.5</td><td>7.1–8.1</td></tr><tr><td>65–74 years</td><td>132</td><td>96.4</td><td>152</td><td>102.9</td><td>17</td><td>12.4</td></tr><tr><td></td><td>129–136</td><td>94–100</td><td>148–156</td><td>100–106</td><td>16.1–18</td><td>11.7–13.1</td></tr><tr><td>75–84 years</td><td>134</td><td>125</td><td>162.1</td><td>141.4</td><td>15.9</td><td>15.5</td></tr><tr><td></td><td>129–140</td><td>121–129</td><td>157–167</td><td>138–145</td><td>14.7–17.1</td><td>14.6–16.4</td></tr><tr><td>Over 84 years</td><td>105</td><td>122</td><td>139.3</td><td>141.6</td><td>16.2</td><td>15.5</td></tr><tr><td></td><td>97–114</td><td>116–128</td><td>129–150</td><td>135–148</td><td>13.8–18.9</td><td>14–17</td></tr><tr><td>Overall standardized</td><td>39</td><td>34.7</td><td>43.5</td><td>37.6</td><td>5.5</td><td>5.0</td></tr><tr><td></td><td>37-41</td><td>33-36</td><td>42-45</td><td>36-40</td><td>(5.2-5.8)</td><td>(4.7-5.3)</td></tr></table> |
e34e289b145b06848a0f26d94653f414ac85fe805d0ada9d081da4338e8f67b9.png | simple | <table><tr><td>Year (GC)</td><td>2005</td><td>2006</td><td>2007*</td><td>2008*</td><td>Average</td></tr><tr><td>Total out-patient malaria cases/1000</td><td>27.098</td><td>22.400</td><td>19.928</td><td>23.950</td><td>23.388</td></tr><tr><td>Malaria in-patients/10,000</td><td>10.670</td><td>6.343</td><td>3.976</td><td>4.270</td><td>6.383</td></tr><tr><td>Malaria in-patient deaths/100,000</td><td>4.010</td><td>2.246</td><td>1.401</td><td>1.365</td><td>2.282</td></tr><tr><td><i>Pf</i> cases/1,000</td><td>6.510</td><td>4.430</td><td>4.061</td><td>4.622</td><td>4.923</td></tr><tr><td><i>Pv</i> cases/ 1,000</td><td>2.768</td><td>2.549</td><td>2.426</td><td>3.025</td><td>2.691</td></tr><tr><td>Confirmed malaria cases/1,000</td><td>9.278</td><td>6.979</td><td>6.487</td><td>7.647</td><td>7.614</td></tr><tr><td>Malaria with severe anaemia in-patients/10,000</td><td>1.114</td><td>0.541</td><td>0.533</td><td>0.678</td><td>0.720</td></tr><tr><td>Malaria with severe anaemia deaths /100,000</td><td>0.729</td><td>0.298</td><td>0.146</td><td>0.360</td><td>0.387</td></tr><tr><td>Malaria in pregnancy out-patients/1,000</td><td>0.345</td><td>0.309</td><td>0.260</td><td>0.319</td><td>0.309</td></tr><tr><td>Malaria in pregnancy in-patients/10,000</td><td>0.264</td><td>0.169</td><td>0.115</td><td>0.161</td><td>0.179</td></tr><tr><td>Malaria in pregnancy deaths/100,000</td><td>0.096</td><td>0.057</td><td>0.032</td><td>0.035</td><td>0.056</td></tr></table> |
dfa16a55bfb914f600b0900359b19b8a4e1f27ba885a0dd0b5d0159d20f0dbc5.png | complex | <table><tr><td rowspan="2">Treatment</td><td colspan="2">Duodenum</td><td colspan="2">Jejunum</td><td colspan="2">Ileum</td></tr><tr><td>d 5</td><td>d 11</td><td>d 5</td><td>d 11</td><td>d 5</td><td>d 11</td></tr><tr><td>PS</td><td>2.5 (2, 5)</td><td>3 (1, 6)</td><td>2.5 (1, 4)</td><td>5 (2, 9)</td><td>3 (1, 5)</td><td>1 (1, 5)</td></tr><tr><td>AS</td><td>2.5 (1, 3)</td><td>2 (1, 6)</td><td>3 (2, 7)</td><td>3 (2, 4)</td><td>1.5 (1, 4)</td><td>2 (0, 2)</td></tr><tr><td>PM</td><td>13 (2, 16)<sup>*</sup></td><td>2 (1, 4)<sup>#</sup></td><td>13 (10, 18)<sup>*</sup></td><td>6 (2, 10)<sup>#</sup></td><td>13 (7, 15)<sup>*</sup></td><td>1 (0, 3)<sup>#</sup></td></tr><tr><td>MA</td><td>3 (2, 5)</td><td>2.5 (1, 6)</td><td>2.5 (2, 4)</td><td>3 (1, 8)</td><td>1 (1, 3)</td><td>1 (1, 4)</td></tr></table> |
0a0c557cb29491bacbb95caa11fd41009f463cc7e897632dd131dbb7a146a82a.png | simple | <table><tr><td>Colorectal</td><td>36 (67.9%)</td></tr><tr><td>Gynecologic</td><td>6 (11.3%)</td></tr><tr><td>Urologic</td><td>5 (9.4%)</td></tr><tr><td>Leimyosarcoma</td><td>3 (5.7%)</td></tr><tr><td>Anal</td><td>2 (3.8%)</td></tr><tr><td>Benign</td><td>1 (1.9%)</td></tr></table> |
3ff588293748435e12e12e8b6b855b2bc993b9a10480f858cfa8f377f7c7311c.png | simple | <table><tr><td>ID</td><td>BDNF</td><td>Pain</td><td>Sleep quality</td></tr><tr><td>3</td><td>Val/Val</td><td>Healthy Control</td><td>Poor quality</td></tr><tr><td>6</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>11</td><td>Val/Val</td><td>CAP</td><td>Good quality</td></tr><tr><td>16</td><td>Val/Val</td><td>CAP</td><td>Poor quality</td></tr><tr><td>22</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>25</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>35</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>36</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>38</td><td>Val/Val</td><td>CAP</td><td>Poor quality</td></tr><tr><td>39</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>40</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>41</td><td>Val/Val</td><td>CAP</td><td>Poor quality</td></tr><tr><td>44</td><td>Val/Val</td><td>CAP</td><td>Good quality</td></tr><tr><td>46</td><td>Val/Val</td><td>CAP</td><td>Good quality</td></tr><tr><td>49</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>52</td><td>Val/Val</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>55</td><td>Val/Val</td><td>CAP</td><td>Good quality</td></tr><tr><td>8</td><td>Met Carrier</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>24</td><td>Met Carrier</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>27</td><td>Met Carrier</td><td>CAP</td><td>Good quality</td></tr><tr><td>29</td><td>Met Carrier</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>32</td><td>Met Carrier</td><td>CAP</td><td>Poor quality</td></tr><tr><td>37</td><td>Met Carrier</td><td>Healthy Control</td><td>Good quality</td></tr><tr><td>43</td><td>Met Carrier</td><td>CAP</td><td>Poor quality</td></tr><tr><td>45</td><td>Met Carrier</td><td>CAP</td><td>Poor quality</td></tr><tr><td>56</td><td>Met Carrier</td><td>Healthy Control</td><td>Good quality</td></tr></table> |
483bf942b7e7e7f73ba54ad7b47cfca9006706557cb0b4f075a40246d352918d.png | simple | <table><tr><td>GEO ID</td><td>Symbol Color</td><td>Medium</td><td>n</td><td>Reference</td></tr><tr><td>GSE6741</td><td>● 20% O<sub>2 </sub>- light green● 2% O<sub>2 </sub>- gold● 0.4% O<sub>2 </sub>- red● 0% O<sub>2 </sub>+ nitrate - dark green</td><td>minimal amino acids 37°C, sparged and stirred exponential phase, OD ~ 0.08</td><td>2</td><td>[15]</td></tr><tr><td>GSE2430</td><td>● untreated control - pink</td><td>BHI, 37°C, shaken; early stationary phase, OD ~ 2.8</td><td>2</td><td>[18]</td></tr><tr><td>GSE4152</td><td>● untreated control - yellow● Cu stressed - blue</td><td>MOPS buffered LB, 37°C, early exponential phase, OD ~ 0.2</td><td>2</td><td>[20]</td></tr><tr><td>GSE2885</td><td>● OD ~ 0.2 - light gray● OD ~ 1.3 - white● OD ~ 2.1 (Fe limited) - purple</td><td>minimal glucose, 37°C, sparged and stirred, three points in batch culture</td><td>2</td><td>[22]</td></tr><tr><td>GSE5604</td><td>● untreated control - light blue</td><td>minimal acetate, 20°C, chemostat with dilution rate 0.06 h<sup>-1</sup></td><td>2</td><td>[17]</td></tr><tr><td>GSE7704</td><td>● control - brown</td><td>minimal citrate, 37°C, shaken, OD ~ 0.6</td><td>3</td><td>[19]</td></tr><tr><td>GSE5443</td><td>● control - dark blue</td><td>LB, 37°C</td><td>2</td><td>[16]</td></tr><tr><td>GSE8408</td><td>● control - dark gray</td><td>minimal succinate and non-sulfur containing amino acids, 30°C, shaken, OD ~ 0.2</td><td>3</td><td>[21]</td></tr></table> |
6e68b79facc8b78528b27ba1b8e8f6faafcb7de647269ea5d5cc07418b79a811.png | simple | <table><tr><td>Group</td><td><i>Treatment</i></td><td>Percentage of Double-strand DNA</td><td>Number of single-strand breaks/DNA fragment</td><td>Inhibition (%)</td></tr><tr><td>A</td><td>Normal</td><td>93.56</td><td>0.07 ± 0.02<sup>a</sup></td><td></td></tr><tr><td>B</td><td>DENA Control</td><td>31.68</td><td>1.32 ± 0.01 <sup>b</sup></td><td></td></tr><tr><td>C</td><td>DENA+V</td><td>47.23</td><td>0.58 ± 0.01 <sup>c</sup></td><td>56.06</td></tr><tr><td>D</td><td>DENA+BC</td><td>52.87</td><td>0.54 ± 0.04 <sup>c</sup></td><td>59.09</td></tr><tr><td>E</td><td>DENA+V+BC</td><td>64.73</td><td>0.48 ± 0.023 <sup>d</sup></td><td>63.6</td></tr></table> |
0e5df84ad68e0cf4ec1278f954b45f0033802d36d7599e37e6a9eba340ad9a6a.png | simple | <table><tr><td>Organ</td><td>Mean</td><td>S.D</td><td>Med</td><td>Min</td><td>Max</td></tr><tr><td>Left wrist</td><td>130.9</td><td>88.83</td><td>106.94</td><td>30.55</td><td>376.01</td></tr><tr><td>Right wrist</td><td>93.65</td><td>82.01</td><td>57.21</td><td>19.72</td><td>385.91</td></tr><tr><td>Thyroid</td><td>40.05</td><td>21.65</td><td>32.36</td><td>11.04</td><td>101.00</td></tr><tr><td>Eye</td><td>30.15</td><td>15.01</td><td>26.67</td><td>10.16</td><td>95.01</td></tr></table> |
c48ba67e5e04ae0bae62712054d889ee62ce3966b0fccebe1e65392ea66c810c.png | simple | <table><tr><td>4B5</td><td>HER2 amplification</td><td>no HER2 amplication</td><td>SP3</td><td>HER2 amplification</td><td>no HER2 amplification</td><td>Herceptest</td><td>HER2 amplification</td><td>no HER2 amplification</td></tr><tr><td>0,1+</td><td>3</td><td>907</td><td>0,1+</td><td>3</td><td>924</td><td>0,1+</td><td>13</td><td>951</td></tr><tr><td>2+</td><td>8</td><td>46</td><td>2+</td><td>13</td><td>36</td><td>2+</td><td>11</td><td>18</td></tr><tr><td>3+</td><td>75</td><td>6</td><td>3+</td><td>69</td><td>4</td><td>3+</td><td>65</td><td>5</td></tr><tr><td>Total</td><td>86</td><td>959</td><td></td><td>85</td><td>964</td><td></td><td>89</td><td>974</td></tr></table> |
c1c388b5b695ff93a558c1c302417d3d40fad4dba39c11096d636ff6daaeefa4.png | complex | <table><tr><td></td><td colspan="5">Mean (SD) Scores (max. score 5)</td></tr><tr><td>Subscales</td><td>AH</td><td>TH</td><td>AC</td><td>SKMC</td><td>p-value</td></tr><tr><td>Teacher Characteristics (17items)</td><td>3.50 (1.08)</td><td>3.84 (0.93)</td><td>3.86 (1.21)</td><td>4.48 (0.46)</td><td>0.008</td></tr><tr><td>Involvement in direct patient care (6 items)</td><td>3.26 (1.06)</td><td>3.85 (1.06)</td><td>3.68 (1.19)</td><td>4.12 (0.51)</td><td>0.03</td></tr><tr><td>Patients (4 items)</td><td>3.44 (1.02)</td><td>3.92 (0.99)</td><td>3.70 (1.24)</td><td>4.18 (0.64)</td><td>0.142</td></tr><tr><td>Physical Facilities (5 items)</td><td>3.20 (1.09)</td><td>3.51 (1.05)</td><td>3.05 (1.04)</td><td>4.37 (0.47)</td><td>0.015</td></tr></table> |
540b2732ad1d46669725e6efdc6c6dd85c66aa937f29810e2f544ca7ebc97a6f.png | complex | <table><tr><td> </td><td colspan="2"><i>MTHFR </i>C677T genotype</td><td> </td><td colspan="2"><i>MTHFR </i>A1298C genotype</td></tr><tr><td> </td><td>ALL group</td><td>Control group</td><td> </td><td>ALL group</td><td>Control group</td></tr><tr><td>CC type</td><td>28 (28.6%)</td><td>29 (31.2%)</td><td>AA type</td><td>54 (55.1%)</td><td>67 (72.0%)</td></tr><tr><td>CT type</td><td>44 (44.9%)</td><td>49 (52.7%)</td><td>AC type</td><td>42 (42.9%)</td><td>25 (26.9%)</td></tr><tr><td>TT type</td><td>26 (26.5%)</td><td>15 (16.1%)</td><td>CC type</td><td>2 (2.0%)</td><td>1 (1.1%)</td></tr><tr><td>χ<sup>2</sup></td><td>1.013</td><td>0.569</td><td>χ<sup>2</sup></td><td>3.652</td><td>0.643</td></tr><tr><td><i>P-value</i></td><td>0.314</td><td>0.451</td><td><i>P-value</i></td><td>0.06</td><td>0.423</td></tr></table> |
be45342b2660055ef9f45c38580858fbdc6ad857bdd3c495e78a828857c037ba.png | simple | <table><tr><td>Task</td><td>NHP mean (<i>SD</i>)</td><td>RHDN+ mean (<i>SD</i>)</td><td>RHDN_Mean (<i>SD</i>)</td><td><i>t</i>-test RHDN+ vs. controls</td><td><i>t</i>-test RHDN_ vs. controls</td><td><i>t</i>-test RHDN+ vs. RHDN+</td></tr><tr><td>Counting</td><td>4 (0)</td><td>3.5 (0.67)</td><td>4 (0)</td><td><i>t</i><sub>(22)</sub> = 2.57; <i>p</i> = 0.017</td><td><i>NA</i>; <i>n.s</i>.</td><td><i>t</i><sub>(22)</sub> = 2.57;<i>p</i> = 0.017</td></tr><tr><td>Odd/even judgment</td><td>22 (0)</td><td>19.92 (2.97)</td><td>21.83 (0.39)</td><td><i>t</i><sub>(22)</sub> = 2.43;<i>p</i> = 0.023</td><td><i>t</i><sub>(22)</sub> = 1.48;<i>p</i> = 0.152</td><td><i>t</i><sub>(22)</sub> = 2.22;<i>p</i> = 0.037</td></tr><tr><td>Number magnitude comparison</td><td>14 (0)</td><td>13.57 (0.45)</td><td>14 (0)</td><td><i>t</i><sub>(22)</sub> = 1.91;<i>p</i> = 0.068</td><td><i>NA</i>; <i>n.s</i>.</td><td><i>t</i><sub>(22)</sub> = 1.92;<i>p</i> = 0.068</td></tr><tr><td>Writing arabic numerals to dictation</td><td>25 (0)</td><td>23 (1.71)</td><td>24.75 (0.45)</td><td><i>t</i><sub>(22)</sub> = 4.06;<i>p</i> = 5 × 10<sup>−4</sup></td><td><i>t</i><sub>(22)</sub> = 1.91;<i>p</i> = 0.068</td><td><i>t</i><sub>(22)</sub> = 3.43;<i>p</i> = 0.002</td></tr><tr><td>Reading arabic numbers</td><td>22 (0)</td><td>20 (2.95)</td><td>22 (0)</td><td><i>t</i><sub>(22)</sub> = 2.34;<i>p</i> = 0.028</td><td><i>NA</i>; <i>n.s</i>.</td><td><i>t</i><sub>(22)</sub> = 2.35;<i>p</i> = 0.028</td></tr><tr><td>Recognition of operations</td><td>4 (0)</td><td>3.92 (0.29)</td><td>4 (0)</td><td><i>t</i><sub>(22)</sub> = 1;<i>p</i> = 0.328</td><td><i>NA</i>; <i>n.s</i>.</td><td><i>t</i><sub>(22)</sub> = 1.00;<i>p</i> = 0.328</td></tr><tr><td>Mental one-digit multiplication</td><td>9.58 (0.67)</td><td>7.25 (1.66)</td><td>8.50 (1.17)</td><td><i>t</i><sub>(22)</sub> = 4.52;<i>p</i> = 1 × 10<sup>−4</sup></td><td><i>t</i><sub>(22)</sub> = 2.79;<i>p</i> = 0.011</td><td><i>t</i><sub>(22)</sub> = 2.13;<i>p</i> = 0.044</td></tr><tr><td>Mental one-digit addition</td><td>9.92 (0.29)</td><td>9.25 (0.97)</td><td>9.83 (0.39)</td><td><i>t</i><sub>(22)</sub> = 2.92;<i>p</i> = 0.03</td><td><i>t</i><sub>(22)</sub> = 0.596;<i>p</i> = 0.557</td><td><i>t</i><sub>(22)</sub> = 1.94;<i>p</i> = 0.065</td></tr><tr><td>Mental one-digit subtraction</td><td>10 (0)</td><td>9.17 (0.83)</td><td>9.92 (0.29)</td><td><i>t</i><sub>(22)</sub> = 3.55;<i>p</i> = 0.002</td><td><i>t</i><sub>(22)</sub> = 1.00;<i>p</i> = 0.328</td><td><i>t</i><sub>(22)</sub> = 2.94;<i>p</i> = 0.008</td></tr><tr><td>Number repetition</td><td>16 (0)</td><td>15.83 (0.39)</td><td>16 (0)</td><td><i>t</i><sub>(22)</sub> = 1.48;<i>p</i> = 0.152</td><td><i>NA</i>; <i>n.s</i>.</td><td><i>t</i><sub>(22)</sub> = 1.48;<i>p</i> = 0.152</td></tr></table> |
7cd89f639e942b287bc176d6366d93c4eb3c38582ada35aaa1f7c295264386bc.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Kenya</td><td colspan="2">Nagpur, India</td><td colspan="2">Belgaum, India</td><td colspan="2">Total</td></tr><tr><td>Pre</td><td>Post</td><td>Pre</td><td>Post</td><td>Pre</td><td>Post</td><td>Pre</td><td>Post</td></tr><tr><td>Registry deliveries<sup>a</sup>, n</td><td>8875</td><td>8394</td><td>9461</td><td>9721</td><td>16,992</td><td>16,715</td><td>35,328</td><td>34,830</td></tr><tr><td colspan="9">Birth location, n (%)</td></tr><tr><td>Hospital</td><td>1203 (13.6)</td><td>1296 (15.4)</td><td>6323 (66.8)</td><td>6995 (72.0)</td><td>12,501 (73.6)</td><td>11,931 (71.4)</td><td>20,027 (56.7)</td><td>20,222 (58.1)</td></tr><tr><td>Clinic</td><td>2514 (28.3)</td><td>2791 (33.2)</td><td>2966 (31.4)</td><td>2638 (27.1)</td><td>3708 (21.8)</td><td>4098 (24.5)</td><td>9188 (26.0)</td><td>9527 (27.4)</td></tr><tr><td>Home/Other</td><td>5158 (58.1)</td><td>4307 (51.3)</td><td>170 (1.8)</td><td>88 (0.9)</td><td>783 (4.6)</td><td>686 (4.1)</td><td>6111 (17.3)</td><td>5081 (14.6)</td></tr><tr><td colspan="9">Birth attendant, n (%)</td></tr><tr><td>Physician</td><td>209 (2.4)</td><td>203 (2.4)</td><td>5701 (60.3)</td><td>6289 (64.7)</td><td>10,446 (61.5)</td><td>10,149 (60.7)</td><td>16,356 (46.3)</td><td>16,641 (47.8)</td></tr><tr><td>Nurse/midwife</td><td>3617 (40.8)</td><td>3929 (46.8)</td><td>3597 (38.0)</td><td>3355 (34.5)</td><td>5838 (34.4)</td><td>5973 (35.7)</td><td>13,052 (36.9)</td><td>13,257 (38.1)</td></tr><tr><td>TBA</td><td>3930 (44.3)</td><td>3154 (37.6)</td><td>110 (1.2)</td><td>45 (0.5)</td><td>225 (1.3)</td><td>159 (1.0)</td><td>4265 (12.1)</td><td>3358 (9.6)</td></tr><tr><td>Family/unattended</td><td>1119 (12.6)</td><td>1108 (13.2)</td><td>53 (0.6)</td><td>32 (0.3)</td><td>483 (2.8)</td><td>434 (2.6)</td><td>1655 (4.7)</td><td>1574 (4.5)</td></tr><tr><td colspan="9">Maternal education, n (%)</td></tr><tr><td>No formal schooling</td><td>249 (2.8)</td><td>228 (2.7)</td><td>262 (2.8)</td><td>259 (2.7)</td><td>3091 (18.3)</td><td>2460 (14.7)</td><td>3602 (10.2)</td><td>2947 (8.5)</td></tr><tr><td>Primary</td><td>6174 (69.6)</td><td>5690 (68.4)</td><td>1575 (16.7)</td><td>1636 (16.9)</td><td>5300 (31.3)</td><td>5207 (31.2)</td><td>13,049 (37.0)</td><td>12,533 (36.0)</td></tr><tr><td>Secondary</td><td>2071 (23.3)</td><td>2019 (24.3)</td><td>5705 (60.4)</td><td>5669 (58.5)</td><td>6786 (40.1)</td><td>7005 (41.2)</td><td>14,562 (41.0)</td><td>14,693 (42.0)</td></tr><tr><td>University +</td><td>378 (4.3)</td><td>376 (4.5)</td><td>1899 (20.1)</td><td>2129 (22.0)</td><td>1730 (10.2)</td><td>2022 (12.1)</td><td>4007 (11.4)</td><td>4527 (13.0)</td></tr><tr><td colspan="9">Maternal age, n (%)</td></tr><tr><td>< 20</td><td>1933 (21.8)</td><td>1884 (22.7)</td><td>189 (2.0)</td><td>182 (1.9)</td><td>1650 (9.7)</td><td>1584 (9.5)</td><td>3772 (10.7)</td><td>3650 (10.5)</td></tr><tr><td>20–35</td><td>6595 (74.3)</td><td>6083 (73.2)</td><td>9226 (97.6)</td><td>9494 (97.8)</td><td>15,318 (90.1)</td><td>15,101 (90.3)</td><td>31,139 (88.2)</td><td>30,678 (88.3)</td></tr><tr><td>> 35</td><td>343 (3.9)</td><td>345 (4.1)</td><td>35 (0.37)</td><td>31 (0.32)</td><td>23 (0.14)</td><td>30 (0.18)</td><td>401 (1.1)</td><td>406 (1.2)</td></tr><tr><td colspan="9">Parity<sup>a</sup>, n (%)</td></tr><tr><td>0</td><td>2263 (25.5)</td><td>2232 (26.6)</td><td>4519 (47.8)</td><td>4568 (47.0)</td><td>7208 (43.5)</td><td>7253 (43.4)</td><td>13,990 (40.1)</td><td>14,053 (40.4)</td></tr><tr><td>1–2</td><td>3550 (40.0)</td><td>3269 (39.0)</td><td>4703 (49.7)</td><td>4892 (50.3)</td><td>8305 (50.1)</td><td>8486 (50.8)</td><td>16,558 (47.5)</td><td>16,647 (47.8)</td></tr><tr><td>> 2</td><td>3056 (34.5)</td><td>2883 (34.4)</td><td>236 (2.5)</td><td>258 (2.7)</td><td>1053 (6.4)</td><td>969 (5.8)</td><td>4345 (12.5)</td><td>4110 (11.8)</td></tr><tr><td>Labor complications, n (%)</td><td>1406 (15.8)</td><td>1269 (15.1)</td><td>1356 (14.3)</td><td>1530 (15.7)</td><td>2428 (14.3)</td><td>3050 (18.3)</td><td>5190 (14.7)</td><td>5849 (16.8)</td></tr><tr><td>Caesarean rate, n (%)</td><td>162 (1.8)</td><td>162 (1.9)</td><td>1879 (19.9)</td><td>2202 (22.7)</td><td>2509 (14.8)</td><td>3103 (18.6)</td><td>4550 (12.9)</td><td>5467 (15.7)</td></tr><tr><td>Multiple births, n (%)</td><td>99 (1.1)</td><td>102 (1.2)</td><td>57 (0.6)</td><td>68 (0.7)</td><td>122 (0.7)</td><td>103 (0.6)</td><td>278 (0.8)</td><td>273 (0.8)</td></tr><tr><td colspan="9">Corticosteroids, n (%)</td></tr><tr><td>Yes</td><td>59 (1.1)</td><td>124 (1.5)</td><td>123 (6.3)</td><td>416 (4.4)</td><td>422 (3.0)</td><td>1225 (7.3)</td><td>604 (2.8)</td><td>1765 (5.1)</td></tr><tr><td>No</td><td>5228 (98.9)</td><td>8209 (98.5)</td><td>1809 (92.8)</td><td>8880 (94.8)</td><td>13,746 (96.3)</td><td>15,446 (92.4)</td><td>20,783 (96.6)</td><td>32,535 (94.5)</td></tr><tr><td>Don’t know</td><td>0 (0.0)</td><td>3 (0.04)</td><td>18 (0.92)</td><td>73 (0.78)</td><td>103 (0.72)</td><td>44 (0.46)</td><td>121 (0.56)</td><td>120 (0.35)</td></tr><tr><td>Registry births, n (%)</td><td>8972</td><td>8510</td><td>9514</td><td>9784</td><td>17,109</td><td>16,815</td><td>35,595</td><td>35,109</td></tr><tr><td> Male, n (%)</td><td>4582 (51.1)</td><td>4281 (50.3)</td><td>4998 (52.5)</td><td>5018 (51.3)</td><td>8927 (52.2)</td><td>8687 (51.7)</td><td>18,507 (52.0)</td><td>17,986 (51.2)</td></tr><tr><td colspan="9">Birth weight (g) <sup>b</sup>, n (%)</td></tr><tr><td>1500–2499</td><td>256 (2.9)</td><td>267 (3.2)</td><td>1336 (14.1)</td><td>1441 (14.7)</td><td>2261 (13.2)</td><td>3292 (19.7)</td><td>3853 (10.9)</td><td>5000 (14.3)</td></tr><tr><td>≥ 2500</td><td>8429 (97.1)</td><td>8145 (96.8)</td><td>8152 (85.9)</td><td>8336 (85.3)</td><td>14,824 (86.8)</td><td>13,441 (80.3)</td><td>31,405 (89.1)</td><td>29,922 (85.7)</td></tr><tr><td>Registry births ≥ 1500 g, n</td><td>8972</td><td>8510</td><td>9514</td><td>9784</td><td>17,109</td><td>16,815</td><td>35,595</td><td>35,109</td></tr><tr><td>Registry births ≥ 1500 g in facilities, n (%)</td><td>3778 (42.1)</td><td>4164 (48.9)</td><td>9342 (98.2)</td><td>9693 (99.1)</td><td>16,323 (95.4)</td><td>16,129 (95.9)</td><td>29,443 (82.7)</td><td>29,986 (85.4)</td></tr><tr><td>Registry births ≥ 1500 g in HBB-trained facilities, n (%)</td><td>3235 (36.1)</td><td>3481 (40.9)</td><td>4053 (42.6)</td><td>4373 (44.7)</td><td>7944 (46.4)</td><td>8131 (48.4)</td><td>15,232 (42.8)</td><td>15,985 (45.5)</td></tr><tr><td> Primary facility, n (%) <sup>c</sup></td><td>2620 (81.0)</td><td>2733 (78.5)</td><td>207 (5.1)</td><td>227 (5.2)</td><td>2713 (34.2)</td><td>2924 (36.0)</td><td>5540 (36.4)</td><td>5884 (36.8)</td></tr><tr><td> Secondary facility, n (%)</td><td>615 (19.0)</td><td>748 (21.5)</td><td>432 (10.7)</td><td>521 (11.9)</td><td>3935 (49.5)</td><td>3930 (48.3)</td><td>4982 (32.7)</td><td>5199 (32.5)</td></tr><tr><td> Tertiary facility, n (%)</td><td>0 (0.0)</td><td>0 (0.0)</td><td>3414 (84.2)</td><td>3625 (82.9)</td><td>1296 (16.3)</td><td>1277 (15.7)</td><td>4710 (30.9)</td><td>4902 (30.7)</td></tr><tr><td>Non-HBB trained facilities, n (%)</td><td>543 (6.1)</td><td>683 (8.0)</td><td>5289 (55.6)</td><td>5320 (54.4)</td><td>8379 (49.0)</td><td>7998 (47.6)</td><td>14,211 (39.9)</td><td>14,001 (40.0)</td></tr></table> |
0b9d9e3fc6e877ddfe6f535d08e4baebe8b0d279c599df016f300845d1ea63f2.png | simple | <table><tr><td>OTU</td><td>Phylum</td><td>Class</td><td>Oder</td><td>Family</td><td>Genus</td></tr><tr><td>OTU077</td><td>Acidobacteria</td><td>Acidobacteria_Gp3</td><td>incertae_sedis</td><td>incertae_sedis</td><td>Gp3</td></tr><tr><td>OTU136</td><td>Acidobacteria</td><td>Acidobacteria_Gp4</td><td>incertae_sedis</td><td>incertae_sedis</td><td>Gp4</td></tr><tr><td>OTU020</td><td>Acidobacteria</td><td>Acidobacteria_Gp6</td><td>incertae_sedis</td><td>incertae_sedis</td><td>Gp6</td></tr><tr><td>OTU058</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Acidimicrobiales</td><td>Unclassified</td><td>Unclassified</td></tr><tr><td>OTU017</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Actinomycetales</td><td>Kineosporiaceae</td><td><i>Kineosporia</i></td></tr><tr><td>OTU002</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Actinomycetales</td><td>Micromonosporaceae</td><td>Unclassified</td></tr><tr><td>OTU006</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Actinomycetales</td><td>Mycobacteriaceae</td><td><i>Mycobacterium</i></td></tr><tr><td>OTU041</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Actinomycetales</td><td>Pseudonocardiaceae</td><td>Unclassified</td></tr><tr><td>OTU028</td><td>Actinobacteria</td><td>Actinobacteria</td><td>Actinomycetales</td><td>Unclassified</td><td>Unclassified</td></tr><tr><td>OTU131</td><td>Gemmatimonadetes</td><td>Gemmatimonadetes</td><td>Gemmatimonadales</td><td>Gemmatimonadaceae</td><td><i>Gemmatimonas</i></td></tr><tr><td>OTU033</td><td>Proteobacteria</td><td>Gammaproteobacteria</td><td>Unclassified</td><td>Unclassified</td><td>Unclassified</td></tr><tr><td>OTU102</td><td>Proteobacteria</td><td>Gammaproteobacteria</td><td>Xanthomonadales</td><td>Xanthomonadaceae</td><td><i>Thermomonas</i></td></tr><tr><td>OTU040</td><td>Proteobacteria</td><td>Gammaproteobacteria</td><td>Xanthomonadales</td><td>Xanthomonadaceae</td><td>Unclassified</td></tr></table> |
6c68e17ac1f7959795204a4644852b3c70437631dfe018e34302eef3be9562ad.png | simple | <table><tr><td>Parameter</td><td>Value</td></tr><tr><td>Target Material</td><td>Ag</td></tr><tr><td>Power</td><td>50 W</td></tr><tr><td>Sputter time</td><td>30 min</td></tr><tr><td>Process stress</td><td>1.8 × 10<sup>−2</sup> torr</td></tr><tr><td>Environment temperature</td><td>27 °C</td></tr></table> |
6f76a5402d1172b21730f4bba3a44d7f11dd0caf77aff270a3515808b83dc73a.png | simple | <table><tr><td>Compound number</td><td>MW</td><td>RBT</td><td>HBAcc</td><td>HBDon</td><td>PSA</td><td>AlogP</td><td>Cerius2 prediction</td><td>VolSurf prediction</td></tr><tr><td>1</td><td>583</td><td>10</td><td>5</td><td>1</td><td>56</td><td>5.6</td><td>High penetrant (1)</td><td><underline>Medium/Undefined</underline></td></tr><tr><td>2</td><td>355</td><td>5</td><td>3</td><td>3</td><td>53</td><td>2.9</td><td><underline>Medium penetrant (2)</underline></td><td><i>Low permeant</i></td></tr><tr><td>3</td><td>292</td><td>5</td><td>4</td><td>3</td><td>73</td><td>1.7</td><td><i>Low penetrant (3)</i></td><td>High permeant</td></tr><tr><td>4</td><td>255</td><td>2</td><td>2</td><td>1</td><td>26</td><td>4.4</td><td>Very penetrant (0)</td><td>High permeant</td></tr><tr><td>5</td><td>255</td><td>2</td><td>2</td><td>1</td><td>26</td><td>4.4</td><td>Very penetrant (0)</td><td>High permeant</td></tr><tr><td>6</td><td>294</td><td>4</td><td>3</td><td>0</td><td>41</td><td>2.9</td><td>High penetrant (1)</td><td>High permeant</td></tr></table> |
f739e082945ed53977fc829eeb73c1c2b2289d4aeab5bf9518398fd9d474600c.png | simple | <table><tr><td>Plant</td><td>Extract</td><td>DPPH radical scavenging assay %</td><td>Iron chelating assay %</td><td>Inhibition % of glycogen phosphorylase (5mg/ml)</td><td>Brine shrimp lethality (LC <sub>50</sub>)</td></tr><tr><td><i>Acacia Senegal</i></td><td>Ethanolic</td><td>NOT ACTIVE</td><td>NOT ACTIVE</td><td>0</td><td>83.8716</td></tr><tr><td> </td><td>Aqueous</td><td>NOT ACTIVE</td><td>NOT ACTIVE</td><td>0</td><td>17.9948</td></tr><tr><td><i>Ambrosia maritima</i></td><td>Ethanolic</td><td>60.8 ± 0.04</td><td>NOT ACTIVE</td><td>2.2</td><td>39.7866</td></tr><tr><td> </td><td>Aqueous</td><td>21.2 ± 0.02</td><td>NOT ACTIVE</td><td>0</td><td>10.6353</td></tr><tr><td><i>Ammi visnaga</i></td><td>Ethanolic</td><td>52.4 ± 0.03</td><td>NOT ACTIVE</td><td>0</td><td>8.1217</td></tr><tr><td> </td><td>Aqueous</td><td>52.4 ± 0.03</td><td>2.5 ± 0.03</td><td>0</td><td>32.6273</td></tr><tr><td><i>Foeniculum vulgare</i></td><td>Ethanolic</td><td>60.7 ± 0.06</td><td>3.6 ± 0.05</td><td>0</td><td>0.012</td></tr><tr><td> </td><td>Aqueous</td><td>69.4 ± 0.003</td><td>NOT ACTIVE</td><td>0</td><td>893.97</td></tr><tr><td><i>Nigella sativa</i></td><td>Ethanolic</td><td>47 ± 0.02</td><td>6.3 ± 0.02</td><td>0</td><td>11684.6</td></tr><tr><td> </td><td>Aqueous</td><td>19.3 ± 0.01</td><td>43.5 ± 0.04</td><td>0</td><td>122.268</td></tr><tr><td><i>Sesamum indicum</i></td><td>Ethanolic</td><td>NOT ACTIVE</td><td>NOT ACTIVE</td><td>8.2</td><td>61.85</td></tr><tr><td> </td><td>Aqueous</td><td>40.3 ± 0.01</td><td>23.2 ± 0.02</td><td>0</td><td>1.7</td></tr></table> |
7b34f4d5f41c93102057ffe324e8dd0f9c7cbdf6749f843815bc9c012840fb42.png | complex | <table><tr><td></td><td>OR</td><td colspan="2">95% Confidence Interval</td><td><i>p</i></td></tr><tr><td colspan="5">Incident unplanned pregnancies</td></tr><tr><td>Pregnancy prior to baseline</td><td>1.01</td><td>0.39</td><td>2.64</td><td>0.98</td></tr><tr><td>Age</td><td>0.90</td><td>0.60</td><td>1.35</td><td>0.61</td></tr><tr><td>Relationship duration</td><td>1.00</td><td>0.98</td><td>1.01</td><td>0.58</td></tr><tr><td>Contraception – none</td><td>Ref.</td><td></td><td></td><td></td></tr><tr><td> Hormonal</td><td>0.40</td><td>0.21</td><td>0.79</td><td><0.01</td></tr><tr><td> Condoms only</td><td>0.86</td><td>0.38</td><td>1.99</td><td>0.73</td></tr><tr><td>Mutual main partners</td><td>2.58</td><td>1.07</td><td>6.25</td><td>0.03</td></tr><tr><td>Socioeconomic status</td><td>0.69</td><td>0.58</td><td>0.83</td><td><0.01</td></tr><tr><td>Exposure to intervention</td><td>0.96</td><td>0.50</td><td>1.85</td><td>0.89</td></tr><tr><td>IPV – none</td><td>Ref.</td><td></td><td></td><td></td></tr><tr><td> Physical abuse only</td><td>1.06</td><td>0.51</td><td>2.21</td><td>0.88</td></tr><tr><td> Sexual abuse with/without physical abuse</td><td>0.74</td><td>0.30</td><td>1.81</td><td>0.51</td></tr><tr><td colspan="5">Incident unwanted pregnancies</td></tr><tr><td>Pregnancy prior to baseline</td><td>0.25</td><td>0.07</td><td>0.80</td><td>0.02</td></tr><tr><td>Age</td><td>1.09</td><td>0.82</td><td>1.46</td><td>0.54</td></tr><tr><td>Relationship duration</td><td>0.98</td><td>0.97</td><td>1.00</td><td>0.06</td></tr><tr><td>Contraception – none</td><td>Ref.</td><td></td><td></td><td></td></tr><tr><td> Hormonal</td><td>0.74</td><td>0.43</td><td>1.30</td><td>0.29</td></tr><tr><td> Condoms only</td><td>1.81</td><td>0.99</td><td>3.30</td><td>0.05</td></tr><tr><td>Mutual main partners</td><td>2.21</td><td>1.13</td><td>4.29</td><td>0.02</td></tr><tr><td>Socioeconomic status</td><td>0.78</td><td>0.64</td><td>0.96</td><td>0.02</td></tr><tr><td>Exposure to intervention</td><td>1.43</td><td>0.85</td><td>2.41</td><td>0.18</td></tr><tr><td>IPV – none</td><td>Ref.</td><td></td><td></td><td></td></tr><tr><td> Physical abuse only</td><td>1.69</td><td>1.05</td><td>2.72</td><td>0.03</td></tr><tr><td> Sexual abuse with or without physical abuse</td><td>0.55</td><td>0.24</td><td>1.27</td><td>0.16</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.